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Summary  
Cullin RING E3 ubiquitin ligases (CRLs) function in the ubiquitin 
proteasome system by catalysing the transfer of ubiquitin from E2 conjugating 
enzymes to specific substrate proteins. CRLs are large dynamic multi-subunit 
complexes that control the fate of many proteins in cells and, therefore, 
constitute attractive drug targets for the development of small-molecule tools 
and potential drug leads, such as inhibitors and chemical inducers of protein 
degradation. 
This work presents the first crystal structure of the pentameric human 
CRL2VHL complex, composed of Cul2, Rbx1, Elongin B (EloB), Elongin C (EloC) 
and pVHL. The structure presents a closed state of full-length Cul2 and a new 
conformation of Rbx1, thought to be in a trajectory from inactive to active state. 
The thermodynamic signature of the interaction between Cul2 and pVHL-EloBC 
(VBC) was determined as well as mutations that contribute toward a selectivity 
switch for Cul2 versus Cul5 recognition. In addition, this work focused on an 
extensive approach to probe the VBC surface with peptides. A first 
methodology involved the structure-based design aimed at targeting the 
Cul2-VBC interaction. Three peptides have been shown to bind at the Cul2 
binding site on EloC, however, with very weak affinities that could not be 
optimised, suggesting its poor ligandability. The second methodology included 
an unbiased screening using phage display libraries of bicyclic peptides. The 
screening campaign yielded peptide hits but their physicochemical properties, 
especially poor solubility, constituted an obstacle to the progress toward a 
biophysical characterisation of their binding to VBC and the development into 
high-affinity probes. 
The findings of this work provide structural and biophysical contributions 
into the whole CRL2VHL complex assembly and functioning and provide insights 
and tools that could aid future targeting of this CRL. 
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1.1 Motivation 
In drug discovery, the ligandability of a target is a very critical property. 
Ligandability is defined as the propensity of a target to bind small molecules,1 
and it constitutes a requirement for druggability i.e. the modulation of a target by 
drug-like small molecules as a mechanism to elicit a therapeutic benefit.2 In 
order to be druggable, a target must be ligandable, however, being ligandable, 
despite increasing the chances, does not always guarantee target druggability. 
Nowadays, different avenues are pursued by the research community to 
explore the ligandability of potential targets, before embarking on costly and 
lengthy drug screening campaigns. Fragment screening approaches to identify 
chemical starting points for optimisation into more potent ligands, typically allied 
with structural and biophysical studies of a particular target, represent a 
prominent and powerful way to probe target ligandability. 
Traditionally, proteins are targeted at well-defined ligand binding sites or 
catalytic grooves and these conventional targets are mainly enzymes and 
protein receptors, such as kinases and G-protein-coupled receptors (GPCRs). 
These key families of proteins constitute only a small portion of the whole 
proteome, highlighting that a great amount of it remains untargeted. In fact, only 
10-14% of the human genome is predicted to be druggable.2 To expand the 
druggable portion of the genome, the focus must shift to unconventional targets. 
These comprise, for example, proteins that endogenously bind peptides or 
other proteins as ligands, or that are involved in protein-protein interactions 
(PPIs), and that are usually deemed undruggable. This is due to their lack of 
small-molecule binding sites, which are often replaced by large and flat 
surfaces.  
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In fact, most of the proteins do not function alone, indeed, their function 
depends on the interaction with other proteins, and PPIs are biologically 
relevant as regulators of most biochemical pathways. The human interactome 
(set of PPIs that occur in a cell), is estimated to comprise around 100,000 
protein interactions,3 and each of this PPI provides an opportunity for 
therapeutic intervention. Therefore, despite challenging, PPIs and surfaces 
provide exciting new opportunities to be explored as potential targets.4 
The challenges in assessing the ligandability of PPIs and protein 
surfaces represent usually a high risk-benefit balance. A protein surface might 
be ligandable but the ligand site might not constitute a PPI. At the same time, 
by identifying a novel ligand site one can contribute to unveiling unknown native 
partners. A complete model system to assess ligandability of a target and 
explore new and known binding sites in a combined fashion is a multi-subunit 
protein complex. On one hand, it is a system that relies on intrinsic PPIs for 
function (known binding sites) and, on the other hand, it is likely that each of the 
subunits might be ligandable on its own (new binding sites). Apart from being 
model systems, studying multi-subunit complexes is essential to understand 
key cell physiology features due to their frequent involvement in critical cellular 
processes, including cell signalling, gene expression, metabolism and cell cycle 
regulation.5 However, several aspects must be contemplated. Probing a large 
complex can be a demanding task in terms of biochemical and biophysical 
techniques available and their limitations, as, for example, most of the 
traditional methods are optimal for proteins under 50 kDa.6 Equally, the 
independent study of the individual subunits of the complex can prove difficult, 
as the proteins might not be stable on their own, since they naturally function 
bound to other proteins and tend to have large hydrophobic surfaces. Overall, 
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only the consolidation of insights gathered from different techniques and 
methodologies can assist toward the final goal of understanding the ligandability 
of a multi-subunit protein target. 
The motivation behind this work contemplates a multi-disciplinary 
approach to address the challenges presented above by investigating the 
ligandability of protein-protein interactions and surfaces within Cullin RING E3 
ubiquitin ligases. 
 
1.2 The ubiquitin proteasome system 
In living organisms, complex signalling mechanisms and networks 
continuously regulate cells. The rates of protein degradation are an important 
feature of protein homeostasis that impact upon cell regulation and half-lives of 
proteins within cells vary greatly according to their function. For example, 
transcription factors have short half-life times as the rapid turnover of these 
proteins is needed in order to allow their levels to rapidly change in response to 
external stimuli. Additionally, faulty proteins are, in healthy systems, detected 
and rapidly degraded to limit the consequences of these defects.7 Protein 
degradation in eukaryotic cells is mediated by two major pathways: the ubiquitin 
proteasome system and lysosomal proteolysis.8 
The discovery of the ubiquitin proteasome system (UPS) was a landmark 
in the understanding of protein regulation in cells and its importance has been 
acknowledged with the award of the Nobel Prize in Chemistry to Avram 
Hershko, Aaron Ciechanover and Irwin Rose in 2004.9,10 Functioning of the 
UPS is dependent on the sequential action of three key players: the E1 
activating enzyme, the E2 conjugating enzyme and the E3 ligase enzyme 
(Figure 1.1). The role of the E1 enzyme consists of the activation of ubiquitin, a 
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highly abundant 76 amino acid protein, by forming a thioester bond with it 
through a cysteine residue. Next, activated ubiquitin is transferred to a cysteine 
residue in the active site of the E2 conjugating enzyme. Finally, the E3 ligase 
enzyme catalyses the transfer of ubiquitin from the loaded E2 enzyme to the 
substrate protein. Ubiquitin is linked to the substrate through an isopeptide bond 
between its C-terminal and a ε-amino group of a specific lysine of the target 
protein.10 
 
 
Figure 1.1 – The ubiquitin proteasome system. The ubiquitin proteasome system 
depends on the concerted action of three enzymes: the E1 activating enzyme, the E2 
conjugation enzyme and the E3 ligase enzyme. Ubiquitin (Ub) is activated by the E1 
enzyme and then transferred to the E2 enzyme. The E3 ligase catalyses the transfer of 
ubiquitin from the E2 enzyme to the substrate (S). 
 
The human genome encodes for two E1 enzymes, at least 38 E2 enzymes and 
over 600 E3 enzymes.11,12 The E3 ligases are responsible for recruiting the 
substrates to be ubiquitinated and confer specificity to the system. Proteins can 
be monoubiquitinated, multi-monoubiquitinated or polyubiquitinated and the 
ubiquitin chain can be linear, branched or mixed (Figure 1.2). The length and 
topology of the ubiquitin chain attached to the protein substrate greatly 
determines the cellular response triggered.13 The outcome of this tagging event 
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can vary from activation of the substrate for proteasomal or lysosomal 
degradation, to direct modulation of protein interactions, activity or protein 
localisation.13 
 
Figure 1.2 – Length and topology of the ubiquitin chain. The number of ubiquitin 
molecules as well as the way they are attached to the substrate determine the cellular 
response to this tagging event. Substrates can be monoubiquitinated once or multiple 
times and can be polyubiquitinated in a linear, branched or mixed fashion. 
 
1.2.1 Cullin RING E3 ubiquitin ligases 
Cullin RING E3 ubiquitin ligases (CRLs) are the focus of this work. They 
constitute one of the three main families of E3 ubiquitin ligases currently known. 
HECT and RBR E3 ligases are the other two families and despite all carrying 
out the last step of ubiquitination, the different classes vary in terms of structure 
and mechanism of ubiquitin transfer.14 Whilst CRLs catalyse the direct transfer 
of ubiquitin from the E2 conjugating enzyme to the substrate, HECT and RBR 
ligases contain themselves a catalytic cysteine that forms a thioester 
intermediate with ubiquitin prior to transfer to the substrate.15 CRLs, of which 
over 230 are estimated in human cells, are responsible for approximately 20% 
of the ubiquitin-dependent protein turnover in cells,16 being implicated in a 
number of cellular processes across different organisms (Figure 1.3).17 
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Figure 1.3 – Roles of CRLs in diverse cellular processes. CRLs are implicated in a 
variety of cellular processes in different organisms.  
 
Structurally, CRLs are organised around a central scaffold subunit, 
Cullin, that brings together the substrate to be ubiquitinated and the E2 enzyme 
loaded with ubiquitin. The substrate is recruited through a receptor subunit, 
whereas the E2 enzyme is recruited through the Rbx RING domain. There are 
seven characterised Cullin proteins, Cul1, Cul2, Cul3, Cul4A, Cul4B, Cul5 and 
Cul7 (Cul9 is the eighth member of the family, although little is still known about 
this protein) and each of them can assemble with a wide variety of receptors, 
originating E3 ligases that, despite sharing the scaffolding core, recruit different 
substrates.18 This combinatorial arrangement is a key aspect for these 
enzymes, accounting for their modularity and diversity of substrates that are 
ubiquitinated. Diversity and specificity are further increased by post-translational 
modifications (PTMs) that are often a requirement for substrate recognition by 
the CRLs, and in some cases other protein or small-molecule factors.16 Apart 
from the regulation of CRLs activity by PTMs, which dictate when ubiquitination 
occurs, other mechanisms are involved in the regulation of the catalytic core. 
For instance, the attachment of NEDD8, a ubiquitin-like protein, to a specific 
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lysine residue in Cullin (neddylation) is an important step in the activation of the 
enzymatic activity.19 Cullins undergo cycles of neddylation and de-neddylation 
as part of their function and regulation. Neddylation is accomplished by specific 
E2 enzymes that bind the RING domain of CRLs and transfer NEDD8 to Cullin, 
whereas de-neddylation is a reaction catalysed by the COP9 signalosome 
(CSN), also a large multi-subunit complex (Figure 1.4B).20 Once de-neddylated, 
CRLs are sequestered by binding of CAND1 (Cullin-associated NEDD8-
dissociated protein 1) that keeps them in an inactive state (Figure 1.4B).21,22 In 
Cul1, for example, CAND1 competes with the substrate receptor, Skp1, for 
binding and it binds only to unneddylated Cullin.23 
 
Figure 1.4 – Mechanisms of regulation of CRLs. A) De-neddylation by the COP9 
signalosome (CSN). B) Sequestering by CAND1 keeps Cullin in an inactive state. 
 
 
 The important roles of CRLs in several biological processes and human 
diseases have rapidly emerged, in particular in cancer, as the genes encoding 
for E3 ligase subunits and their native substrates are often found as oncogenes 
or tumour suppressors.24 These, amongst other motivations, justify the growing 
interest in this class of enzymes for research and therapy.25  
 
1.2.1.1 The VHL ligase: CRL2VHL 
The CRL complex investigated in this work is the VHL ligase, CRL2VHL. 
The central scaffold of the VHL ligase is Cul2, which recruits at the N-terminal 
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domain the von Hippel-Lindau protein (pVHL) as substrate receptor, through an 
adaptor subunit constituted by Elongin B (EloB) and Elongin C (EloC) and at the 
C-terminal domain the RING box protein, Rbx1 (Figure 1.5). 
 
 
Figure 1.5 – The CRL2VHL complex. A) Diagram model of CRL2VHL. B) Structural 
model of CRL2VHL. The pentameric complex is organised around the central scaffold, 
Cul2, which brings together the substrate and the E2 conjugation enzyme loaded with 
ubiquitin. The substrate (S), shown as HIF-1α peptide on B), is recruited by pVHL, 
which binds to the N-terminal domain of Cul2 through the adaptor subunit composed of 
EloB and EloC. The E2 enzyme is recruited to the complex through the RING domain 
of Rbx1. Model obtained using PBD 4AJY52 for VBC in complex with HIF-1α peptide. 
 
pVHL is a tumour suppressor protein. Mutation of both alleles of the VHL 
gene result in the von Hippel-Lindau syndrome, a relatively rare hereditary 
cancer syndrome characterised by a variety of tumours, being the most 
frequent hemangioblastomas of the central nervous system and retina, renal 
cells carcinoma and pheochromocytoma.26 While its function as the substrate 
receptor of CRL2VHL is the best characterised, studies suggest that pVHL has 
also E3 ligase independent functions, where it interacts and regulates other 
proteins such as fibronectin or collagen, for example, but does not promote their 
polyubiquitination and consequent degradation.27  
The dimer composed by EloB and EloC (EloBC) acts as an adaptor 
between the substrate receptor and the scaffold in Cul2 and Cul5 containing 
CRLs. Apart from its function in E3 ubiquitin ligases, EloBC forms a trimeric 
A) B) 
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complex with Elongin A (EloA), functioning as positive regulator of the RNA 
polymerase II.28 pVHL binds to EloBC through a conserved motif, referred to as 
BC-box. VHL disease and sporadic clear cell renal carcinoma are, in a large 
number of cases, promoted by deletion or mutation of the BC-box, precluding 
pVHL to bind EloBC.29  
Cul2 is the scaffolding core of the VHL ligase and has a vital role in cells, 
as supported by genetic evidence. It is anticipated that full knockout of Cul2 
may cause embryonic lethality, given that it is responsible for the ubiquitination 
and degradation of proteins with important functions in cell cycle and 
progression – and indeed there are no published studies with mouse knockouts 
of Cul2.30 Mouse knockouts of Cul1, Cul3, and Cul4B resulted in embryonic 
lethality, suggesting indispensable roles of these proteins during early 
development. Cul4A knockout resulted in skin carcinogenesis, proliferation 
defects and male infertility, whereas the knockout of Cul7 resulted in birth 
lethality. On the other hand, Cul9 knockout resulted in a viable embryo, 
suggesting this protein is not needed for embryonic development.30  
The last member of the complex, Rbx1, is a RING box protein essential 
for the catalytic activity of CRL2VHL and many other CRLs, being implicated in 
both neddylation and ubiquitination reactions. Rbx1 is essential during mouse 
embryonic development30 and is overexpressed in multiple human cancer 
tissues.31 Its function in the complex is to recruit the E2 conjugating enzyme 
loaded with NEDD8 or ubiquitin. Rbx1 has been also shown to function as 
NEDD8 ligase for Rub1 (the yeast homolog of NEDD8).32 
At least six proteins have been identified as substrates of the CRL2VHL 
complex.33 Sprouty2 (Spry2) regulates cell migration and proliferation in 
response to growth factors and is recognised by pVHL for degradation.34 
 
	
34 
Another known substrate is Rbp1, the largest subunit of the RNA polymerase II. 
Rbp1 is hydroxylated under oxidative stress conditions, recruited by pVHL and 
polyubiquitinated by the CRL2VHL complex. It is thought that after being 
ubiquitinated, the fate of Rbp1 is determined by the cellular context.35,36 
Similarly, another subunit of the RNA polymerase II, Rpb7, has been reported 
to be degraded after being polyubiquitinated by the VHL ligase.37 The atypical 
protein kinase C (PKC) is another identified substrate recruited by pVHL, which 
is equally polyubiquitinated and degraded by the proteasome. In addition, the 
epidermal growth factor receptor (EGFR), has also been shown to be targeted 
by the CRL2VHL ligase for degradation.38 The mediated degradation of the 
hypoxia inducible factor 1 alpha subunit (HIF-1α) is, however, the most widely 
studied and best characterised function of the CRL2VHL ligase. Oxygen 
concentration tightly regulates HIF transcriptional activity. Under normal levels 
of oxygen (normoxia) HIF-1α is efficiently hydroxylated by oxygen-dependent 
prolyl hydroxylase domain (PHD) enzymes at specific proline residues (Pro402 
and Pro564) within the so-called oxygen destruction domain (ODD) of HIF-1α, 
which functions as a degron.39 The hydroxyproline PTM is recognised via the 
β domain of pVHL and HIF-1α is recruited to the CRL2VHL complex to be 
ubiquitinated and targeted for degradation by the proteasome.40 Upon decrease 
of the oxygen levels (hypoxia), PHD activity is inhibited and HIF-1α is no longer 
hydroxylated, escapes E3 recognition and accumulates in the cell, triggering a 
transcriptional response to hypoxia.41 Stabilisation of HIF-1α in cells has proven 
beneficial in diseases such as chronic anaemia and acute ischemic disorders 
and for this reason the CRL2VHL complex is considered an attractive therapeutic 
target.42 Work by other members of the Ciulli laboratory has recently generated 
potent pVHL inhibitors using structure-guided drug design.43 Compound VH298 
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was characterised in cells as a highly selective inhibitor active on-target against 
pVHL, and elected as a chemical probe of the hypoxia signalling pathway.44 
Using these pVHL-targeting ligands as a starting point, bivalent molecules have 
been designed, which recruit proteins into proximity of the CRL2VHL to deplete 
protein levels inside cells and in vivo (Figure 1.6).45 Targeting CRL2VHL to 
induce protein degradation provides an attractive chemical biology approach for 
target validation46,47 and a new therapeutic modality in drug discovery.48 
 
Figure 1.6 – Targeting the CRL2VHL complex. A) Inhibitors of the pVHL-HIF-1α 
interactions. B) Bivalent molecules (proteolysis targeting chimeric molecules, 
PROTACs) that recruit specific proteins to the CRL2VHL complex to be ubiquitinated 
and targeted for degradation. 
 
1.3 Targeting protein-protein interactions  
Protein-protein interactions are involved in the control and regulation of 
cellular processes that range from enzyme catalysis to cell signalling and 
development and to protein homeostasis. PPIs have a strong influence in the 
cellular localisation and abundance of the proteins involved, and often 
determine the fidelity and specificity of their function.49 The highly organised 
and responsive protein networks that regulate most biological processes further 
underscore the importance of PPIs, providing many opportunities for 
therapeutic intervention. In fact, each PPI in such networks may play a role in 
physiological and pathophysiological states, and could thus represent a 
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prospective drug target with potential therapeutic relevance.50 In this context, 
the development of chemical tools or probes that can help the understanding of 
mechanisms and biological roles of specific PPIs is of extreme relevance. 
Despite the great research and therapeutic opportunities of targeting 
PPIs, the physicochemical nature of these interfaces makes it a challenge to 
develop small molecules that bind to these sites and potentially disrupt these 
contacts. PPIs can be classified according to their binding epitope as primary, 
secondary and tertiary.51 In primary PPIs, a linear peptide binds to a protein 
surface, and usually the binding event is driven by recognition of a PTM; in 
secondary PPIs, a peptide with secondary structure binds to a protein surface; 
and finally, tertiary PPIs involve multiple contact points and require a tertiary 
structure (Figure 1.7). 
 
 
Figure 1.7 – Classes of protein-protein interactions. A) Primary protein-protein 
interaction between HIF-1α peptide in yellow and pVHL in green (PDB: 4AJY).52 B) 
Secondary protein-protein interaction between MDM2 in cyan and p53 in blue 
(PDB: 1YCR).53 C) Tertiary protein-protein interaction between IL-2 in salmon and 
IL-2Rα in magenta (PDB: 1Z92).54 
 
Contrary to the more traditional binding sites defined at the active sites of 
receptors or enzymes, which tend to be buried from solvent and contain 
well-defined and deep pockets, PPIs usually involve flat surfaces of extended 
area, or in any case smaller pockets to merely accommodate protein side 
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chains.55 Therefore, the identification and development of binding ligands to 
protein surfaces, whether direct or allosteric modulators of PPIs, remains a 
difficult and unsolved problem. Fortunately, much progress has been made in 
recent years to tackle this issue. In particular, it is becoming increasingly clear 
that the development of drug-like PPI inhibitors, and small-molecule ligands to 
protein surfaces, greatly benefits from the availability of a peptidic ligand to that 
binding site, either from the natural interacting partner or from synthetic 
sources. 
 
1.3.1 Peptides as tools to explore PPIs and surfaces 
Peptides are good candidates to accomplish effective targeting of PPIs 
due to their ability to closely mimic many structural features of protein 
interfaces, as described above. Some remarkably successful examples of using 
peptides from the natural protein partner as a starting point to drug design 
include well-characterised systems such as MDM2-p5356,57 or pVHL-
HIF1α.43,52,58 Such peptidic ligands can inform on the nature and details of key 
interactions essential to achieve affinity and selectivity at the targeted binding 
site. They also provide important displacement tools to ensure specificity of 
interaction of compound series in ligand development processes. Furthermore, 
peptides constitute an interesting alternative in their own right as PPI 
modulators, presenting a number of advantages over non-peptidic small-
molecules: biocompatibility, and low toxicity to the organism; chemical flexibility, 
such as the ability to adapt to large and often flexible surfaces; modularity, thus 
enlarging the structural diversity, enhancing selectivity and leading to high 
potency.59 Notwithstanding, peptides present low stability in plasma, cleavage 
by proteolytic cellular enzymes and in vivo clearance by hepatic and renal 
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activities, which represent major drawbacks for their use as drugs, especially 
when compared to proteins, antibodies or drug-like compounds.60 These 
limitations are largely associated with the flexible conformation adopted by short 
peptides in solution. 
One way of stabilising the secondary structure of short peptides is by 
using a stapling approach.61 Stapled peptides involve cross-linking at different 
peptide positions bridging regions proximal in space, and are often designed 
based on the crystal structure of a certain PPI.62 Conformational stabilisation in 
particular of α-helical peptides by hydrocarbon stapling has proven successful 
in different systems with the resulting molecules acting as antiviral, antimicrobial 
and anticancer, modulators of signalling cascades and modulators of 
transcription and translation processes.61  
Another way of constraining the conformation of peptides and hence 
develop them into molecules with more adequate structural features and 
physicochemical properties for protein targeting is by covalent cyclisation. 
Cyclic peptides present favourable binding properties by reducing the entropic 
penalty upon binding. In addition, their large surface area provides opportunities 
to achieve high target binding affinity and selectivity.63 The constrained 
structure of cyclic peptides provides also increased proteolytic stability in vivo 
when compared to their linear counterparts.64 Cyclic peptides can present 
different formats and arrangements, therefore, the term is general and it 
encompasses several classes of peptidic molecules.65 Bicylic peptides, for 
example, are one of the cyclic peptides subclasses and can be obtained by the 
covalent attachment of two flexible peptidic loops onto a central rigid scaffold.66 
Generally, these peptides present improvements in binding affinities as well as 
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greater resistance to intracellular degradation and metabolic activities 
compared to monocyclic peptides. 67 
The potential of cyclic peptides is underpinned by the number of derived 
drugs being approved or in clinical studies by the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA), as is the case of 
oritavancin, an antibiotic for bacterial infections, or romidepsin, an anti-cancer 
agent, for example.63  
 
1.4 Biophysical techniques 
The interrogation and characterisation of PPIs and protein surfaces is a 
challenging aim that relies deeply on biochemical, biophysical and structural 
biology techniques.6 A brief introduction to the biophysical techniques used 
throughout this thesis to characterise protein-protein or ligand-protein 
interactions is given below. In-depth coverage of all techniques available to 
study PPIs and binding of small molecules is beyond the scope of this thesis, 
and the reader is referred to recent reviews on this topic.68,69 
 
1.4.1 Protein X-ray crystallography 
X-ray crystallography is an essential technique for structure 
determination of protein and protein-ligand complexes that relies on the 
scattering of X-rays by electrons. It requires the object of analysis to be 
crystallisable and to produce well-diffracting crystals.69 The result of the 
exposure of a crystal to X-rays is a diffraction pattern that holds information 
about the tri-dimensional structure of the protein or protein-ligand complex. 
Subsequent data processing allows the reconstruction of an electron density 
map that can be interpreted in terms of individual atoms and molecules. From 
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this interpretation, an atomic or molecular model can be generated and refined 
to reach the best agreement between the observed reflection amplitudes (Fobs) 
and those calculated from the model (Fcalc). This agreement can be evaluated 
by a number of indicators, being the one most widely used the crystallographic 
R-factor.70  
A critical aspect of X-ray crystallography that determines the extent of 
information retrieved from an experiment is the resolution at which the crystal 
diffracts X-rays. Typically, large molecules or large multi-subunit complexes 
diffract X-rays to resolutions greater than 3.5 Å, which constitutes a hindrance 
to the field, as solving and refining structures at low resolution is still a 
challenging task.71 However, the increasing number of low-resolution structures 
deposited in the Protein Data Bank (PDB) over the years proves the 
experimental and computational advances for structure determination that help 
tackling the problems associated with low-resolution data.72 Therefore, 
biological information that can only be obtained from low-resolution data is now 
valued and the threshold for acceptability has changed with a number of 
significant structures solved at low resolution, as is the case of the human DNA 
dependent protein kinase catalytic subunit (solved at 4.3 Å)73 or the structure of 
the human antibodies 100 and 114 in complex with the Ebola virus fusion 
glycoprotein (solved at 6.7 Å),74 for example. 
 
1.4.2 Differential scanning fluorimetry 
A differential scanning fluorimetry (DSF) experiment determines the 
thermal stability of a protein under certain conditions.  The protein solution is 
mixed with an environmentally-sensitive fluorescent dye, SyproOrangeTM, and 
the temperature of the sample is increased gradually, typically from 25 to 95 °C. 
 
	
41 
This is monitored by continuous fluorescence readings. Once the protein is 
denatured, it unfolds and exposes hydrophobic surfaces. The dye binds 
non-specifically to these hydrophobic patches, leading to an increase in the 
measured fluorescence (relative fluorescence units, RFU). The plot of RFU 
versus temperature originates a typically sigmoidal curve. The melting 
temperature (TM) is defined as the temperature at which half of the protein is 
denatured and can be calculated as the inflection point of this curve – or the 
minimum of the derivative function (-dRFU/dT). In the presence of a stabiliser, 
the TM of a protein is expected to increase and vice-versa, a destabiliser 
decreases it.75 
 
1.4.3 Isothermal titration calorimetry  
Isothermal titration calorimetry (ITC) is a label-free technique that allows 
the thermodynamic characterisation of bimolecular interactions. The principle 
relies on the direct measurement of the heat absorbed or released upon the 
mixing of two solutions, each containing one species of interest. If the two 
species bind to each other, the measured heat signal will include a contribution 
from the binding event. By measuring the heat change throughout a titration, 
ITC enables direct and accurate determination of the binding constant (Ka), the 
stoichiometry of the reaction (N value), and the change in enthalpy (ΔH). The 
change in entropy (ΔS) can then be calculated from ∆𝐺 =  ∆𝐻 − T∆𝑆 . 
Altogether, these parameters provide a full thermodynamic profile for a given 
interaction.76  
1.4.4 Nuclear magnetic resonance 
Nuclear magnetic resonance (NMR) is a powerful technique that enables 
the study of ligand-protein interactions over a wide range of affinities. In this 
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technique, changes in the chemical shift, nuclear overhauser effects (NOEs), 
diffusion constants or relaxation times are measured and used to inform about 
the nature of a certain bimolecular interaction. The experiments can be 
ligand-observed or protein-observed, depending on which resonances are 
being monitored. In both cases, the resonance peaks are analysed and 
expected to change as a result of a binding event (Figure 1.8).77  
 
 
Figure 1.8 – Nuclear magnetic resonance experiments. A) Ligand-observed NMR. 
Example of a CPMG experiment - in the presence of a protein that binds the ligand, the 
signal of the ligand is expected to decrease in intensity. B) Protein-observed NMR. 
HSQC spectra, in which peaks corresponding to N-H groups of residues affected by 
the binding of a ligand are shifted compared to a reference spectrum. 
 
Despite the existence of several ligand-observed experiments, only one 
was used in this work: relaxation-edited Carr-Purcell-Meiboom-Gill (CPMG). 
CPMG relies on the different re-orientational frequencies of small-molecules 
and macromolecules in solution (which result in different T2 transverse 
relaxation times). Upon binding of a protein to a small molecule, the relaxation 
time of the latter decreases. This is translated in a reduction of the 
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small-molecule signal in a spectrum of sample containing protein-ligand 
complex relative to a spectrum of the small molecule alone (Figure 1.8A).78  
Protein-observed NMR relies on changes in the chemical environment of 
interacting protein residues upon a binding event, that translate into a change in 
the chemical shift of the residues involved in the interaction. In order to monitor 
the changes in the chemical shifts of the target protein, a two-dimensional 
1H-15N heteronuclear single quantum coherence (HSQC) spectrum is recorded 
in the absence (reference) and in the presence of a ligand. The residues 
affected by the binding of the ligand to the protein will present a different 
chemical shift than in the reference spectrum (Figure 1.8B). These changes, 
known as chemical shifts perturbation (CSP) allow the mapping of a binding site 
on a protein, as long as the peaks are assigned to the corresponding residue.79  
 
1.4.5 Biolayer interferometry 
Biolayer interferometry (BLI) is a label-free technique that relies on the 
principle of optical interferometry. BLI measures molecular interactions by 
analysing the interference pattern of white light reflected from two surfaces – a 
layer of immobilised protein on the biosensor tip and an internal reference layer. 
Changes in the number of molecules bound to the biosensor tip cause a shift in 
the interference pattern that can be measured in real-time. Only molecules 
binding or dissociating from the biosensor are able to shift the interference 
pattern and thus generate a response – unbound molecules or changes in the 
refractive index of the surrounding medium do not affect the interference 
pattern. From measuring dose-response curves it is possible to extrapolate a 
binding affinity (Kd) for a particular interaction. In addition, BLI experiments can 
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provide useful kinetic parameters such as on and off-rate constants (kon and 
koff).80 
 
1.4.6 AlphaLISA 
In the alphaLISA experiments (amplified luminescent proximity 
homogeneous assay) two interaction partners are individually attached to donor 
and acceptor beads. Upon irradiation with light at 680 nm, the donor beads, 
containing a photosensitiser (phtalocyanine), produce singlet oxygen excited 
state (1O2) from environment oxygen (O2). Singlet oxygen diffuses up to 
approximately 200 nm during its half-life time of approximately 4 µs. When the 
two partners are brought together in space by binding to each other, the beads 
come to proximity and the singlet oxygen reacts with a thioxene moiety in the 
acceptor bead, resulting in emission of light at around 615 nm (Figure 1.9A).81 
AlphaLISA can be used for measuring direct interactions between partner 
molecules, however, the multiplicity of the bead derivatisation generates 
multiple binding sites close to each other and, as a result, multivalent 
interactions that artificially increase the signal but also the affinity between 
binding partners. This makes the technology unsuitable to measure accurately 
direct binding Kd values between partners attached to the beads (Figure 1.9A), 
however, it makes it ideal to develop screening assays as competitive 
experiments (Figure 1.9B). In this format, a competitor ligand is titrated to 
measure its ability of disrupting the interaction between the two bead-bound 
partners. Upon effective displacement, decrease in the intensity of the signal is 
observed, since the beads are taken apart by the displacer. This allows the 
measurement of an IC50 value, defined as the concentration at which half of the 
displacement has occurred. 
 
	
45 
 
 
Figure 1.9 – AlphaLISA principles. A) Direct experiment. Upon interaction, A and B 
bring the beads together. The donor bead is excited with light at 680 nm and transfers 
singlet oxygen to the acceptor bead that emits luminescence at 615 nm. B) 
Competition experiment. In the presence of a competitor (C), B no longer binds to A, 
the beads are not close in proximity and there is reduced emission of light by the 
acceptor bead, resulting in a loss of signal.  
 
1.5 Prior art 
Prior work in the Ciulli laboratory has led to the identification of two novel 
binding sites in the trimeric subunit of the CRL2VHL complex constituted by 
pVHL, EloB and EloC (VBC) that are distinct from the HIF-1α binding site 
(Figure 1.10). These binding sites were identified in a fragment screening 
campaign that resulted in the crystal structures of three fragments in complex 
with VBC being solved (work by Dr. Inge van Molle, University of Cambridge). 
One of the binding sites was located on pVHL and the other one was located on 
EloC in an interface that, at the time, was thought to be involved in the 
interaction with Cul2 (Figure 1.9), based on the expected structure analogy with 
other CRL complexes for which structures were available then. This hypothesis 
was confirmed upon the release of the quaternary structure of Cul21–163–VBC 
(PDB: 4WQO)82 in 2015, during the course of this project. Work is undergoing 
on the development and optimisation of these fragments by other members of 
the laboratory. 
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Figure 1.10 – VBC binding sites. Two new binding sites identified in the VBC subunit 
of the CRL2VHL complex in a fragment screening campaign.  
 
This encouraging discovery elucidated two potential ligandable sites, 
other than the HIF binding site, in VBC and motivated efforts of further 
understanding how targeting these sites, or other new binding sites, would 
influence the CRL2VHL complex. The combination of the advantages of using 
peptides to target proteins with the previous success in the laboratory in 
developing potent modulators of the pVHL-HIF-1α interface designed from a 
peptide-bound structure reasoned the choice of peptides to probe these 
surfaces. Thus, a multi-disciplinary approach was devised to understand and 
chemically probe the CRL2VHL complex, as model system of the multi-subunit 
Cullin RING E3 ligases family. 
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1.6 Aims 
The aims of this project can be summarised in three main points:  
1) To gain structural and biophysical insights into the CRL2VHL ligase 
complex and contribute to a better understanding of its assembly, interaction, 
dynamics and functioning as a protein complex. 
2) To exploit the gained structural and biophysical knowledge as basis to 
design peptide-like chemical probes to explore the ligandability of the Cul2-VBC 
interface. 
3) To probe protein surfaces within structural components of the VHL 
ligase with the ultimate goal of modulating protein-protein molecular recognition 
within the protein complex. 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2  
STRUCTURAL AND BIOPHYSICAL INSIGHTS INTO THE  
CRL2VHL MULTI-SUBUNIT PROTEIN COMPLEX 
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2.1 Introduction 
Cullin RING E3 ubiquitin ligases (CRLs) are the major subfamily of E3 
ligases, enzymatic machineries that catalyse the transfer of ubiquitin from an E2 
conjugating enzyme to a target substrate. Cullin is the core subunit of the CRL 
complexes and acts as a scaffold that brings to proximity the substrate and the 
E2 conjugating enzyme. The substrate is recruited by the receptor and the E2 
enzyme loaded with ubiquitin is recruited by the RING finger protein.83 All cullins 
present an elongated N-terminal domain (NTD) linked to a globular C-terminal 
domain (CTD).18 The information available on this important family is limited by 
the existence of crystal structures of full length protein only of Cul1,84 Cul4A85 
and Cul4B.85 In addition, there are also structures for partially assembled 
components and there are several structures of portions of other Cullin proteins 
i.e. NTD or CTD alone or in complex with other subunits. However, the only 
structures available of whole CRL complexes are those of CRL4ADDB2 (ref. 85), 
CRL4BDDB2 (ref. 85), and CRL1Skp2 (ref. 84). This lack of structural information 
restricts the full understanding of the mechanisms of activity and functioning of 
CRL multi-subunit molecular machines. Structural insights are critical also for 
drug discovery, as they can provide the basis for exploring PPIs with 
small molecules and modulate their function.86 For instance, the structural 
knowledge of PPIs within certain CRLs has facilitated the ability to hijack E3 
ligase complexes into recruiting non-natural selective substrates for 
ubiquitination and subsequent proteasomal degradation.45,87,88  
The aim of the work presented in this chapter was to gain structural 
insights on the mechanisms of functioning of the CRL2VHL and to understand the 
driving forces of particular PPIs within the complex. It is described the use of 
X-ray crystallography to unveil the first structure of the CRL2VHL complex to 
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3.9 Å resolution and the characterisation of the Cul2–VBC interaction, using 
biophysical techniques such as AlphaLISA and ITC. Residues that are critical 
for the strength of the Cul2–VBC PPI were identified and the basis for the 
selectivity of CRL2VHL for Cul2 over Cul5 was also explored.  
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2.2 Results 
2.2.1 Protein expression and purification 
The CRL2VHL complex was assembled by mixing a trimeric subunit 
composed of pVHL, EloB and EloC (VBC) with a dimeric subunit composed of 
Cul2 and Rbx1. The choice to express the pentameric complex as two separate 
subunits was supported by the availability of protocols for the expression and 
purification of these components.  
VBC was expressed in E. coli according to a previously published 
protocol.52 Briefly, BL21(DE3) E. coli bacteria were co-transformed with a 
plasmid for the expression of pVHL with a hexahistidine tag at its N-terminus 
and a second plasmid for the expression of both EloB and EloC. Co-expression 
of these three proteins resulted in VBC complex formation that was then 
purified by affinity chromatography, followed by ion-exchange chromatography 
and, finally, by size-exclusion chromatography. During the purification process 
the hexahistidine tag was removed by cleavage with TEV protease. Following 
this protocol, VBC was purified routinely with an estimated purity above 95% 
and with a yield of about 15 milligrams per litre of culture.  
The Rbx1–Cul2 heterodimer subunit was co-expressed in a baculovirus 
system in Sf21 insect cells. The pFastBacDual plasmid containing Rbx1 and 
Cul2 with a N-terminal Dac tag (affinity tag based on penicillin-binding protein 5 
that binds ampicillin)89 was a gift from Dr. Mark Peggie (DSTT). This plasmid 
was transformed into DH10Bac E. coli cells in order to generate the bacmid and 
the colonies containing the bacmid were selected by blue/white screening. The 
isolated bacmid was then transfected into Sf21 cells in adherent cell culture and 
the P0 virus was harvested after seven days of culture. The cell pellet was used 
to confirm the success of the transfection through assessing the expression of 
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Cul2 by immunoblot. The virus stock was amplified by infecting Sf21 cells in 
suspension cell culture with the P0 virus. The cells were incubated for five days 
at 26.5 °C, with moderate shaking (130 rpm) in the dark and after this time the 
supernatant was collected (P1 virus) and stored at 4 °C in the dark. Protein 
expression consisted in infecting Sf21 cells in suspension cell culture at a 
density of 1.5 million cells/ml with 1:100 P1 virus, followed by incubation of 
three days in the dark, at 26.5 °C and with moderate shaking (130 rpm). The 
amount of virus used for infection and the length of incubation were optimised in 
order to obtain the highest amount of protein. The Rbx1–Cul2 purification 
protocol was based on a protocol developed by Dr. Axel Knebel and Clare 
Johnson (MRC-PPU/DSTT), and it has been slightly optimised to improve the 
yield and quality of the protein by modifying lysis buffer and lysis method and by 
introducing a gel filtration step. After harvesting the cells by centrifugation and 
lysis by French press method, the Dac tag-containing Cul2 in complex with 
Rbx1 was isolated from the cell lysate using ampicillin-modified sepharose 
resin. The Dac tag was then cleaved with TEV protease while the complex was 
bound to the resin. Rbx1–Cul2 was recovered through filtration and the filtrate 
was purified through gel filtration chromatography, in order to isolate monomeric 
Rbx1–Cul2 (Figure 2.1). The yield varied from 0.4-2.5 milligrams of protein per 
litre of culture. 
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Figure 2.1 – Purification of Rbx1–Cul2 by size-exclusion chromatography. 
Chromatogram resulting from Rbx1–Cul2 purification on a HiLoad 16/600 Superdex 
200 gel filtration column. The first peak is eluted in the void volume and corresponds to 
aggregated Rbx1–Cul2, the second peak corresponds to monomeric Rbx1–Cul2 and 
the following peaks correspond to lower molecular weight contaminants. The 
Rbx1-Cul2 sample is obtained with a high degree of purity, as confirmed by the 
SDS-PAGE. 
 
2.2.2 Crystal structure of the CRL2VHL 
The CRL2VHL complex composed by Cul2, EloBC, pVHL and Rbx1 was 
re-constituted by mixing VBC and Rbx1–Cul2, and purifying the pentameric 
complex by size exclusion chromatography (Figure 2.2). The appearance of a 
new peak eluting earlier than Rbx1–Cul2 suggested the formation of the 
pentameric   Rbx1–Cul2–VBC complex. This was confirmed by SDS-PAGE that 
showed the presence of the five subunits under the same chromatographic 
peak. Separately, the same complex was prepared in the presence of a 
HIF-1α 19-mer peptide (residues 559-577) bound to pVHL, mimicking one of 
the natural substrates of the CRL2VHL ubiquitin ligase. 
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Figure 2.2 – Co-elution gel filtration of the CRL2VHL complex. Elution profile from an 
analytical Superdex 200 Increase gel filtration column. 7.5 µM VBC (purple), 5 µM 
Rbx1–Cul2 (yellow) and a mixture of 7.5 µM VBC and 5 µM Rbx1–Cul2 (green) and 
corresponding SDS-PAGE. The elution profile of the mixture of VBC and Rbx1–Cul2 
supported by the SDS-PAGE confirms the formation of a pentameric complex. 
 
The sample was concentrated and used to set up crystallisation 
screenings (JSCG+ from Qiagen and ProPlex from Molecular Dimensions) of 
both complex forms (with and without the HIF-1α 19-mer peptide). Hit 
conditions were identified for the HIF-1α containing complex in the two 
screenings. The hits were reproduced and one of the initial conditions was 
followed up and optimised by grid screening, additive screening and 
introduction of streak seeding. In the final condition, promising diffracting 
crystals were obtained at 20 °C within two days, in a crystallisation solution 
containing Tris pH 7.6, ammonium sulphate, PEG4000 and 1,4-dioxane or 
acetonitrile (Figure 2.3). Despite diffracting X-rays, the crystals obtained were, 
to some extent, elastic and fragile. A number of cryoprotectant solutions were 
tested in an attempt to improve the quality of the data collected and 20% (v/v) 
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2-methyl-2,4-pentanediol (MPD) in the mother liquor was identified as the most 
adequate cryoprotectant based on the quality of the diffraction. The dataset for 
crystals of the CRL2VHL complex that led to solving the structure of the complex 
was collected at the Diamond Light Source synchrotron and the crystal 
diffracted X-rays up to 3.9 Å. Despite numerous efforts to improve the quality of 
the crystals and of the datasets collected, this was the best result obtained. The 
Matthews coefficient90 calculation retrieved a solvent percentage of 63.9%, 
consistent with the presence of one protomer per asymmetric unit arranged in a 
C2221 space group (Table 2.1).  
 
 
Figure 2.3 – Optimisation of crystallisation conditions. Process of optimisation of 
the CRL2VHL crystals from the initial hit condition to the crystals used for data collection. 
 
The structure was solved at 3.9 Å using a combination of molecular 
replacement (MR) and iterative rounds of model building and refinement. An 
homology model of Cul2 (obtained through Chimera)91 based on the structures 
of Cul1, Cul4, Cul5NTD and Cul5CTD (PDB’s 1U6G,92 4A0K,85 4JGH,93 3DPL,19 
respectively) was used as template model to find a molecular replacement 
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solution for the structure of Cul2 in MrBUMP.94 Next, EloBC dimer was placed 
by MR in Phaser,95 using as a template the corresponding subunits from a 
VBC–HIF-1α structure (PDB 4AJY)52. By then, in the region corresponding to 
the Rbx1 N-terminal tail (residues 17-35) clear unmodelled electron density 
could be observed. This region is conserved in all Cullin-bound Rbx1 structures 
available in the PDB, allowing its correct positioning into the structure. This was 
followed by the identification of the RING domain of Rbx1 by MR using as 
template an existing Rbx1 structure (PDB 2LGV)96 in Phaser. Other models of 
the Rbx1 RING domain based on structures in complex with other Cullins were 
also tried as templates for MR, but yielded no or unsatisfactory results, in which 
the solutions were not appropriately fitting the electron density. The area where 
pVHL was expected to be found, according to the previous structure of VBC in 
complex with Cul21-163,82 was, at this point, filled with patches of positive 
electron density. However, fitting in a complete model of pVHL proved quite 
challenging and despite various attempts at molecular replacement using a 
diversity of template models, no reasonable solution was found. Nonetheless, 
the electron density corresponding to the three helix cluster structure of the 
VHL-box97 was unambiguous and allowed the manual fitting of this region that 
is conserved in all the available crystal structures. Unfortunately, for the 
remaining residues (54-156) constituting the substrate-binding domain of pVHL, 
and for the 19-mer HIF-1α peptide no electron density was observed. 
 
 
	
59 
Table 2.1 – Data collection and refinement statistics. Statistics in parentheses 
indicate those for the highest resolution shell. 
 
 
The above described steps were intercalated with rounds of refinement 
in Refmac598 and Phenix99 and map sharpening by negative B-factor correction 
was performed to improve the quality of the electron density maps and facilitate 
successful model building (Figure 2.4B).100 Correctness and quality of the MR 
solutions were assessed by the MR score and by visual inspection of the 
solution, considering the adequate fitting to the electron density and packing of 
Wavelength  (Å) 0.9282
C2221
Rmerge (%) 11.4 (73.2)
I/σ(I) 10.2 (2.2)
100 (100)
5.7 (5.3)
0.857 (0.798)
18326
30.15/34.61
Average B factor  (Å2) 191
7734
0.003
0.692
Ramachandran analysis
   Preferred regions (%) 90.65
   Allowed regions (%) 9.13
   Outliers (%) 0.22
   α, β, γ (o) 90, 90, 90
Data collection
Space group
Cell dimensions
   a, b, c (Å) 86.0, 191.0, 238.9
95.48 - 3.9
Unique reflections
Rwork/Rfree (%)
Molecules/ASU 1
Resolution (Å) 95.48 - 3.90 (4.27 – 3.90)
Completeness (%)
Redundancy
No. non-hydrogen atoms
R.m.s. deviations
   Bond lengths (Å)
   Bond angles (o)
CC (1/2)
Refinement
Resolution (Å)
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the structure. Throughout the molecular replacement, docking and refinement 
rounds, the Rwork and Rfree values were considered to evaluate the 
appropriateness of the resulting models.  
The CRL2VHL structure forms extensive crystal contacts with eight 
symmetry related molecules. The crystal contacts’ surface extends through an 
area of ~ 3300 Å2, which corresponds to about 60% of the surface area of the 
whole complex (~ 5200 Å2). Cul2 is contacting four Cul2 symmetry molecules 
and two Rbx1 subunits from two of these symmetric molecules, establishing 21 
hydrogen bonds and 5 salt bridges and accounting for the most extensive area 
of crystal contacts. The VHL box packs against another VHL box from a 
symmetric molecule, while the EloBC subunit is not extensively involved in any 
crystal contacts. Lastly, the Rbx1 RING domain establishes mainly hydrophobic 
crystal contacts with Rbx1–Cul2 from another asymmetric unit (ASU). These 
contacts extend through an area of ~ 360 Å2, which corresponds to about 17% 
of the total area of interface of Rbx1 with Cul2 (~ 2100 Å2). 
The final model (PDB: 5N4W) is constituted by the full-length Cul2 
binding Rbx1 at the C-terminal domain and the VHL-box-EloBC at the 
N-terminal domain, revealing for the first time the whole Cul2 structure and the 
interface between Rbx1 and Cul2. 
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Figure 2.4 – Crystal structure of the CRL2VHL complex. A) Diagrams of the primary 
structure of each of the protein subunits, illustrating the constructs (coloured bars) used 
to obtain the crystal structure. B) Representation of the 2Fo−Fc electron density 
contoured at 1σ over a portion of the model with the backbone and side chains shown 
in green. C) Crystal structure of the CRL2VHL where each of the protein subunits are 
identified; Cul2 is divided in N-terminal (NTD) and C-terminal (CTD) domain and the 
NTD is composed of three helical bundles, constituted by five α-helices (A-E). D) The 
three helical bundles of the NTD are superimposable with a maximum RMSD of 4.5 Å 
over the Cα. E) The CTD of Cul2 is organised in a four-helical bundle (4HB) motif 
(helices H20-H23), an α/β domain (helices H24, H25 and H29) and a winged-helix 
motif, WH-B (helices H29-H31). Rbx1 binds to the CTD and functions as recruiter of 
the E2 conjugating enzyme to the complex. 
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2.2.2.1 Cullin-2 structure highlights its inherent flexibility 
The structure of Cul2 in the CRL2VHL reveals a similar architecture to 
structures of other Cullins. It is characterised by the classical elongated shape 
divided in two main domains: the Cullin NTD that recruits the substrate-binding 
domain through an adaptor subunit and the CTD, a globular domain that binds 
Rbx1, which in turn recruits the E2 conjugating enzyme to the complex. 
Residues 1-384 are comprised in the NTD and arranged in three helical 
bundles (also called Cullin repeats) each composed of five α-helices. These 
three Cullin repeats superpose with a root mean square deviation (RMSD) for 
the Cα atoms of up to 4.5 Å (Figure 2.4D). The CTD (residues 385-745), at the 
other end, is organised in a four-helical bundle (4HB) linked to the NTD, an α/β 
domain and a winged-helix motif (WH-B) – Figure 2.4E. Some residues at the 
CTD (625-634 and 645-660) were disordered and could not be modelled in the 
structure. 
Cul2 was one of the few members of the Cullin-family lacking structural 
information on the full NTD. By superposing all the existing structures of 
complete Cullin NTDs the flexibility of this domain becomes evident 
(Figure 2.5). It was observed that all the NTDs align most closely through the 
second Cullin repeat, showing considerable differences in their first and third 
helical bundles’ relative position, which is consistent with intra-domain bending 
motion (Figure 2.5A). Additionally, the structural alignment of full-length Cul1, 
Cul2 and Cul4A highlights an interesting difference on how the CTD is packed 
against the NTD in each of the structures (Figure 2.5B-C). The globular domain 
in Cul2 is substantially moved towards the NTD in regards to other Cullins. The 
distances between the very top residue at the CTD (the Lys that gets modified 
with NEDD8 i.e. Lys689 in Cul2, Lys720 in Cul1 and Lys705 in Cul4) and the 
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top residue in helix α1 of the NTD (Phe10 in Cul2, Leu17 in Cul1 and Thr62 in 
Cul4) are at least 10 Å shorter in Cul2 (100 Å for Cul2, 110 Å for Cul1 and 
113 Å for Cul4). Cul1CTD is rotated by 29o compared to Cul2CTD, whereas 
Cul4CTD presents an angle of rotation of about 33o compared to Cul2CTD. 
Flexibility of Cullins is deemed essential for the mechanism of 
polyubiquitination of substrates.101 The structural analysis of Cul2 underpins the 
previously reported flexibility of the scaffold and suggests that non-neddylated 
Cul2, alike the other non-neddylated Cullins, presents a closed state 
conformation. 
 
Figure 2.5 – The CRL2VHL complex is dynamic and flexible. A) Superposition of the 
crystal structures of the full NTD of Cul1 (PDB 1U6G),92 Cul2 (PDB 5N4W), Cul3 (PDB 
4HXI),102 Cul4A (PDB 4A0K),85 Cul4B (PDB 4A64) and Cul5 (PDB 4JGH)93 illustrating 
the existence of hinge points in the linkers between cullin repeats. B) Full length 
structures of Cul2, Cul4A and Cul1 superimposed by the CTDs reveal considerable 
inter-domain flexibility through a hinge point between NTD and CTD. In the Cul2 
structure the CTD is considerably closer to the NTD than in other cases. C) Close up 
view of the CTDs of Cul1, Cul2 and Cul4A when the proteins are aligned by the third 
cullin repeat of the NTD illustrating the different relative orientations of the CTDs in the 
full-length structures. 
 
 
Lys 
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2.2.2.2 Rbx1 presents a new orientation 
The Rbx1 structure is composed of an N-terminal tail arranged in a long 
β-strand engaging the Cullin CTD and a variant RING finger domain. The 
variant RING presents an extended region containing a third zinc ion 
coordinated by three cysteines and one histidine, in addition to the canonical 
region containing two zinc ions.84 The structure and position of the N-terminal 
tail of Rbx1 in the complex are highly conserved amongst different CRL 
structures. Van der Waals contacts mainly established by Phe22 and Trp27 
anchor the β-strand of Rbx1 to Cullin CTD. On the contrary, the RING domain is 
flexible and it has been found in a number of different orientations, even in 
different molecules within the same asymmetric unit of a previously solved 
crystal structure.19 Interestingly, the conformation of Rbx1 in the structure 
presented here was unprecedented. The observation of minor crystal contacts 
formed by Rbx1, as described in section 2.2.2, supports that the observed 
conformation of Rbx1 captures a significantly populated conformation in 
solution. It sits between Rbx1-Cul5~NEDD8 and Rbx1-Cul5 conformations 
resembling a transient state en route amid the two (Figure 2.6). The flexibility 
associated with the RING domain has been studied before with the intent of 
elucidating the structural and mechanistic details of the catalytic activity of RING 
ubiquitin ligases.19,84,92,103-105 It has been demonstrated that the RING domain 
dramatically re-orients its position relative to Cullin upon neddylation of Cul5.106 
This conformational change could be considered as an adaptation of the 
enzyme prior to ubiquitination. The area of interface between Rbx1 and Cul5 
(1707 Å2), in this so-called open conformation, is contributed solely by the 
N-terminal tail (Table 2.2). In fact, the total areas of interface between Rbx1 and 
the different Cullin subunits differ in regards to the orientation of the Rbx1 RING 
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domain (Table 2.2). In this new crystal structure, the linker between the 
N-terminal tail and the RING domain, albeit not completely extended, is not fully 
retracted either and the Rbx1–Cul2 PPI covers an area of about 2100 Å2. Such 
interface area is greater than in the Rbx1–Cul5~N8 and in the Glomulin–Rbx1–
Cul1 complexes but smaller in comparison to any of the other structures (Table 
2.2). 
These findings suggest a probable trajectory of the Rbx1 RING domain 
from the non-neddylated to neddylated forms of the complex, en route to the 
fully active E3 ligase.  
 
Figure 2.6 – Rbx1 presents a new orientation. Superposition of the CTDs of six 
cullins - Cul1 (PDB: 1U6G),92 Cul2 (PDB: 5N4W), Cul4 (PDB: 4A0C),85 Cul5 
(PDB: 3DPL),19 Cul5~NEDD8 (PDB: 3DQV),19 Glomulin-Rbx1-Cul1 (PDB: 4F52)107 - 
complexed with Rbx1. The new structure of Rbx1 in complex with Cul2 unveils a novel 
orientation of its RING domain, resembling an en route conformation between 
Rbx1-Cul5 and Rbx1–Cul5~NEDD8. 
Table 2.2 – Different areas of interface in different Rbx1–Cullin complexes. The 
areas of interface were calculated (PISA) as well as the rotation angle and shift along 
the rotation axis (Chimera), and compared to previously published structures. 
 
Interaction pair Area of interface Rotation angle Shift along the axis PDB
(Å2) 	(o) (Å)
Rbx1-Cul5~NEDD8 1707 124 10.2 3DQV
Rbx1-Cul2 2122 - - 5N4W
Rbx1-Cul5 2307 118 -1.1 3DPL
Rbx1-Cul4 2708 118 -1.9 4A0C
Rbx1-Cul1 3396 114 -3.4 1U6G
Glomulin-Rbx1-Cul1 1718 138 17.1 4F52
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2.2.2.3 The interface between Cul2 and VBC 
The Cul2–VBC interface is spread across three contact regions 
(Figure 2.7A). The first comprises the N-terminal loop of Cul2, which assumes a 
role in stabilising the interaction by establishing critical hydrophobic contacts 
(Figure 2.7B), with Leu3 enclosed in a hydrophobic pocket on EloC (delineated 
by Met105 and Phe109) and Pro5 involved in contacts with Val181 in pVHL and 
Met105 in EloC (Figure 2.7B). The importance of residues belonging to the N-
terminal loop in this PPI is observed in Cul2 and Cul3.102 The second region of 
interaction involves charge complementarity at the interface between helix α5 of 
Cul2 and the substrate receptor, with Lys159 (pVHL) forming an hydrogen bond 
with Gln111 (Cul2) and Asp187 (pVHL) establishing a salt bridge with Lys114 
(Cul2, Figure 2.7C). These electrostatic contacts were thought to be responsible 
for the selective recruitment of Cul2 over Cul5 to this complex.82 In the last area 
of interaction, helix α2 of Cul2 is packed against pVHL and EloC surfaces, with 
residues Asn36, Phe39, Tyr43 and Val47 contributing to form a mainly 
hydrophobic interface (Figure 2.7D). There is no direct interaction between EloB 
and Cul2. The total buried surface areas of the Cul2–VBC PPI and the 
orientation of the VHL-box-EloBC relative to Cul2 are in agreement with those 
observed in the quaternary structure of Cul2NTD (Figure 2.8 and Table 2.3). 
Moreover, superposition of the two structures results in an RMSD of 0.866 Å for 
the Cα atoms, suggesting a structurally rigid and conserved interface. 
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Figure 2.7 – The Cul2–VBC interface. A) Contacts between Cul2NTD and VBC. As in 
similar CRL complexes, helix α2 of Cullin is the closest to the adaptor and substrate 
receptor subunits, establishing, predominantly, hydrophobic contacts. B) The 
N-terminal tail of Cul2 plays a substantial role in the PPI. Leu3 is accommodated in a 
hydrophobic pocket on the surface of EloC and Pro5 is involved in a three-way 
interaction between Val181 from pVHL and Met105 from EloC. C) Residues Asp187 
and Lys159 in pVHL establish an electrostatic network with residues Lys114 and 
Gln111 in the helix α5 of Cul2. D) Residues Asn36, Phe39, Tyr43 and Val47 participate 
in hydrophobic contacts at the interface between helix α2 and EloC and pVHL. 
 
 
Figure 2.8 – Superposition of the structures of Cul21-163–VBC and CRL2VHL. The 
structure of the CRL2VHL complex (yellow) is superposed with the quaternary structure 
of Cul21-163–VBC (cyan). The structures align with and RMSD of 0.866 Å over the Cα 
atoms. 
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Table 2.3 – Comparison of the areas of interface between Cul2 and VBC in the two 
structures available. 
 
 
2.2.3 Neddylation of the CRL2VHL complex 
It is well established that the attachment of a ubiquitin-like molecule, 
NEDD8, to the CTD of Cullin is required for activation of the ligase activity.23,108-
111 It is not clear, however, whether the neddylation happens before of after 
substrate recruitment. To assess this, an in vitro neddylation assay112 was 
performed in the presence and in the absence of the HIF-1α 19-mer peptide. 
The E1 and E2 reagents and the protocol were provided by Dr. Axel Knebel 
(MRC-PPU/DSTT). In this experiment, two E2 conjugating enzymes were 
tested, UBE2M and UBE2F. The neddylation reaction was incubated for two 
hours at 37 °C and the samples were then analysed by SDS-PAGE 
(Figure 2.9). The bands corresponding to Cul2 were confirmed by immunoblot. 
PDB pVHL-Cul2 EloC-Cul2 Total
4WQO 322 944 1270
5N4W 328 1022 1350
Buried surface area involving Cul2 interfaces (Å2)
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Figure 2.9 – Neddylation assay. A neddylation assay was performed with Rbx1–Cul2, 
CRL2VHL and CRL2VHL:HIF as substrates to evaluate the importance of the presence of 
the CRL2 substrate for the reaction to occur. Two E2 conjugating enzymes were 
tested, UBE2M and UBE2F. UBA3-APP-BP1 corresponds to the E1 enzyme. 
 
The results showed that all the substrates for neddylation i.e. Rbx1–Cul2, 
CRL2VHL and CRL2VHL:HIF were converted to the neddylated form in the 
presence of either of the two E2 enzymes tested. Although unlikely to happen in 
vivo, Cul2 is neddylated in the absence of VBC in vitro.113 Having that in mind, 
in this in vitro assay, no difference was observed in the neddylation profile of 
the CRL2VHL complex in the presence or in the absence of the substrate-like 
peptide. 
 
2.2.4 Biophysical characterisation of the Cul2–VBC interaction  
The lack of biophysical data regarding PPIs within the CRL2VHL complex 
motivated an in-depth characterisation of specific interactions. Despite 
persistent efforts to obtain Cul2 alone as functional protein it was not possible to 
achieve soluble, monomeric protein that could form a complex with VBC 
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(discussed in Chapter 3). As Cul2 and Rbx1 had to be co-expressed to obtain 
soluble and functional protein, the investigation of the PPI between these two 
subunits was prevented, and, therefore, it was decided to focus on the PPI 
between Cul2 and VBC. ITC experiments were performed, titrating VBC into 
Rbx1–Cul2. Expectedly strong binding affinity (Kd = 42 nM) and large 
exothermic binding enthalpy (ΔH = – 17.2 kcal x mol-1) at 303 K were measured 
(Figure 2.10C). As a way of comparison, data already available on Cul5–EloBC 
complexes, namely Cul5NTD–ASB9–EloBC and Cul5NTD–SOCS2–EloBC, 
reported binding affinities of 140–220 nM114,115 and 7–47 nM,116-118 and binding 
enthalpies of ΔH = – 8.3 kcal x mol-1 and ΔH = – 4.8 kcal x mol-1, respectively, 
for the corresponding interactions. The temperature-dependence of the binding 
parameters was also investigated and a change in heat capacity              
ΔCp = – 760 cal x mol x K-1 was determined (Figure 2.10D). The change in heat 
capacity is a thermodynamic parameter defined as the change in energy (heat) 
with temperature (ΔCp = ΔH/ΔT).119 In biological systems, negative ΔCp  values 
are often observed, meaning that an interaction becomes more exothermic with 
the increase of temperature. ΔCp values determined for other similar complexes 
are significantly less negative than the one obtained for the Cul2–VBC system 
(Figure 2.10E), which suggests a greater buried surface area upon Cul2–VBC 
interaction, leading to a more stable complex. Consistent with this hypothesis, 
based on the crystal structures available, the area buried upon interaction in 
Cul2–VBC is 2621 Å2, which is much greater than in Cul5–SBC (1945 Å2) and 
in Cul5–VifCβFBC (1605 Å2, Table 2.4). 
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Figure 2.10 - Biophysical characterisation of the interaction between VBC and 
Cul2. Isothermal titration calorimetry (ITC) data where VBC (200 µM) was titrated into 
Rbx1−Cul2 (20 µM) at A) 293 K, B) 298 K and C) 303 K. D) Temperature dependency 
of the thermodynamic parameters – ΔH, ΔG and -TΔS. The change in heating capacity, 
ΔCp, was derived from the change in enthalpy with the temperature. E) Comparison of 
ΔCp values for similar CRL systems. 
 
The hydration of polar and apolar groups has been shown to promote 
changes in the heat capacity and this relation has been modelled by the 
equation: ΔCphydration = Ca ΔSASAa + Cp ΔSASAp, where SASA is the 
solvent-accessible surface area (apolar and polar) buried upon interaction and 
Ca and Cp are constants empirically determined representing the area 
coefficient per Å2 contribution of residues in heat capacity change. Served by 
the newly solved crystal structure, the theoretical ΔCp values were calculated 
using the different constants Ca and Cp (Table 2.5), which differ according to the 
datasets used to determine them, for example, the size and nature of the 
sample (proteins or cyclic dipeptides).119-124 Interestingly, it was observed that 
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the experimental ΔCp was larger than the theoretical values in most of the 
cases. This could indicate a conformational re-arrangement in solution upon 
binding that is not fully accounted for in the theoretical calculations. 
Together, the biophysical and structural data suggest an extensive and 
tight PPI between the adaptor-receptor subunits and the scaffold in the CRL2VHL 
complex. 
 
Table 2.4 - Buried surface area in the cullin interface with the receptor domains in 
three CRL complexes. PDBs 5N4W, 4JGH and 4N9F for CRL2VHL, CRL5SOCS2 and 
CRL5Vif, respectively. The areas were calculated with GetArea. 
 
 
Table 2.5 - Comparison between experimental and theoretical ΔCp values119-123,125 for 
the Cul2-VBC interaction. 
 
 
2.2.5 Critical residues for the Cul2–VBC interaction 
Identification of hotspots and elucidation of the main drivers of the tight 
PPI between Cul2 and VBC was the next step of investigation. Guided by 
structural analysis, the individual contributions of potential key residues were 
Polar Apolar Total
VBC 5556 7915 13471
Cul2 17339 26443 43782
Cul2-VBC 21997 32635 54632
ΔSASA -899 -1723 -2621
SBC 7270 10909 18179
Cul5NTD 7710 11709 19418
Cul5NTD-SBC 14361 21291 35652
ΔSASA -619 -1326 -1945
VifCBFBC 10068 14102 24170
Cul5NTD 6540 9737 16278
Cul5NTD-VifCBFBC 16085 22757 38842
ΔSASA -523 -1082 -1605
Area (Å2)
Source ΔCp (cal/mol/K)
Experimental -760
Spolar et al. -425
Murphy & Friere -540
Myers et al. -400
Makhatadze & Privalov -692
Robertson & Murphy -384
Theoretical
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quantified. This was accomplished by mutating contact residues involved in the 
PPI and assessing changes in binding affinities between mutants and wild-type 
proteins. The mutations were pointed at the three main regions of the Cul2–
VBC interface, namely 1) the EloC pocket and adjacent area; 2) the 
helix α5-pVHL charge complementarity region; and 3) the hydrophobic contacts 
between helix α2 and EloC.  
In the first region of the Cul2–VBC interface mutations were designed to 
evaluate the importance of the hydrophobicity and bulkiness of the side chain 
filling the EloC pocket. Leu3 in Cul2 was mutated to alanine and also to glycine 
to allow direct comparison with previous work.82 Additionally, Pro5, a residue 
considered to potentially play a role in stabilising the conformation of the 
N-terminal loop of Cul2, which seemed important to direct the interaction, was 
mutated to alanine. Besides, Pro5 is also involved in hydrophobic contacts with 
Val181 (pVHL) and Met105 (EloC). In the other subunits, Val181 in pVHL was 
mutated to glycine and Met105 and Phe109 in EloC were mutated to alanine, 
addressing the consequences of disrupting the EloC hydrophobic pocket. In the 
second region, to understand the importance of electrostatic interactions in the 
complex formation, Gln111 and Lys114 in helix α5 of Cul2 were mutated to 
leucine and glutamate, respectively, and Lys159 and Asp187 in pVHL were 
mutated to glutamate and lysine, respectively. Lastly, in the third region of the 
interface residues Asn36, Phe39, Tyr43, Val47 on Cul2 were mutated to 
alanine, as those residues are involved in hydrophobic contacts with pVHL and 
EloC surfaces. 
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2.2.5.1 Site-directed mutagenesis, protein expression and purification 
The mutations were performed by site-directed mutagenesis and the 
primers used are reported in Chapter 6. DNA sequencing of the plasmids 
confirmed the correct identity of each mutation. VBC mutant proteins were 
expressed and purified according to the protocol already described. For the 
Rbx1–Cul2 mutants, virus stocks for the mutant proteins were generated and 
then used for protein expression; the purification protocol used was the same 
as that which was previously described. All the mutant proteins were analysed 
by mass spectrometry to confirm the correct change in molecular weight for the 
corresponding mutation. 
 
2.2.5.2 AlphaLISA experiments 
All the mutant proteins generated were initially tested in an AphaLISA126 
assay to determine IC50 values from dose-response curves. A competition 
experiment was designed, to assess the ability of a competitor (protein with 
mutation) to disrupt the interaction between the two native protein subunits. 
VBC and Rbx1–Cul2 wild type were also titrated for reference. According to this 
experiment, all the mutations were disruptive to the Cul2–VBC interaction 
(Figure 2.11), although the extent of the disruption varied greatly (the raw data 
can be consulted in the Appendix I). It was observed that the most destructive 
mutations i.e. the ones leading to a larger increase in the IC50 values were 
mostly of residues located in the EloC pocket area. Particularly, the mutation of 
Met105 and Phe109 increased the IC50 by 75 and 55-fold, respectively. These 
results also showed that while Q111L and D187K mutations had a considerably 
disruptive effect, K114E and K159E mutations in the helix α5 interface had a 
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modest effect in the binding affinity. The mutations of residues in helix α2 
interface led to an increase in the IC50 values by about 3-fold. 
 
Figure 2.11 - Residues in the EloC hydrophobic pocket reveal critical for the 
strong binding affinity of Cul2−VBC. A) Plot of the log(IC50) values resulting from the 
AlphaLISA competition experiment where mutant proteins of VBC or Cul2 were used to 
displace the native interaction between bead-bound wild type protein. Mutations at the 
EloC pocket are highlighted in yellow, mutations at helix α5 interface are highlighted in 
purple and mutations at helix α2 interface are highlighted in green. The fitting and 
calculation of IC50 values was performed with GraphPad Prism 7 software and the error 
bars represent the error in the fitting function. B) Dose-response curves of the raw 
AlphaLISA data showing representative displacers from the three interaction areas in 
comparison with VBC wt. The experiments were performed in quadruplicate and the 
data points shown are the average values for each concentration. The error bars 
represent the standard deviation of each point. 
 
2.2.5.3 ITC experiments 
Based on the AlphaLISA results, protein mutants were selected for ITC 
experiments to determine Kd values. VBC mutants V181G, M105A, F109A, 
K159E and D187K were titrated, in order to quantify the importance of the 
hydrophobic environment in the EloC pocket and of the residues involved in the 
electrostatic interactions. There was also interest in quantifying the effect of 
mutating Leu3 and Pro5 in Cul2 by ITC, however, the mutant proteins were 
highly unstable resulting in unreliable data. The ITC experiments were 
performed titrating wt and mutant VBC proteins into Rbx1–Cul2 (Table 2.6 and 
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Appendix I). The same trend as in AlphaLISA was observed by ITC, with 
mutations M105A and F109A being the most disruptive and promoting, under 
these conditions, an increase of 20 and 37 fold in the Kd values, respectively, 
which was accompanied by a significant loss of binding enthalpy. On the other 
hand, the mutation K159E resulted in a 5-fold decrease of the affinity and the 
mutations of V181G and D187K decreased the binding affinity by about 3-fold. 
 
Table 2.6 - Isothermal titration calorimetry data. Kd values and thermodynamic 
parameters for the interaction between VBC mutant proteins and Rbx1−Cul2 
determined by ITC. VBC proteins (100 µM) were titrated into 10 µM of Rbx1–Cul2. ITC 
titrations performed in the exact same conditions are compared. VBC M105A and 
F109A titrations were performed at 303 K to obtain better quality data, as their 
interactions are of lower affinity, hence lower ΔH. All other titrations were performed at 
298 K. The errors in the table reflect the quality of the fitting. 
 
 
Together, the biophysical data are consistent with a ranking of hotspots 
at the Cul2–VBC PPI, being Met105 and Phe109, at the peripheral hydrophobic 
pocket of EloC, identified as the most critical amongst the mutations tested. 
 
2.2.6 Swapping residues and selectivity for Cul2 versus Cul5 
The mechanism behind the selectivity between recruitment of Cul2 
versus Cul5 by EloBC-containing CRL complexes remains elusive, although 
VBC Temperature (K) N
wt 10 ± 3 298 -10958 ± 198 -12700 ± 177 -1742 ± 266 1
K159E 54 ± 9 298 -9920 ± 94 -11900 ± 174 -1930 ± 198 0.9
D187K 27 ± 9 298 -10339 ± 197 -11300 ± 264 -961 ± 330 0.8
V181G 28 ± 7 298 -10315 ± 154 -9868 ± 174 447 ± 232 0.9
wt 9 ± 1 303 -11017 ± 63 -14800 ± 61 -3783 ± 88 0.9
M105A 317 ± 39 303 -8873 ± 74 -9870 ± 141 -993 ± 159 0.9
F109A 177 ± 16 303 -9221 ± 53 -9260 ± 79 -41 ± 95 1
KD (nM) ΔG  (cal/mol) ΔH (cal/mol) TΔS (cal/mol)
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explored in several publications.82,97,127 One of the existing hypotheses is that 
the electrostatic patch on pVHL surface is responsible for recruiting Cul2,82 
nonetheless, the data presented in the previous section shows that by inverting 
the charge of these two residues, and therefore, inverting the electrostatics 
patch charge, VBC still binds to Cul2. To deepen understanding of selectivity 
determinants, the CRL5SOCS2 complex was studied in parallel. CRL5SOCS2 is one 
of the Cul5 ligases in which SOCS2 is the substrate receptor and EloBC is the 
adaptor subunit (SBC).116,128 The choice of this complex was motivated by the 
existence of a crystal structure of Cul5NTD-SBC.93 By ITC, it was observed that, 
despite using the same adaptor subunit, SBC does not bind Cul2. This 
intriguing observation led to the investigation of whether by mutating a 
combination of amino acid residues it would be possible to swap the selectivity 
of SBC with VBC for Cullin, or, in other words, rescue the binding of SBC to 
Cul2 (gain-of-function mutation) and, at the same time decrease the affinity to 
Cul5 (loss-of-function mutation) and vice-versa. The structural analysis of Cul2–
VBC versus Cul5–SBC (Figure 2.12A) revealed that Arg186 in SOCS2 (Ser183 
in pVHL) would clash with Gln111 in Cul2, which would explain the lack of 
interaction observed. In addition, it also showed that Lys159 and Asp187 in 
pVHL, important to the Cul2–VBC PPI, correspond to a glutamine (Gln164) and 
a tyrosine (Tyr190) in SOCS2, respectively. In other words, a positive and a 
negative amino acid residue in pVHL are replaced with two neutral amino acids 
in SOCS2, conferring a significantly different interface. Gln164 is involved in a 
hydrogen bond with Asn108 from EloC, while Tyr190 establishes an intra-
molecular electrostatic interaction with Arg168. In addition, in SBC, Arg186 
establishes hydrogen bonds with the backbone of Thr117 and with Gln113 of 
Cul5 (Figure 2.12A). These analyses and hypotheses were settled on the 
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assumption that the binding mode at the Cullin–adaptor interface is conserved, 
as observed in the crystal structures. Based on these observations, triple 
mutants for VBC and SBC were generated: mutations K159Q, S183R, D187Y 
were performed in pVHL (VQRYBC); and the reverse mutations Q164K, R186S 
and Y190D were performed in SOCS2 (SKSDBC). 
 
2.2.6.1 Site-directed mutagenesis, protein expression and purification 
The mutations were performed by site-directed mutagenesis (the primers 
can be consulted in Chapter 6) and confirmed by DNA sequencing. Expression 
and purification of VQRYBC was performed as for the wild type protein, according 
to the protocol already explained. SBC and SKSDBC were expressed and 
purified according to a protocol published previously,116 involving affinity 
chromatography, ion-exchange chromatography and size exclusion 
chromatography. VQRYBC and SKSDBC were analysed by mass spectrometry to 
confirm the success of the mutations. 
 
2.2.6.2 AlphaLISA and ITC experiments  
Initially these variants were tested in the AlphaLISA competition assay 
(Figure 2.12B), and the results suggested a switch in the recruitment. A drastic 
weakening of the interaction between VQRYBC and Cul2 was observed, and, 
pleasingly, it was also observed that SKSDBC rescued, to some extent, the 
binding to Cul2, compared to SBC. Based on these encouraging results, ITC 
experiments were performed to evaluate the loss or gain in function upon triple 
mutation (Figure 2.12C-F and Table 2.7). A 25-fold loss in the binding affinity of 
SKSDBC to Cul5 (Kd from 10 nM to 250 nM) was observed alongside with a 
partial rescue of the binding to Cul2 (Kd = 2.5 µM). Consistently, total loss of 
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binding between Cul2 and VQRYBC was observed, together with partial rescue 
of binding to Cul5 (Kd = 2.9 µM). The partially rescued non-native interactions 
confirmed a switch in the ability to recruit Cullin, albeit with Kd values that were 
weaker than the ones measured for the native interactions (Figure 2.12G). 
Interestingly, the loss of binding affinity of SKSDBC to Cul5 was accompanied by 
an increase in the enthalpy of the reaction, suggesting an interaction with a 
thermodynamic profile closer to that of Cul2–VBC (Figure 2.12C).  
Taken together, these findings provide new insights into the selectivity of 
VBC and SBC for Cul2 and Cul5, respectively, identifying amino acid positions 
that direct this selectivity and mutations that enable switching Cullin recruitment 
within CRLs. 
 
 
	
80 
 
 
 
 
 
- 2.0
0.0
- 4.0
- 6.0
- 8.0
- 10.0
- 12.0
0.0 0.5 1.0 1.5 2.0
Molar ratio
kc
al
/m
ol
 o
f i
nj
ec
ta
nt - 2.0
0.0
- 4.0
- 6.0
- 8.0
- 10.0
- 12.0
kc
al
/m
ol
 o
f i
nj
ec
ta
nt
kc
al
/m
ol
 o
f i
nj
ec
ta
nt
kc
al
/m
ol
 o
f i
nj
ec
ta
nt
0.0 0.5 1.0 1.5 2.0
Molar ratio
Molar ratio Molar ratio
0.0 0.5 1.0 1.5 2.0
- 2.0
0.0
- 4.0
- 6.0
- 8.0
- 10.0
- 12.0
- 14.0
- 16.0
- 18.0
- 2.0
0.0
- 4.0
- 6.0
- 8.0
- 10.0
- 12.0
- 14.0
- 16.0
- 18.0
0.0 0.5 1.0 1.5 2.0
Cul2
Cul5
pVHL
SOCS2
Q113
T117
Q164
R186
K114
Q111 K159
D187
S183
Y190
A) B)
C) D)
E)
G)
F)
1.2E5
1.0E5
8.0E4
6.0E4
4.0E4
2.0E4
0
- 10 - 8 - 6 - 4
R
es
po
ns
e 
(A
U
)
log(IC50 (M))
SBC SKSDBC
VBC VQRYBC
Cul5
Cul2
10 nM
42 nM
230 nM
2.9 µM
2.5
 µM
VQRYBC x Cul5
VBC x Cul5
SBC x Cul5
SKSDBC x Cul5
VQRYBC x Cul2
VBC x Cul2
SBC x Cul2
SKSDBC x Cul2
VBC
SBC
VQRYBC
SKSDBC
 
	
81 
Figure 2.12 - Swapping residues and selectivity for Cul2 or Cul5. A) Structures of 
Cul5–SBC and Cul2–VBC aligned by the EloC subunit show residues involved in the 
electrostatic network between substrate receptor and Cullin, in both cases. Arg186 
(SOCS2) clashes with Gln111 in Cul2 suggesting a potential reason for SBC not 
binding Cul2. B) AlphaLISA data shows loss of binding affinity of VQRYBC towards Cul2 
and rescue of binding of SKSDBC towards Cul2. The experiments were performed in 
quadruplicate and the data shown are an averaged value. The error bars represent the 
standard deviation. The fitting was performed with GraphPad Prism 7 software. C)-F) 
Isothermal titration calorimetry data. Titrant solution (200 µM) was diluted into 20 µM of 
titrate over 19 injections of 2 µl at 303 K. C) Titration of Cul5NTD into SBC (blue) and 
SKSDBC (black). D) Titration of SBC (blue) and SKSDBC (black) into Cul2. E) Titration of 
VQRYBC (green) and VBC (black) into Cul2. F) Titration of Cul5NTD into VQRYBC (green) 
and VBC (black). G) Summary of the results obtained in the biophysical experiments  
 
Table 2.7 - Isothermal Titration Calorimetry processed data of the experiments of the 
swapped domains. 200 µM of titrant diluted into 20 µM of titrate over 19 injections of 2 
µl at 303 K. The errors refer to the fitting function. 
 
  
VBC x Cul2 4.2 x 10-8 ± 5.0 x 10-9 -10068 ± 70 -17210 ± 113 -7142 ± 133
VQRYBC x Cul2  
SBC x Cul2
SKSDBC x Cul2 2.5 x 10-6 ± 2.7 x 10-7 -7652 ± 64 -12980 ± 524 -5328 ± 528
VBC x Cul5
VQRYBC x Cul5 2.9 x 10-6 ± 3.0 x 10-7 -7554 ± 59 -7400 ± 386 154 ± 39
SBC x Cul5 9.8 x 10-9 ± 2.1 x 10-9 -10936 ± 124 -5161 ± 33 5775 ± 128
SKSDBC x Cul5 2.3 x 10-7 ± 3.2 x 10-8 -9058 ± 81 -8354 ± 109 704 ± 136
Kd (M) ΔG  (cal/mol) ΔH (cal/mol) TΔS (cal/mol)
ND
ND ND ND
ND
ND
ND
ND ND ND
NDND
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2.3 Discussion 
Ubiquitin ligases catalyse the transfer of ubiquitin to target proteins, 
which triggers a cellular response that varies according to the length and 
topology of the ubiquitin chain. Despite significant progress towards 
understanding the mechanisms underlying E3 ligase function, regulation and 
ubiquitination activity,15 many aspects regarding the mechanistic details of 
specific interactions within the CRL complexes remain elusive. In fact, structural 
information at atomic level of the function and mechanism of the whole CRL 
machines remains limited.  
The new structure of a full-length Cul2 complex provides insights that 
contribute to the understanding of the ubiquitination mechanism. It reveals 
flexibility of the central Cullin scaffold and corroborates the existence of hinge 
bending within the protein, which is deemed key for the ligase activity.101 The 
hinge points found in the linkers between the Cullin repeats (first and second 
and second and third), allow the first and third helical bundles to come close or 
apart, alternating between an elongated and contracted shape. The other hinge 
point, located between the NTD and CTD, allows the rearrangement of these 
two domains and, in fact, it was observed that in the structure solved, the CTD 
of Cul2 is considerably moved towards the NTD, when compared to other CRL 
structures. Recent molecular dynamics studies have correlated these 
movements and proposed a relationship between Cullin and Rbx1 dynamics 
and the ubiquitin chain length and topology built on the substrate.105 The new 
CRL2VHL structure presents for the first time the interface between the 
E2-recruiting RING, Rbx1, and Cul2, in which Rbx1 adopts a new orientation. 
Superposition with other Rbx1–Cullin structures suggests a pose in a trajectory 
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from a closed to an open form, which is postulated to capture a route from the 
inactive to the active conformation of the ligase. 
CRLs must function as highly dynamic multi-subunit complexes. In fact, 
these complexes rely on their inherent flexibility to bring together substrate and 
ubiquitin that would otherwise be more than 50 Å apart, as found in some 
crystal structures.84 Flexibility is also essential to accommodate multiple 
attachment of ubiquitin at distinct positions in the chain during catalytic 
elongation cycles. This feature is dictated by the relative organisation and 
dynamics of CRL subunits and their ability to work in concert. The new CRL2VHL 
structure, additionally to the intra- and the inter-subunit movements observed in 
comparison to other CRL structures, recapitulates many such dynamic features. 
For instance, the impossibility to obtain crystals in the absence of the HIF-1α 
19-mer peptide suggests that the presence of the substrate was needed to 
confer some conformational arrangement that facilitates crystallisation. On the 
other hand, it is hypothesised that the substrate-binding domain of pVHL is 
highly flexible and might be present in more than one orientation in the crystal, 
explaining the lack of substantial electron density in this area. Although not 
captured by a single-structure crystallographic model, this observation suggests 
a functionally important dynamics of pVHL that could be driven by the presence 
of the bound substrate (HIF-1α peptide). Nussinov and others129,130 have 
elucidated pVHL’s inter-domain flexibility through the presence of a linker region 
containing a conserved proline residue, which was proposed to act as a hinge, 
allowing the rotation of the substrate binding domain to position the substrate 
accurately for ubiquitination. In addition to the above, the high average 
B-factors observed after refinement for the overall structure also corroborate 
these dynamic features. The resolution of the CRL2VHL structure limited the 
 
	
84 
amount of information that could be obtained, and, despite intensive efforts to 
improve the quality of the crystals and collect better quality datasets this was 
not possible. 
In this chapter, the biophysical nature of a key PPI interface of CRL 
complexes was also explored. The interface established between Cul2 and the 
receptor and adaptor subunits is conserved and characterised by a large buried 
surface area. The structural features are reflected into characteristic 
thermodynamic signatures, including enthalpy-driven interaction, tight binding 
affinity and a large and negative change of heat capacity. It was determined 
that the interaction is contributed over extended regions, suggesting a 
spreading of hotspot residues across the interface. This work identified a 
number of hydrophobic residues in a distal pocket of EloC, which recognises 
the N-terminal tail of Cul2, as the major contributors to the PPI affinity. This 
information can guide the design of molecules to target this specific region 
within CRL2VHL and potentially other EloBC-containing CRL2 and CRL5 
complexes. Moreover, the competitive AlphaLISA assay developed for these 
experiments can be of great value for the screening of modulators of the Cul2–
VBC interaction. 
The selective recruitment of Cullin in EloBC-containing complexes is still 
an intriguing feature due to the similarities of the two PPIs in Cul2 and Cul5 
CRLs. Kamura et al. demonstrated the importance of the entire Cul-box region 
(about 20 amino acids) of the substrate recognition subunit in determining the 
selectivity for Cul2 vs. Cul5 recruitment.97 In this work, upon swapping of three 
topologically conserved residues at the receptor-scaffold interface in VBC and 
SBC, the ability of these proteins to bind Cul5 and Cul2, respectively, was 
altered. This result constitutes an unprecedented proof-of-concept for switching 
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Cullin selectivity within CRLs by mutating individual amino acids and it can lead 
to interesting applications to elucidate CRLs biology and contribute to their 
validation as a drug target. It is likely that the Cullin selectivity is fine-tuned by 
other residues in addition to the ones identified in this work, considering they 
are not strictly conserved across all known Cul2 or Cul5 binders. In fact, it is 
known that mutation of Trp53 in Cul5 results in a 30-fold loss of affinity to SBC 
and this is due to an important interaction with Pro184 in SOCS2.93 In Cul2, the 
corresponding residue to Trp53 is Ala48 and this could be one of the reasons 
why the binding affinity of VQRYBC to Cul5 is not fully rescued to the binding 
affinity of the native Cul5-SBC interaction. 
 
In summary, the structural and biophysical data presented in this chapter 
shine new light into the structural assembly and dynamics functioning of CRL 
multi-subunit complexes and unveil mechanistic details and selectivity 
determinants for the Cul2-receptor protein-protein interaction. 

 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3  
PROBING THE CRL2VHL COMPLEX 
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3.1 Introduction 
Peptides are attractive tools to target PPIs due to their ability to 
reproduce structural features of molecular recognition at usually large and flat 
surfaces. Encouraged by the potential of using peptides as chemical probes for 
PPIs,131 the Cul2–VBC surface was explored with peptidic moieties designed to 
mimic the native interaction using sequences derived from Cul2.  
Considering the practical aspects of exploring the Cul2–VBC interaction 
and developing peptides to target such interaction, it was deemed beneficial to 
have protocols that allow easy expression and purification of Cul2 and VBC with 
high yields to be used for biophysical and biochemical assays. VBC is routinely 
recombinantly expressed with high yields from bacteria and Rbx1–Cul2 can be 
expressed and purified from insect cells. However, expression in insect cells is 
a lengthy and costly procedure that yields relatively low amount of protein. The 
bacterial expression system, on the other hand, is cost-effective and fast, easy 
to handle and for most recombinant proteins it generates abundant yields.132  
In this chapter, it is described work aimed at establishing procedures for 
Cul2 purification using a bacterial host and to develop peptides by 
structure-guided design to probe the Cul2–VBC interaction. The peptides were 
biophysically evaluated for binding towards VBC by a palette of biophysical 
techniques including BLI, DSF, ITC and NMR. The results pointed out important 
insights to further develop these peptides into higher-affinity ligands that could 
be used as chemical tools to deepen our understanding of the assembly and 
biological functioning of CRL complexes. 
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3.2 Results 
3.2.1 Design, expression and optimisation efforts to obtain soluble and 
monomeric Cul2NTD constructs 
The work focused on two truncations of Cul2 with different lengths, one 
comprising the first Cullin repeat (residues 1-163) and the other one comprising 
the full NTD (residues 1-384). The design of the constructs was based on the 
work of Nguyen et al.82 However, since the goal was to study the interaction 
between the N-terminus of Cul2 and VBC, it was decided to have the 
solubilising tag at the C-terminus of the protein rather than at the N-terminus. 
Two solubilising tags, SUMO and MBP, were tested and a hexahistidine tag 
was added at the C-terminus (downstream of the solubilising tag) for purification 
purposes. Details of the cloning can be found in Chapter 6. Protein expression 
trials in E. coli were carried out for all constructs containing the different tags 
(Table 3.1). Parameters such as temperature and concentration of 
isopropyl-β-D-thiogalactopyranoside (IPTG) used to induce protein expression 
can influence protein expression in E. coli and can be tuned to achieve optimal 
expression conditions.133 In this case, a range of temperatures, 16-25 °C, and 
concentrations of IPTG, 0.05-0.5 mM, were tested. It was observed that, 
although the protein was overexpressed in all cases, none of the constructs 
was soluble under any of the conditions tested. The next step was to attempt 
protein expression in the presence of GroEL and GroES chaperones 
(Chaperone plasmid set, TaKara). Molecular chaperones are known to be 
involved in protein folding in vivo,134 therefore, by co-expressing a protein target 
in the presence of chaperones the recovery of expressed proteins in the soluble 
fraction is usually increased. To do this, the Cul2-expression vectors were 
transformed into BL21 E. coli cells containing pGro7 plasmid (see Chapter 6, 
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section 6.1.5). In this system, the expression of GroEL and GroES chaperones 
is regulated by arabinose and the concentration used was tuned for each of the 
systems (0.5-1.5 mg/ml). The presence of the chaperones enhanced the 
solubility of the MBP-tagged constructs and up to 50% of the protein was found 
in the soluble fraction. Conversely, despite being overexpressed, the 
SUMO-tagged constructs remained totally insoluble. Based on these results, 
the MBP-tagged constructs expressed in the presence of chaperones were 
chosen for further studies. 
 
Table 3.1 – Summary of the Cul2 constructs tested and solubility results. 
 
 
 
The expression and purification efforts of MBP-tagged constructs of 
Cul21-163 and Cul21-384 will be described in the next sections. 
 
3.2.1.1 Expression and purification of Cullin-21-163-MBP-6xHis  
The Cullin-21-163-MBP-6xHis construct comprised the first cullin repeat, 
constituted by the N-terminal loop and the first five α-helices. After expression 
trials to determine the optimal conditions, Cul2 expression was induced with 
0.5 mM IPTG and the cells were incubated overnight at 16 °C, 200 rpm 
shaking. The cells were harvested by centrifugation and lysed by French press 
prior to purification. Originally, the first step of purification consisted of an affinity 
Construct Tag Chaperones Solubility
No Insoluble
Yes Insoluble
No Insoluble
Yes Soluble
No Insoluble
Yes Insoluble
No Insoluble
Yes Soluble
Cul21-163
SUMO-6xHis
MBP-6xHis
Cul21-384
SUMO-6xHis
MBP-6xHis
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chromatography with a His trap (column packed with nickel sepharose resin). 
However, after several attempts at purification, it was observed that the amount 
of Cul2 recovered by gradient elution with imidazole was much lower than the 
amount present in the lysate. This was very intriguing, and after some literature 
search it was found that Cul2 binds nickel.135 This explained the poor recovery 
of protein from the His trap column in the elution step at the expected imidazole 
concentration (~100 mM). Considering that the protein contained a maltose 
binding protein (MBP) as tag and the existence of MBP trap affinity purification 
columns (packed with dextrin sepharose resin), the His trap step was replaced 
with MBP trap affinity purification.  
Protein expression, cell harvesting and cell lysis were performed as 
before and, this time, Cul21-163-MBP-6xHis was recovered by elution with 
maltose from the MBP trap column (Figure 3.1A). Next, a gel filtration step was 
performed and the size-exclusion chromatography (SEC) trace consisted of a 
single peak corresponding to Cul2 that, however, was eluted before the 
expected volume (Figure 3.1B). According to the molecular weight (MW) of the 
protein (63 kDa) and to the calibration of the column (performed using the gel 
filtration standard calibration kit, BioRad), monomeric Cul21-163-MBP-6xHis was 
expected to have an elution volume of ~70 ml in the HiLoad 16/600 Superdex 
200 column. Instead, Cul21-163-MBP-6xHis eluted at 50 ml, which corresponds 
to a MW of approximately 440 kDa, suggesting that the protein was purified as 
an aggregate. In the chromatogram it was also visible a second peak that 
eluted at the volume corresponding to a species of about 45 kDa. It was 
speculated that this could be the result of spontaneous cleavage of MBP (as its 
MW is 45 kDa). To prevent Cul2 aggregation, given that Cul2 binds Ni2+, one 
idea was to dilute the aggregate sample in buffer containing 10 mM NiCl2 as 
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this could stabilise the monomeric species. After dilution, the sample was 
analysed again by gel filtration but, unfortunately, no monomeric species was 
observed also in the presence of NiCl2. 
 
Figure 3.1 – Chromatograms of the purification of Cul21-163-MBP-6xHis and 
respective SDS-PAGE. A) The protein is eluted from the MBP trap with a gradient of 
maltose (0-5 mM). B) Size-exclusion chromatography profile of Cul21-163-MBP-6xHis 
after the MBP trap. The SDS-PAGE confirms the identity of Cul21-163-MBP-6xHis (A) 
based on the MW and the presence of a species with MW ~45 kDa (B). 
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In order to identify conditions that could stabilise the monomeric species, 
a solubility assay was performed, based on the protocol described by Bondos et 
al.136 The assay involved diluting the aggregate in buffers containing different 
additives. Then, the protein was spun down in centricons of 100 kDa cutoff, the 
idea being that the aggregate would be retained (expected MW according to 
SEC > 440 kDa), whereas monomeric protein (MW 63 kDa) should go through 
the membrane. Samples from the retained phase and from the filtrate were 
loaded on a SDS-PAGE and Cul2 was identified by immunoblot. In this way, 
conditions that led to a stabilisation of the monomeric species could be 
identified. The results showed that the greatest amount of Cul2 in the 
flow-through was obtained in the presence of the detergent BRIJ58, glucose or 
KCl (conditions 5, 9 and 11, Figure 3.2), hinting at the presence of monomeric 
species. According to that, small-scale purifications were performed in the 
presence of each of those additives. In SEC, the monomeric species was only 
observed in the presence of BRIJ58. However only approximately 25% of the 
total protein preparation was found in a monomeric state and it was observed 
by SEC that upon isolation of the monomeric species, it would aggregate again. 
In conclusion, none of the additives tested allowed durable stabilisation of 
monomeric Cul21-163-MBP-6xHis. 
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Figure 3.2 – Solubilisation assay. Different additives were tested to favour the 
monomeric fraction of Cul21-163-MBP-6xHis. Samples from the aggregate (Ag) and flow 
through (Ft) were analysed by immunoblot with anti-Cullin-2 antibody at 1:2000. 
 
Another avenue explored was the denaturation of purified aggregate of 
Cul2 in the presence of 8 M urea, followed by refolding using different 
conditions (L-arginine, L-proline, glucose and ammonium sulphate) and 
methods (dilution, refolding on the column and dialysis). The refolding was 
assessed by SEC. For example, when the refolding was attempted on the 
column (Figure 3.3), contrarily to the aggregate, the protein was eluted closer to 
the predicted volume according to its molecular weight. In the Superdex 200 
Increase column (analytical column), the expected elution volume for 
Cul21-163-MBP-6xHis is around 12 ml, which was approximately the elution 
volume observed for the samples tested, suggesting the protein had been 
refolded. To assess whether the refolded samples of Cul2 were active, they 
were tested for binding to VBC by co-elution gel filtration. It was expected that 
upon mixing, the two proteins would form a single complex and elute in the 
format of a single peak, however this did not happen, indicating that the protein 
was not active (data not shown).  
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Figure 3.3 – Refolding experiments with Cul2. The aggregated sample was purified, 
denatured in 8 M urea and then refolded on the column (Superdex 200 Increase) with 
buffer (100 mM HEPES pH 7.0, 100 mM NaCl, 1 mM TCEP) containing different 
additives.  
 
Despite the different additives and methods of refolding tested, no active 
monomeric Cul2 was obtained. 
 
3.2.1.2 Expression and purification of Cullin-21-384-MBP-6xHis 
Considering the previous results, the idea of a longer construct was 
contemplated as a way of blocking an exposed hydrophobic surface at the end 
of the first helical bundle, which is usually packed against another helical 
bundle. Expression of Cul21-384-MBP-6xHis comprising the full NTD in the 
presence of the chaperones was induced with 0.5 mM IPTG and carried out at 
16 °C overnight. Cells were harvested by centrifugation, lysed by French press 
and loaded on the MBP trap. The peak collected from elution with maltose was 
loaded on a gel filtration and the SEC trace revealed the presence of multiple 
species of Cul21-384-MBP-6xHis. The most abundant species was eluted in the 
void volume, suggesting also this construct was prone to aggregation 
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(Figure 3.4). The addition of 5% glycerol in the purification buffers was tested to 
prevent aggregation but no improvement was observed. Moreover, as with the 
shorter construct, it was observed that the aggregation was 
equilibrium-dependent i.e. upon isolation of the monomeric species the sample 
would start aggregating.  
 
 
Figure 3.4 – Size exclusion chromatography trace of Cul21-384-MBP-6xHis. The 
chromatogram and the SDS-PAGE suggest the presence of multiple species of 
Cul21-384-MBP-6xHis. 
 
Previous work by Li et al.137 reported the mutation of residues Val367 
and Leu371, two hydrophobic solvent-exposed residues, to arginine and 
aspartate, respectively, to improve the solubility of Cul1. The same principle 
was applied to this construct of Cul2, hoping to revert the aggregation issue. To 
decide which residues to mutate, Cul1 and Cul2 were structurally aligned and 
residues Val340 and Leu344 of Cul2 were identified as corresponding to 
residues Val 367 and Leu371 in Cul1. In addition to Val340 and Leu344, it was 
decided to also mutate Val384. The valine residues were mutated to arginine 
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and the leucine was mutated to aspartate (Cul21-384RDR). The mutations were 
performed by site-directed mutagenesis and confirmed by DNA sequencing. 
The protein was expressed using the same protocol as above. 
Cul21-384RDR-MBP-6xHis was eluted from the MBP trap column as a very sharp 
peak. When loaded on the gel filtration column (HiLoad 16/600 Superdex 200), 
the chromatographic profile suggested that the sample was aggregated as the 
peak eluted shortly after the void volume, therefore, implying that the mutations 
did not improve the aggregation problem.  
Another condition tested for the purification of Cul21-384RDR-MBP-6xHis 
was to lower the NaCl concentration to 100 mM in all the buffers, an attempt to 
disfavour hydrophobic contacts and minimise aggregation. Surprisingly, upon 
loading of the MBP trap, part of the sample was eluted while washing the 
column, before starting the maltose gradient elution (Figure 3.5A). SDS-PAGE 
confirmed that this sample was Cullin-21-384RDR-MBP-6xHis (sample A) and it 
was kept separated from the sample eluted with maltose (sample B). Sample A 
was run in the gel filtration column and, it was observed that approximately 40% 
of the sample was eluted at the expected volume, according to the respective 
molecular weight, suggesting the presence of monomeric species. On the 
contrary, in sample B only about 10% of sample was monomeric and the 
remaining ~90% eluted in the void volume. Thus, lowering the NaCl 
concentration did not help to enhance the population of monomeric fraction.  
However, somehow a fraction of monomeric Cul2 was obtained from this 
experiment and was used to try to understand what could help its stabilisation.  
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Figure 3.5 – Purification of Cul21-384RDR-MBP-6xHis. A) MBP trap elution profile, 
where, unexpectedly, part of the sample was eluted during the wash step (sample A). 
B) Size exclusion chromatography of samples A and B. Sample A contained a great 
amount of monomeric Cul21-384-MBP-6xHis (A2), while most of sample B was 
aggregate. C) SDS-PAGE from samples from MBP trap and gel filtration runs confirms 
the identity of the peaks as being Cul21-384RDR-MBP-6xHis. 
 
To assess whether the monomeric species of Cullin-21-384RDR-MBP-6xHis 
from sample A was active i.e. binding to VBC, a co-elution gel filtration 
experiment was run. Cullin-21-384RDR-MBP-6xHis and VBC were mixed in a 1:1 
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ratio and the elution profile was analysed. Comparing to the individual sample’s 
profile there was a new peak eluting before the peak of Cul2, consistent with a 
higher molecular weight sample, as would be expected for Cul2–VBC 
(Figure 3.6). The SDS-PAGE confirmed the presence of VBC under this first 
peak (which did not happen when VBC was loaded alone), corroborating the 
assembly of the Cul2–VBC complex. However, based on the chromatogram, it 
was estimated that only about 10% of VBC was forming a complex with Cul2. 
This was consistent with aggregation, which was also suggested by the 
presence of some higher molecular weight species in the chromatographic 
trace of Cul2 (Figure 3.6, yellow trace) and of the mixture (Figure 3.6, green 
trace). 
 
Figure 3.6 – Co-elution gel filtration of Cul2 and VBC. Monomeric 
Cul21-384RDR-MBP-6xHis was mixed with VBC in a 1:1 ratio and the size-exclusion 
chromatography trace (green) was analysed and compared to the chromatographic 
traces of VBC (purple) and monomeric Cul21-384RDR-MBP-6xHis (yellow). 
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Apart from the co-elution gel filtration, BLI and ITC experiments were 
carried out with the monomeric fraction of Cul2 isolated from this experiment. 
However, no clear binding could be detected and this might be explained by the 
high content of Cul2 aggregate present in the samples used, as it was seen in 
the gel filtration traces.  
In an effort to stabilise monomeric Cul2, a thermal shift screening of 
different buffer conditions was performed. The more stable the protein is, the 
higher the TM is expected. 
 
 
Figure 3.7 – Thermal shift buffer screening. Amplification curves of 5 µM 
Cul21-384RDR-MBP-6xHis in the presence of different additives.  
 
The results of the buffer screening were inconclusive as no clear melting 
curve was detected in any of the conditions tested (Figure 3.7). It was observed 
that the fluorescence signal at the beginning of the experiment was already 
extremely high. The reasoning for this observation was that Cul2 is a very 
hydrophobic protein and, consequently, the typical melting curves consisting of 
a peak of fluorescence intensity upon denaturation of the protein were not 
observed and no conclusion in regards to the thermal stability of the protein 
could be made. 
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The purification in the conditions that led to the isolation of a 
considerable amount of monomeric Cul2 was repeated several times but it was 
not possible to reproduce the original result. 
Other parameters like lysis and purification conditions were tested with 
the Cul21-384RDR-MBP-6xHis construct. Different buffers, varying the salt 
concentration and including additives such as Tween-20 and NiCl2 were tested 
but there was no increase of the monomeric fraction according to the SEC 
profile. In addition, as a great amount of soluble aggregate of Cul2 could be 
purified and assuming the aggregation was reversible, the aggregate was 
diluted and additives such as ArgHCl, CoCl2 and glycerol were tested but no 
improvement was observed either. The solubility assays performed for the 
shorter construct were also performed in this case, however, it was observed 
that in none of the conditions the protein went through the membrane, 
suggesting it was always present as an aggregate. 
Lastly, the denaturation and refolding protocols were also tested for 
Cullin-21-384RDR-MBP-6xHis. In this case, the refolding was only attempted on 
the column and by dialysis, using arginine as additive. Nonetheless, it was 
observed that it was not possible to refold the longer construct or, if refolded, it 
was immediately aggregating.  
 
In summary, despite the intensive efforts, unfortunately it was not 
possible to achieve a soluble, monomeric and stable construct of Cul2 
expressed in E. coli. 
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3.2.2 3- to 11-mer Cul2 peptides 
Considering the important role of the N-terminal loop of Cul2 in 
establishing the interaction with VBC, and given the inability to express soluble 
Cul2NTD alone, it was contemplated that peptides able to reproduce the 
N-terminal tail could recapitulate the interaction, providing tools to develop 
chemical probes and target this PPI. Based on the structural analysis of this 
interface, peptides varying from three to eleven residues were synthesised and 
tested for binding to VBC. 
 
3.2.2.1 Peptide synthesis and purification 
The peptides were synthesised in an INTAVIS automated peptide 
synthesiser using solid phase Fmoc chemistry. The synthesis consisted of 
several cycles of deprotection, washing and coupling steps; each cycle resulted 
in the incorporation of one amino acid. After the final deprotection step, the 
peptides were cleaved from the resin using a solution of TFA, water and 
triisopropylsilane (TIS) (92.5:2.5:5). The peptides were obtained as C-terminal 
amides and were purified by HPLC in basic conditions (0.1% NH4OH) in a 
gradient of 0-100% of acetonitrile in water over 15 minutes. The purity and 
identity of the peptides was determined by analytical HPLC-MS (see Chapter 
6). 
 
3.2.2.2 Biolayer interferometry  
The nine peptides synthesised were tested for binding to VBC by BLI at 
increasing concentrations, from 27 µM to 7 mM. For this experiment, 
biotinylated VBC (see Chapter 6, section 6.1.14) was attached to 
streptavidin-coated tips. The 9-mer and 11-mer peptides could not be tested 
 
	
104 
because they were insoluble in the conditions of the experiment. For the 
remaining peptides the results showed that at least six amino acids were 
needed in order to observe binding towards VBC (Figure 3.8 and Table 3.2). 
The binding was recapitulated with the 6-, 7-, 8- and 10-mer peptides and the 
8-mer peptide showed the best response in terms of fitting and reproducibility. 
The same experiment was performed in the presence of VBC in complex with 
the HIF-1α 19-mer peptide (VBCH) and the results obtained were similar 
(Table 3.2). Nevertheless, in both cases the binding affinities determined were 
in the millimolar range, therefore, the next step was to enhance the binding 
affinity of the peptides towards VBC.  
 
Table 3.2 – Binding affinities of N-terminal Cul2 peptides to VBC and VBCH 
determined by BLI. 
 
 
Peptide
MSL
MSLK
MSLKP
MSLKPR 3.3 ± 0.3 11.0 ± 0.9
MSLKPRV 3.5 ± 0.2 5.3 ± 0.4
MSLKPRVV 2.0 ± 0.2 4.5 ± 0.5
MSLKPRVVD
MSLKPRVVDF 4.0 ± 0.3 5.8 ± 0.5
MSLKPRVVDFD
no binding
KD VBCH (mM)
no binding
no binding
ND
ND
no binding
no binding
no binding
Kd VBC (mM)
ND
ND
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Figure 3.8 – Biolayer interferometry experiments with the N-terminal Cul2 
peptides. Biotinylated VBC was immobilised on the tips and the peptides were tested 
in a concentration range from 27 µM to 7 mM. The different colours represent the 
different concentrations and corresponding responses. The assay was performed in 
20 mM HEPES pH 7.6, 100 mM NaCl, 1 mM DTT, 0.02% Tween-20 at 25 °C. 
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3.2.3 8-mer peptide derivatives 
Considering the 8-mer peptide (MSLKPRVV) had the best fitting (see 
Figure 3.8), tighter binding affinity and reproducibility in the previous BLI assay, 
it was chosen as template for a series of modifications to determine the 
requirements for the interaction and potentially increase the strength of binding.  
An alanine scanning was performed to identify hotspots in the peptide. 
Furthermore, as the binding affinity of the 8-mer peptide was relatively weak 
(2 mM), a structure-based approach to try to enhance the affinity was 
employed. Considering the key role of the side chain of Leu3 from Cul2 
accommodated in the EloC hydrophobic pocket, the replacement of leucine with 
bulkier side chain groups was tested. Thus, a small library of 8-mer peptides in 
which the leucine residue was substituted with natural and non-natural amino 
acids was designed and tested for binding to VBC.  A total of 19 peptides were 
synthesised and purified as described in section 3.2.2.1. All the peptides were 
characterised by analytical HPLC-MS and the traces can be consulted in 
Chapter 6.  
 
3.2.3.1 Alanine scanning 
The alanine scanning consisted of replacing, one at a time, all the amino 
acid residues in the 8-mer peptide by an alanine residue. The peptides were 
then tested for binding to VBC by BLI, as described in section 3.2.2.2, and the 
sensorgrams were compared to the one of the parental peptide, considering the 
response signal (Figure 3.9). Based on the results, mutations that led to 
complete disruption of the binding event were identified. It was observed that by 
replacing Pro5 or Arg6 with alanine, the binding of the peptide towards VBC 
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was totally lost. This was in agreement with the structural analysis of Cul2–VBC 
discussed in the previous chapter.  
 
Figure 3.9 – Biolayer interferomery experiments with the alanine scan peptides. 
Biotinylated VBC was immobilised on the tips and the peptides were tested in a 
concentration range from 27 µM to 7 mM. The different colours represent the different 
concentrations and corresponding responses. The assay was performed in 20 mM 
HEPES pH 7.6, 100 mM NaCl, 1 mM DTT, 0.02% Tween-20 at 25 °C. 
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arrangement by establishing intramolecular hydrogen bonds with the carbonyl 
groups from the backbone of Ser2 and Lys4. In addition, replacing Lys4 with 
alanine promoted 10-fold worsening of the binding affinity, however, the 
replacement of other amino acids in the peptide with alanine did not seem to 
perturb the interaction as much. This was an interesting result, suggesting that 
the structural pre-arrangement of the peptide was important to establish the 
interaction.  
 
 
3.2.3.2 Leucine replacement 
A total of 11 amino acids were used to replace Leu3 (Table 3.3). The 
main criteria for choosing these amino acids was to modulate the bulkiness of 
the side chain group, for example, leucine was replaced with phenylalanine and 
t-butylglycine, among others, to increase the volume occupied by the side 
chain. The only exception was arginine, which was chosen to try to catch an 
electrostatic contact at the bottom of the EloC pocket. As before, the peptides 
were tested by BLI for binding to VBC and VBCH. 
The BLI results showed that the EloC pocket could accommodate all the 
derivative peptides, except when leucine was replaced by tryptophan, which 
was probably overly bulky and was found to decrease the binding affinity in 
comparison to the parental peptide (Table 3.3). Replacement of leucine with 
arginine, contrarily to what was predicted, did not improve the binding affinity. In 
addition, it was also observed that the replacement of leucine with t-butylglycine 
and dimethylcysteine (peptides G and J) led to an improvement of the binding 
affinity to the micromolar range. Particularly for peptide J, the Kd values 
determined were 0.3 mM and 0.5 mM for VBC and VBCH, respectively, which 
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encouraged further in-depth characterisation, with the aim to better understand 
its binding interaction.  
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Table 3.3 – Results from the BLI experiment with the peptide variants replacing 
leucine. The Kd of peptide E to VBC could not be determined (ND) as the data could 
not be fitted by the 1:1 model function, suggesting, perhaps, aggregation. Peptide L 
was only tested against VBC. 
 
Peptide Leu3 replacement Kd (mM) VBC 
Kd (mM) 
VBCH 
A Leucine 2.0 ± 0.2 4.5 ± 0.5 
B Tryptophan 18 ± 1 34 ± 5 
C Phenylalanine 3.1 ± 0.2 3.1 ± 0.4 
D Tyrosine 7.4 ± 0.4 8.9 ± 0.2 
E Norleucine ND 1.7 ± 0.2 
F Norvaline 1.9 ± 0.2 3.3 ± 0.3 
G t-butylglycine 0.9 ± 0.1 2.0 ± 0.2 
H Phenylglycine 2.1 ± 0.6 3.1 ± 0.1 
I Cyclohexylglycine 8.9 ± 0.7 1.4 ± 0.2 
J Dimethylcysteine 0.3 ± 0.1 0.5 ± 0.1 
K Thioproline 2.2 ± 0.4 6.3 ± 1.0 
L Arginine 2.5 ± 0.2 - 
 
	
111 
3.2.3.2.1 Characterisation of peptide J binding to VBC 
The binding of peptide J to VBC was characterised by different 
biophysical techniques, in addition to BLI, and all showed consistent results 
(Figure 3.10). Titration of 5 mM of peptide into 100 µM of VBC by ITC 
(Figure 3.10B) resulted in the determination of Kd = 5.28 x 10-4 ± 0.65 x 10-4 M 
(average of two experiments). This three-digit micromolar Kd was concordant 
with the Kd value obtained by BLI. Peptide J was also titrated in the AlphaLISA 
competition assay (described in 2.2.5.2), alongside the parental peptide (A), to 
assess its ability to displace Rbx1–Cul2 from VBC (Figure 3.10C). It was 
observed that both peptides were able to displace Rbx1–Cul2 from VBC with an 
IC50 = 2.2 x 10-4 M, a surprising result, considering the low binding affinity of the 
peptides determined by BLI and ITC. Due to the narrow dynamic range of the 
experiment, this assay could not distinguish the binding of peptide J from 
peptide A (Kd = 2.0 ± 0.2 mM by BLI). Nonetheless, it clearly validated the 
binding to the Cul2 binding site. Protein-observed NMR also suggested that the 
peptide was binding to VBC (concentration-dependent peak shifting observed, 
data in Appendix I). Additionally, chemical shift perturbation (CSP) analysis 
corroborated the AlphaLISA experiment by suggesting that peptide J was 
binding to the EloC pocket (Figure 3.11). All the residues that shifted in the 
presence of the peptide were identified based on the resonance peak 
assignment138 available for VBC and the distances relative to the reference 
peak (VBC in the absence of peptide) were calculated. Only residues that 
shifted more than the average plus one standard deviation (𝑥 + 𝜎 ) were 
considered as significantly shifted. Mapping the significantly shifted residues on 
the structure suggested that the residues more affected by the presence of the 
peptide were near the EloC pocket. There were also some other peaks shifting 
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that correspond to residues in different areas of the protein. It is expected that 
amino acids at a certain distance from the binding site might rearrange upon 
binding of a ligand and, hence, promote shifts. On the other hand, it was 
observed that some peaks corresponding to a certain set of residues were 
always shifted, independently of the ligand titrated (observation based on data 
from other experiments) and those were not taken into account. 
 It is anticipated that the structure of Cul2 N-terminal loop bound to VBC 
can differ significantly when in the context of an 8-mer peptide compared to 
when in the context of the full-length protein. The structural knowledge of the 
binding mode of the peptide in complex with VBC would help to inform 
molecular design to enhance binding. Considering this, efforts were taken into 
co-crystallising peptide J with VBC. Soaking of the peptide into VBC crystals 
was considered, however, according to previous VBC crystal structures, the 
peptide seemed too long to reach the binding site through the channels formed 
by crystal contacts from packing. Therefore, a co-crystallisation approach was 
taken: peptide J and VBC were mixed in 20:1 ratio and the mixture was used to 
set up sparse-matrix screenings (JCSG+ and Classics from Qiagen and 
ProPlex from Molecular dimensions). There was one hit condition in the JCSG+ 
screen, which was reproduced, however, the crystals were too small 
(Figure 3.10D). Despite some optimisation efforts there were no great 
improvements and since there was no confidence that the crystals were protein 
crystals this condition was not followed up. 
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Figure 3.10 – Biophysical characterisation of peptide J binding to VBC. A) BLI 
results. Peptide J was titrated against VBC and a Kd value was determined based on 
the fitting of the response data points. B) ITC experiment. 5 mM of peptide J titrated 
against 100 µM VBC at 298 K (red); a control experiment was performed, in which 
peptide J was titrated in the same conditions against buffer (black) and this data was 
used to subtract the heat of dilution from the first experiment. C) AlphaLISA results of 
the titration of peptides A and J in a competition experiment to displace Rbx1–Cul2. 
D) Co-crystallisation efforts of peptide J with VBC. Crystal objects appeared in 0.1 M 
citrate pH 5.0, 3.2 M AmSO4.  
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Figure 3.11 – Titration of peptide J into VBC analysed by protein-observed NMR. 
A) HSQC spectra with zoom in of shifted peaks. B) Residue mapping of the residues 
shifted by CSP. Residues in white are shifted more than the average plus one standard 
deviation (𝒙 + 𝝈); residues in pink are not assigned in our spectra. 
 
3.2.4 Cyclic pentapeptides 
The motivation for designing cyclic peptides arose from previous results 
suggesting that the conformational pre-arrangement of the peptide was required 
for the binding event. As seen before, the shortest peptide able to bind VBC 
was constituted by 6 amino acids (MSLKPR) and mutation of Pro5 or Arg6 to 
alanine in the context of an 8-mer peptide resulted in total loss of binding. Pro5 
and Arg6 seem to play important roles in stabilising the folded conformation 
(Figure 3.12) and, therefore, it was hypothesised that this folded arrangement 
was a requirement for Cul2 peptides to bind to VBC.  
It was hypothesised that a way of stabilising this structural arrangement 
was by cyclising the peptide, closing a ring between the arginine side chain and 
the serine backbone. Thus, a small library of cyclic peptides with five amino 
acids (Ser-Leu-Lys-Pro-X), in which the side chain of the last amino acid could 
be linked to the backbone of the first residue was designed, synthesised and 
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purified. As with the linear peptides, the leucine residue was substituted with 
natural and non-natural amino acids in an attempt to tighten the binding 
affinities (Figure 3.13). The cyclic peptides were tested for binding to VBC using 
BLI, DSF and ligand-observed NMR.  
 
   
Figure 3.12 – N-terminal loop of Cul2 interacting with EloC and pVHL in the 
crystal structure. The first six amino acids of Cul2 present themselves in the crystal 
structure with a conformation that resembles a cyclic peptide. This conformation seems 
to be stabilised by the side chain of Arg6 that establishes hydrogen bonds with the 
backbone of Ser2 and Lys4. 
 
3.2.4.1 Peptide synthesis and purification 
The design, synthesis and purification of the cyclic peptides was planned 
and executed in collaboration with Dr. Andrea Testa. In these pentapetides, 
Arg6 was replaced by aspartate or glutamate bearing an O-allyl protecting 
group in the side chain. The linear peptides were synthesised as in previous 
sections, however, using a low-loading capacity resin (0.2-0.4 mmole/g), to 
allow the cyclisation to be performed on-resin and avoid intermolecular 
cyclisation. After synthesis of the linear intermediates, simultaneous 
deprotection of the carboxylate group of the side chains of aspartate or 
Ser2 
Leu3 
Lys4 
Pro5 
Arg6 
EloC 
pVHL 
EloB 
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glutamate and the N-terminal Fmoc was performed using stoichiometric amount 
of Pd(PPh3)4 and an excess of piperidine in THF. This was followed by 
cyclisation reaction, performed with HATU, HOAT and DIPEA, which linked the 
side chain of the C-terminal residue to the backbone of the N-terminal 
residue.139 By using glutamate or aspartate as C-terminal amino acids, the size 
of the macrocycle varied by one carbon atom. Then, the cyclic peptides were 
cleaved from the resin and the remaining side chain protecting groups were 
removed using 95% TFA in water. The peptides were purified by HPLC in basic 
conditions and characterised by analytical HPLC-MS. These experiments were 
performed in parallel with the linear peptide derivatives, thus prior to the 
discovery of the stronger binding shown by the dimethylcysteine derivative in 
the position corresponding to Leu3 (corresponding to peptide J). For this 
reason, dimethylcysteine was not included in this initial library of cyclic peptides 
 
Scheme 3.1 – Synthesis of the cyclic pentapeptides. 
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Figure 3.13 – Library of cyclic peptides. Chemical structures of the cyclic peptides 
containing five amino acids, different ring sizes and different side chains in place of 
Leu3. 
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3.2.4.2 Biophysical characterisation 
The peptides were tested for binding towards VBC by BLI, DSF and 
ligand-observed NMR. The results, in some cases, showed very weak binding 
but in most of the cases no binding was detected (results not shown). Some of 
the peptides were also soaked into VBC crystals, datasets were collected from 
these crystals but unfortunately no peptides were found to be bound in any of 
these structures. 
 
3.2.5 Peptides targeting the charge complementarity interface 
The interaction in the EloC pocket is essentially driven by hydrophobic 
contacts and this poses a potential problem in identifying ligands due to lack of 
specificity. Having this in consideration, targeting another point of interaction 
between Cul2 and VBC was contemplated. Despite the flat characteristics of the 
PPI involving helix α5 of Cul2 and VBC, it seemed possible to target this 
interaction with peptides that could recapitulate the electrostatic charge 
complementarity feature (Figure 3.14A). Hence, peptides containing 10 or 15 
residues of the helix α5 of Cul2 were synthesised. The synthesis and 
purification of these peptides were carried out as described earlier.  
 
3.2.5.1 Biophysical characterisation 
The 10-mer peptide was extremely insoluble, therefore, only the 15-mer 
peptide (NH2-DCLYRYLNTQFIKKN-CONH2) was tested for binding towards 
VBC. The peptide was first tested by DSF and it was found to promote a 
decrease in the TM of VBC of about 3 °C (Figure 3.14B). Next, a ligand-
observed NMR experiment (CPMG) was run and a modest decrease in the 
signal of the peptide was observed in the spectrum in the presence of VBC 
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(Figure 3.14C). This result suggested that the 15-mer peptide could bind to 
VBC, although it appeared to be a very weak interaction. In addition, 
protein-observed NMR was employed to investigate the binding site of the 
15-mer peptide. The peptide was titrated at increasing concentrations into a 
sample of 2H,15N-VBC and HSQC spectra were collected for each concentration 
tested. The superposition of the spectra highlighted a number of peaks 
corresponding to residues in VBC that were perturbed and shifting in a 
concentration-dependent manner in the presence of the peptide, including 
Lys159, a residue directly involved in the interaction (Figure 3.14D). This result 
hinted that the peptide was binding at the expected binding site. However, 
unfortunately, most of the residues at the peptide’s binding site were not 
distinguishable in the HSQC spectra, and, therefore, the interaction site could 
not be confirmed. Finally, a Kd = 1.8 x 10-3 M was determined by BLI for the 
interaction of the peptide with VBC (Figure 3.14E). Altogether, the set of 
biophysical experiments performed suggested binding of the 15-mer peptide to 
VBC. However, the data also pointed to a relatively weak binding affinity. 
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Figure 3.14 – Biophysical characterisation of the 15-mer peptide targeting the 
charge complementarity interface. A) Charge complementarity interface in the 
structure of Cul2 (yellow) bound to VBC (pVHL in purple and EloC in blue). B) DSF 
data showed a negative shift for the melting temperature of VBC in the presence of an 
excess of 15-mer peptide. C) Ligand-observed NMR data. CPMG experiment showed 
a reduction of the 15-mer peptide signal in the presence of VBC (red). D) 
Protein-observed NMR. Zoom in of the HSQC spectra showing the concentration-
dependent shift of residue Lys159 directly involved in the interaction. E) BLI data of the 
titration of the 15-mer peptide against VBC, yielding a Kd of 1.8 x 10-3 M. 
   
3.2.6 Clamp peptides 
In an attempt to increase the binding affinity of the Cul2 peptides for 
VBC, an idea to design a peptide linking two epitopes related to the Cul2–VBC 
interaction emerged (Figure 3.15). The two epitopes are constituted by a 6-mer 
peptide of the Cul2 N-terminus and an 8-mer peptide that should recapitulate 
the electrostatic interactions between Cul2 and pVHL. The goal was to increase 
the tightness of the interaction by increasing the points of contact between the 
peptide and VBC. Thus, a flexible linker composed of glycine, serine and lysine 
residues was designed considering the distance between the two attachment 
points.140 This distance, in the crystal structure, is of 18.8 Å. From analysis of 
the Cul21-163-VBC crystal structure,82 the average distance covered by an amino 
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acid in a peptide without secondary structure (amino group to amino group of 
the next residue) is of 3.2 Å, thus the linker was designed to have a fully 
extended length between the two epitopes larger than the distance measured in 
the crystal structure. Two peptides were designed, one containing the original 
leucine and a second one in which the leucine was replaced by 
dimethylcysteine, as in peptide J. These peptides, designated as clamp 
peptides, were synthesised and purified and their binding towards VBC was 
evaluated. The peptide synthesis and purification was performed according to 
the methods already described. 
 
 
Figure 3.15 – Clamp peptide. A) Illustration of the peptidic linker designed to join the 
two epitopes in the structure in the crystal structure of Cul2–VBC. B) Chemical 
structure of the clamp peptide A. 
  
  
Peptidic linker 
  
A 
B 
B 
A 
A) 
B) 
EloB 
pVHL 
EloC 
 
	
122 
3.2.6.1 Biophysical characterisation 
The clamp peptides were very insoluble at high concentrations, which 
constituted an obstacle for the biophysical characterisation. The only reliable 
results were obtained in the AlphaLISA competition assay (Figure 3.16) where 
no significant difference was observed between the two peptides, clamp A and 
clamp J. However, in this assay it was observed a 6-fold decrease in the IC50 in 
comparison to the parental peptide J (36 µM vs. 220 µM, respectively) 
suggesting a greater ability of the clamp peptide J to displace Cul2 from VBC. 
 
Figure 3.16 – Dose-response curves of the AlphaLISA data showing the ability of 
the clamp peptides to displace Cul2. Clamp peptides were titrated into a mixture of 
bead-bound VBC and Rbx1–Cul2. The experiments were performed in quadruplicate 
and the data points shown are the average values for each concentration. The error 
bars represent the standard deviation of each point. 
 
Efforts were conducted to obtain a crystal structure of either of the clamp 
peptides bound to VBC and use it to guide ligand optimisation. 
Co-crystallisation experiments were set up, however, no hits were identified. 
The low solubility of these peptides associated with the low binding affinity to 
VBC hindered the identification of suitable crystallisation conditions, and they 
were not pursued further.  
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3.3 Discussion 
Probing the interaction surface between VBC and Cul2 with peptides 
carries great potential and opportunities for the development of modulators of 
this interaction. Previous work in the Ciulli laboratory has led to the 
development of potent small-molecule disruptors of the pVHL–HIF-1α PPI 
based on the structure of pVHL bound to a 19-mer parental peptide derived 
from HIF-1α.43,52 It was therefore deemed as an attractive strategy to explore 
the potential to apply a similar approach to other non-HIF binding surfaces on 
VBC. In addition, the identification of fragments binding to a new pocket on the 
EloC subunit suggested that this surface on VBC could be ligandable, thus 
exploring avenues to target it with peptides was of interest. This chapter 
described efforts conducted towards the ultimate goal of developing a chemical 
probe for this PPI. 
A construct that allows easy expression of Cul2 with a high yield and in 
an active and stable form would be of great advantage for the biophysical 
evaluation of potential inhibitors of the Cul2–VBC interaction and would allow 
the development of robust assays to screen modulators of this PPI. The 
merging of these two parallel tactics could aid in the investigation of Cul2–VBC 
interaction and would help to determine whether targeting this site provides 
effective approaches and chemical probes to interrogate CRLs biology and 
modulate their activity. 
Protein aggregation is a major issue in recombinantly-expressed 
proteins. Aggregation can be caused by the intrinsic properties of certain 
proteins but it can also be related to factors affecting the expression and 
purification conditions. The co-expression of MBP-tagged Cul2NTD with 
chaperones yielded significant amounts of soluble Cul2NTD, however, it was 
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shown that the protein was extremely prone to aggregation, existing as a 
mixture of multiple species. The one-off experiment where monomeric species 
of Cul21-384-MBP-6xHis was obtained in a considerable amount hinted the 
aggregation could be promoted by the binding to the MBP trap. However, this 
hypothesis was rapidly discarded as it was observed that the monomeric 
species was unstable, forming aggregate as soon as it was isolated. Despite 
the different constructs, tags, expression conditions, lysis methods, purification 
methods and solubilisation efforts, it was not possible to obtain active, stable 
and monomeric Cul2NTD using E. coli as expression system. In fact, there is no 
report of soluble Cul2 expressed in E. coli, with exception of the work from 
Nguyen et al.,82 where Cul21-163 is co-expressed with VBC. Perhaps this was an 
ambitious goal with high risk-benefit balance, that albeit frustrating provided 
evidence that certain human proteins simply require an eukaryotic expression 
system to yield functional recombinant proteins.141,142 
Cul2-derived peptides binding to the EloC site could provide valuable 
insights on how to target the Cul2–VBC PPI. The biophysical results indicated 
that at least six residues (MSLKPR) were needed to observe a binding event 
and the experiments performed allowed to confidently estimate a Kd value of 
approximately 2 mM for the interaction between an N-terminal 8-mer peptide of 
Cul2 and VBC. In addition, Pro5 and Arg6 residues play an important role in the 
binding of the peptide, as the respective mutations to alanine resulted in 
complete loss of binding. This observation is supported by the crystal structure 
where the arginine residue seems to fold back and establishes intramolecular 
hydrogen bond contacts that stabilise the peptide fold, which seems to be 
induced by the proline residue.  
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Replacing Leu3 with a set of natural and non-natural amino acids 
confirmed that side chains bulkier than leucine’s are tolerated for binding. There 
was no significant improvement in the binding affinity for any of the peptides 
tested with the exception of peptides G and J. In these two cases, the leucine 
residue was replaced by a t-butylglycine and a dimethylcysteine, respectively, 
and the Kd values determined by BLI dropped below the millimolar range 
(~ 900 µM for peptide G and ~ 300 µM for peptide J). The biophysical 
characterisation of peptide J suggested moderate binding to VBC and it 
disclosed the opportunity to develop Cul2 peptides into high-affinity binders. 
The strength of the interaction was boosted about 4-fold simply by increasing 
the volume of the side-chain fitting the EloC pocket. Determining the binding 
pose of peptide J would facilitate the structure-based design and help the 
optimisation of the ligand. If this is not achievable by X-ray crystallography in 
the future, perhaps, computational or NMR methods could be applied to predict 
the binding mode and guide ligand design. 
Structural pre-arrangement of peptides could enhance binding affinities 
by reducing the entropic penalty upon binding. A library of cyclic pentapeptides 
was conceived based on this consideration and based on the conformation of 
the N-terminal tail of Cul2 observed in the Cul2–VBC crystal structure. 
Unfortunately, weak or no binding affinities were observed, which could 
potentially be explained by suboptimal cyclisation constraining the peptides or it 
could also be related to the purely hydrophobic nature of the interaction. 
Considering the lack of specificity conferred by a merely hydrophobic 
interaction, other PPI contacts were explored. The 15-mer peptide targeting the 
helix α5-VBC interaction proved to be a very weak binder. Perhaps a way of 
tightening the interaction could be to stabilise the helical conformation of the 
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peptide by peptide stapling,61  for example, mimicking the original PPI. On the 
other hand, the clamp peptides linked two epitopes of Cul2 and promoted a 
6-fold reduction in the IC50 value compared to the parental 8-mer peptide J. 
There were issues with the solubility of these peptides that could be addressed 
in the future by replacing the linker with a more hydrophilic chain, for example. 
Once these peptides are soluble at higher concentrations, a proper biophysical 
assessment can be performed. From then, structural information on the binding 
mode could help ligand-optimisation.  
 
In conclusion, it has proven very challenging to target the PPI between 
VBC and Cul2, potentially because of its hydrophobic driven and relatively flat 
features (the buried surface area is 1022 Å2), which might compromise the 
development of high affinity ligands. Other drug discovery tools such as peptide 
stapling,61 tethering,55 or even helix mimetics,62 for example, might be helpful 
toward this goal. Another approach to target this kind of PPIs could be the use 
of bicyclic peptides as they cover a large surface area and are able to closely 
mimic PPI features.143 In a later stage, combining the information obtained from 
the fragment work with the peptide work could lead to the design of merged 
molecules that could act as potent chemical probes to study CRLs biology. 


 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4  
BICYCLIC PEPTIDES AND STUDIES OF THEIR BINDING 
TOWARDS THE VBC COMPLEX 
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4.1 Introduction 
Cyclic peptides are considered an attractive modality for the 
development of chemical tools and molecular therapeutics as they can combine 
key features such as good binding affinity, target selectivity and low toxicity.63 
However, the application of cyclic peptides to probe protein surfaces is 
relatively under explored. The term bicyclic peptide used in this chapter refers 
to cyclic peptides containing two relatively flexible loops attached onto a rigid 
central scaffold. Bicyclic peptides tend to have a more constrained structure, 
when compared to monocyclic or linear ones. This arrangement allows a closer 
mimicry of antibodies in terms of their molecular recognition, binding affinity and 
specificity properties (Figure 4.1).144  
 
Figure 4.1 – Differences between a small-molecule, a bicyclic peptide and an 
antibody. The small-molecule (purple) is a VHL inhibitor (PDB: 4W9C)43; the bicyclic 
peptide (blue) is a inhibitor of the urokinase-type plasminogen activator 
(PDB: 4MNX)145; and the antibody (red) is the human IgE-Fc (PDB: 5LGK).146 
 
In addition, these structural features have been shown to introduce 
improvements in binding affinities as well as resistance to intracellular 
degradation and metabolic activities.147 Hence, bicyclic peptides are suitable 
Small molecule Bicyclic peptide Antibody 
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candidate probes to modulate protein-protein interactions as they are able to 
establish extensive contacts (buried surface areas > 700 Å)148 with globular 
proteins and they are expected to bind tightly to protein surfaces. 
Heinis and Winter149 have described a strategy to select bicyclic peptide 
ligands, which combines the phage display technology with the covalent 
attachment of a chemical core onto a linear peptide. Phage display is an in vitro 
screening technique for the identification of ligands for proteins and it entails the 
expression of a peptide sequence as fusion to the coat protein of a 
bacteriophage. Thereby the phage-displayed peptides are physically linked to 
their encoding DNA, permitting the selection of binding partners by iterative 
rounds of biopanning and amplification, followed by DNA sequencing.150 This is 
one of the major advantages of this technology, together with the possibility of 
screening over a billion different molecules at the same time. The ultimate goal 
of a phage display screening is to identify a consensus sequence or motif that is 
enriched throughout the rounds of biopanning, consistent with a tight, 
target-specific binder. 
In this chapter, the application of phage-display technology to the 
screening of bicyclic peptide libraries against VBC is described. The libraries 
used were obtained from Prof. Christian Heinis (EPFL, Lausanne). The peptides 
displayed at the N-terminus of the minor coat protein pIII of the phage contained 
three reactive cysteine residues (spaced apart by a variable number of random 
amino acids), which allowed conjugation with 1,3,5-tris-(bromomethyl)benzene 
(TBMB).143 As a result, a peptide formed by two peptidic loops linked by a 
mesitylene core is generated (Figure 4.2) and screened against the target of 
interest. Each phage particle presents five copies of the pIII protein, therefore, 
five peptides are displayed on its surface. The libraries were constructed using 
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degenerate primers to code for the randomised regions of amino acids, in 
between the conserved cysteine residues.151 
 
 
Figure 4.2 – Phage display of bicyclic peptides. Representation of the peptides 
displayed on the phage coat being cyclised with TBMB prior to screening. 
 
The rationale was, therefore, to identify peptide binders of the VBC 
complex using an unbiased approach. It was intended to understand whether 
bicyclic peptides could be accommodated in either the HIF-1α site or the new 
binding sites identified by fragment screening from previous work in the Ciulli 
laboratory, and whether other binding sites within the complex could be 
identified. In this chapter, the results of a phage display screening of three 
libraries of bicyclic peptides are presented and the respective results are 
discussed. 
  
cysteine
random	amino	acid
Br
Br
Br
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4.2 Results 
4.2.1 Phage display screening 
Three phage-display libraries of bicyclic peptides were screened against 
VBC and VBCH (Table 4.1). The differences between each library lay on the 
number of randomised amino acids that constitute each loop. The reason to 
perform the screening against VBC and VBCH was to potentially discriminate 
between ligands of the VBC–HIF-1α interface and of other binding sites as a 
mean to aid their identification. The size of each library was determined 
experimentally by counting the number of bacterial colonies formed after 
transformation.143 
 
Table 4.1 – Phage display libraries of bicyclic peptides. VL1, VL2 and VL3 libraries 
were screened. The library size, expected bicyclic format according to possible loop 
lengths [(X)mx(X)n] are presented. The library size was experimentally determined.143  
 
 
Briefly, the screening protocol152 (Figure 4.3) consisted first in the 
amplification of the library using E. coli as host organism. The amplification is an 
important step to ensure that each member of the library is represented at least 
10 times, on average.151 Then, the amplified phages were isolated from the 
bacteria and the peptides displayed on the phage coat were cyclised by 
incubating a diluted phage solution with excess of TBMB under reducing 
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conditions (1h at 42 °C). Next, in a step named biopanning, the phages were 
screened against the target, which had been prior immobilised covalently on 
tosyl-activated magnetic beads (Dynabeads M-280 tosyl-activated, Invitrogen). 
The phage solution of bicyclic peptides was incubated with the magnetic beads 
loaded with VBC or VBCH for 1h at room temperature, allowing peptides to bind 
to the protein. After this step, the beads were washed thoroughly to dissociate 
the unbound phages and then the phages that were still attached to the protein 
(binders) were eluted with a solution of glycine at low pH. In the next step, the 
process was repeated from the beginning, starting with the amplification of the 
phages from the previous round. In total, four rounds of biopanning were 
performed for the screening of each library, in an attempt to enrich the binders. 
The DNA of thirty clones from the last round of biopanning of each library was 
sequenced and the peptide amino acid sequences were analysed. 
 
Figure 4.3 – Phage display screening methodology applied. The methodology 
applied consisted on 4 rounds of biopanning, which contemplated phage amplification, 
cyclisation with TBMB, screening against the immobilised target and enrichment of the 
binders. 
 
Throughout the rounds of biopanning, a negative control was performed 
in parallel, where the phage solution was incubated with the beads in the 
Phage display 
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Enrichment 
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with TBMB 
DNA  
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absence of protein. It was expected that the number of colonies obtained in the 
negative control would be lower than the number of colonies from the 
biopanning round, which was indeed observed in all cases. 
 
4.2.1.1 Screening of the VL1 library 
The VL1 library had a complexity of 5 x 108, the number of random 
amino acids varied between 7 and 8, and the loops forming the bicyclic 
peptides could assume 5 different formats, (3x4, 4x3, 4x4, 3x5 or 5x3). The 
screening of this library in the format of bicyclic peptides led to the identification 
of 19 different peptide sequences against VBC and another 19 against VBCH 
(Table 4.2). Surprisingly, there were no common sequences between the VBC 
and VBCH screening. Some sequences of the peptides identified were 
observed more than once but the sequences within each of the screenings 
(VBC or VBCH) were very variable and no consensus motif could be identified.  
 
Table 4.2 – Screening of the VL1 library. Sequences of peptides pulled down after 
the fourth round of biopanning against VBC (left panel) and VBCH (right panel). The 
number on the left of each peptide reflects the number of occurrences of the sequence. 
 
VL1 vs. VBC VL1 vs. VBCH
1 ACQEACDIWPCG 2 ACPRMCHTLPCG
1 ACIIWCTLIFCG 1 ACVPQCGDPQCG
2 ACWSYCPTYICG 1 ACTTECAVKQCG
1 ACQMVCQHTICG 5 ACRARCPLEQCG
2 ACSYYCSWTQCG 1 ACVNNCHAPICG
1 ACGNTCANLSICG 1 ACAVQCHFPHCG
1 ACAPWCYILWHCG 1 ACVPGCATMCACG
1 ACPQTCLVSHRCG 2 ACVLFCFFLLCCG
5 ACAYSCVLQGICG 1 ACAGANCINSCG
1 ACQDLCWWSNLCG 1 ACQTTVCHFDCG
4 ACSISMCNVTCG 4x3 3 ACLPRQCQDLCG
1 ACMRSICTDGTCG 1 ACTNLTCSSHCG
2 ACSNYHCPQHECG 1 ACPALSCSASNCG
1 ACIRHTCELSNCG 2 ACQHRKCYAFVCG
2 ACLDLRCQLPYCG 1 ACWDVRCSQLFCG
1 ACLFVLTCLFYCG 1 ACLQHACMDIRCG
2 ACPFGVDCQYLCG 2 ACASRTCNVLSCG
1 ACSSVQFCGHLCG 2 ACHSTKSCRNSCG
1 ACTQRNHCAPLCG
3x4
3x5
4x4
5x3
3x4
3x5
4x3
4x4
5x3
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4.2.1.2 Screening of the VL2 library 
The VL2 library comprised 14-mer peptides, with nine of the fourteen 
residues random, and had a complexity of 1 x 107. The loop sizes and 
arrangements of these bicyclic peptides could vary between 3x6, 6x3, 4x5 or 
5x4. The biopanning of this library cyclised with TBMB generated 21 different 
peptide sequences against VBC and 20 against VBCH out of 30 sequencing 
results in each case (Table 4.3). This time, there were five peptide sequences in 
common between the screening of VBC and VBCH. 
 
Table 4.3 – Screening of the VL2 library. Sequences of peptides pulled down after 
the fourth round of biopanning against VBC (left panel) and VBCH (right panel). The 
number on the left of each peptide reflects the number of occurrences of the sequence. 
The sequences in red were simultaneously pulled down against VBC and VBCH.  
 
 
Additionally, it was also observed some similarity between sequences within the 
same target. For instance, the ‘NSGTCR’ motif was found in three sequences in 
the bicyclic peptide format 5x4 against VBC; the motif ‘QWTCS’ was found in 
VL2 vs. VBC VL2 vs. VBCH
1 ACGPVCPTSQLLCG 1 ACQWTCSWFTCNCG
4 ACEERCPMAQSGCG 1 ACQWTCSRFTCSCG
1 ACLRGCQNAQTTCG 3 ACEERCPMAQSGCG
1 ACGLRGCQHTEFCG 2 ACEERCPMAYSGCG
1 ACIQSVCYQGSKCG 1 ACDERCPMAYSGCG
1 ACFDQLCWFYGICG 1 ACPRICSQQSSACG
1 ACDLRACQHNEPCG 1 ACFHYCVFFLCYCG
3 ACQRTMCLLPQFCG 1 ACHWMPCYTPQSCG
1 ACQLQPCHGIPKCG 1 ACEDHFCTVYTPCG
1 ACWHNSCYSSGQCG 1 ACPLSPCPDIRSCG
1 ACWKVSCPSSRNCG 1 ACPVKTCPPAMNCG
1 ACPSQSCEFLRMCG 1 ACRFSTCNPQLECG
1 ACPSAACSQGIVCG 5 ACFDQLCWFYGICG
1 ACPGAFCPKLNTCG 1 ACSSVPCQLAALCG
1 ACSNSGTCRGSYCG 2 ACGLRGCQHTEFCG
1 ACQNSGTCRSAYCG 1 ACGLRRGCQHTEFCG 5x5
1 ACSQPSMCRIMACG 1 ACQSSVVCSGSHCG
2 ACYPPRLCRSASCG 2 ACSNSGTCRSGYCG
4 ACDPASRCRQDPCG 2 ACDPASRCRQDPCG
1 ACGFTLGCAQQQCG 1 ACLLPHTSCQVECG 6x3
1 ACSNSGTCRSGYCG
3x6
5x4
4x5
3x6
4x5
5x4
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two sequences of the 3x6 format against VBCH and the motif ‘EERCPMA’ was 
found in three peptides of the VBCH screening. Despite the still large variability 
of the peptide sequences pulled down, these results were encouraging. 
  
4.2.1.3 Screening of the VL3 library 
The VL3 library contained 15-16-mer peptides with 10-11 random amino 
acids. This third library had a complexity of 6 x 107 and the loops of the peptides 
could acquire one of following configurations: 4x6, 6x4, 5x5, 5x6 or 6x5. The 
screening of the cyclised library against VBC resulted in a remarkable 
enrichment of the sequence ACQLKRLNCHNSPLCG that was found in 20 
peptides out of the 30 sequenced. The remaining two sequences identified, 
ACGHYKSCAYNQFCG and ACSNTRQCPSYHLRCG, were found 7 and 3 
times, respectively. However, none of these sequences was observed amongst 
the 24 peptides found in the screening against VBCH (Table 4.4). The 
sequence with the highest level of enrichment for VBCH was 
ACLKSPLCAQAPQACG that was found 4 times and differs only in two amino 
acid residues from the fourth sequence of the 5x6 format. 
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Table 4.4 – Screening of the VL3 library. Sequences of peptides pulled down after 
the fourth round of biopanning against VBC (left panel) and VBCH (right panel). The 
number on the left of each peptide reflects the number of occurrences of the sequence. 
 
 
4.2.1.4 Screening of VL1, VL2 and VL3 together 
The results obtained from the independent screening of each library did 
not yield a convergent consensus sequence and were, in fact, quite variable. 
Therefore, it was decided to pull together the phages from the last round of 
each screening (separately for VBC and VBCH) and perform an ultimate round 
of biopanning. The idea was that the best binders of each library would be 
competing with each other and the best binders amongst the three libraries 
would, in principle, be enriched.  The results showed 7 different peptide 
sequences being enriched against VBC and 9 against VBCH (Table 4.5) out of 
the 10 clones sequenced for each screening.  There were two sequences in 
common between the biopanning against VBC and VBCH but no general 
VL3 vs. VBC VL3 vs. VBCH
7 ACGHYKSCAYNQFCG 5x5 1 ACTLLSCQSLHRTCG
3 ACSNTRQCPSYHLRCG 5x6 1 ACMSQSCGTYSAYCG
20 ACQLKRLNCHNSPLCG 6x5 2 ACAQVSCSQRQQLCG
1 ACPKSLCNQSMSLCG
1 ACLRQTCVQSESICG
1 ACWKGSCRTSQSFCG
2 ACFFYGLCLVFIGHCG
1 ACSQHWACPMSSGSCG 5x6
1 ACNRYVRCASNSAFCG
1 ACLKSPLCAYAPQGCG
4 ACLKSPLCAQAPQACG
1 ACLSVISCIGTQPCG
1 ACGKARFCFGNALCG
1 ACQLSSQCTNQNNCG
1 ACLAALKCSQSSACG
2 ACALQVGCELAPMCG
1 ACQAVPPCMLTQICG
1 ACPKQGMCKLNASCG
1 ACMPQALCSLYGTCG
1 ACLHRAPCLLMQHCG
1 ACLKAPLCAQAPACG
1 ACSHRDVNCPIELCG 6x4
1 ACEMFRPPCTHRDICG
1 ACRQLVWSCGERMLCG
6x5
4x6
5x5
 
	
140 
consensus was observed, however, peptides with the format 4x5 or 5x4 
seemed to be preferred in regards to others in the screening against VBC. 
 
Table 4.5 – Screening of VL1, VL2 and VL3. Sequences of peptides pulled down 
after the round of biopanning against VBC (left panel) and VBCH (right panel). The 
number on the left of each peptide reflects the number of occurrences of the sequence. 
The sequences in red were simultaneously pulled down against VBC and VBCH. 
 
 
In a final attempt to improve the output of the phage display screening, 
phages from all the steps of the screening (round 1, 2, 3 and 4 from VL1, VL2 
and VL3) against VBC and VBCH were screened together against VBC in one 
last round. Only 10 colonies were sequenced and the results showed that 
instead of obtaining a convergent sequence, as expected, 7 different peptide 
sequences were enriched (Table 4.6).  
 
Table 4.6 – Last round of biopanning against VBC. Sequences of peptides pulled 
down after the last round of biopanning against VBC. The number on the left of each 
peptide reflects the number of occurrences of the sequence. 
 
 
VBC VBCH
1 ACLYTCESIFLKCG 2 ACEERCPMAQSGCG 3x6
1 ACEERCPMAQSGCG 1 ACQSSVVCSGSHCG
2 ACGLRGCQHTEFCG 1 ACDPASRCRQDPCG
1 ACFDQLCWFYGICG 1 ACPKQGMCKLNASCG
1 ACYPPRLCRSASCG 1 ACPTQDPCLSSIECG
3 ACDPASRCRQDPCG 1 ACQPTSPCMAPLLCG
1 ACSNTRQCPSYHLRCG 5x6 1 ACPKSLNCNQSMSLCG
1 ACFFYGLCLVFIGHCG
1 ACYNAKMSCLDPYCG 6x4
3x6
4x5
5x4
5x4
5x5
5x6
VBC
2 ACLYTCESIFLKCG 3x6
3 ACGLRGCQHTEFCG 4x5
1 ACPTQDPCLSSIECG 6x5
1 ACQPTSPCMAPLLCG 5x5
1 ACYNAKMSCLDPYCG 6x4
1 ACYPPRLCRSASCG 5x4
1 ACFEMTCPKQSFLCG 4x6
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The phage display screening did not yield a unique consensus motif but, 
instead, it generated a diverse set of bicyclic peptides with different 
combinations of ring sizes and sequences. Some of the sequences were 
heavily enriched though as it was observed in the VL3 screening against VBC, 
where 20 out of 30 colonies shared the same peptide sequence and this was 
encouraging. On the other hand, the screening of the VL2 library resulted in a 
number of hits conserved between VBC and VBCH. Despite the overall result 
being different from the expected, it was hoped that the different binding motifs 
could provide suitable starting points for optimisation of the peptides into potent 
binders. 
 
4.2.2 Synthesis of the bicyclic peptides identified from the phage display 
screening 
Considering the diversity of bicyclic peptides obtained, to increase the 
chance of finding real binders of the VBC complex, all the peptide sequences 
identified in the phage display screening were synthesised for further 
evaluation. In total, 126 bicyclic peptides were synthesised. The synthesis of 
the bicyclic peptides contemplated two steps: synthesis of the linear peptide 
and cyclisation with TBMB. The linear peptides were synthesised in 15 µmole 
scale and the work up and cleavage from the resin were performed by mixing 
the resin in a solution of TFA:H2O:1,2-ethanedithiol:phenol:thioanisole (v/v, 
90:2.5:2.5:2.5:2.5) for 3h at room temperature. Next, the TFA mixture 
containing the peptides was filtered and the linear peptides were precipitated 
with cold diethyl ether. This precipitate was filtered, washed with diethyl ether, 
dissolved in a water:acetonitrile solution and lyophilised. For the cyclisation of 
the peptides, the protocol followed consisted of an alkylation reaction achieved 
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by the dilution of the peptide in 40 mM NH4HCO3 pH 8.0 in the presence of 
1 mM of TBMB for 1h at 30 °C, consistent with the protocol described by 
Rebollo et al.153 At this point it was observed that most of the peptides were not 
completely soluble in these conditions, as the formation of a white thin solid was 
observed. Even in the cases where the peptides were soluble in acetonitrile, a 
white precipitate was observed upon addition of the buffer. 
 
 
Figure 4.4 – Schematic reaction of the cyclisation of the linear peptides with 
TBMB to originate bicyclic peptides. The reaction is carried out in a diluted solution 
of peptide in 40 mM (NH4)HCO3 pH 8.0 buffer in the presence of 1 mM of TBMB for 1h 
in a 30 °C water bath, according to previous literature.153 
 
The reaction mixture was then lyophilised and the next step was the 
purification of the peptides by HPLC. The purification of the bicyclic peptides 
was optimised on an analytical scale (Zorbax SB300 C18 4.6x250 mm column) 
for some of the bicyclic peptides and the optimal conditions for the isolation of 
the products of interest were identified. However, the efforts to scale up this 
purification step to the preparative range and to develop an automated method 
for the cyclisation-purification have not been completely successful as it was 
observed that the same conditions could not be applied to all the peptides due 
to differences in number of amino acids, total charge and polarity. Having this in 
Br
Br
Br
S
S
S
SH 
SH 
HS + 
NH4HCO3 
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consideration it was decided to use the crude mixture for preliminary 
biophysical evaluation, assuming the cyclised peptide was present as the major 
species in the mixture. The success of the cyclisation reaction was assessed by 
MALDI-TOF mass spectrometry and in total, 86 peptides were confirmed to be 
cyclised. 
 
4.2.3 Initial screening of the bicyclic peptides 
Considering the 15 µmole scale at which the peptides were synthesised, 
assuming an average yield of 60% (based on a sample of 10 peptides), a 
molecular weight of 1500 Da and a quantitative cyclisation reaction, the crude 
mixture was dissolved in 450 µl of DMSO to a rough concentration of 20 mM. 
These 86 peptides were then tested as crude mixtures for binding towards VBC 
by two orthogonal techniques, DSF and BLI. 
 
4.2.3.1 Differential Scanning Fluorimetry 
The DSF assay, also known as thermal shift, measures the thermal 
stability of a protein and subsequent change in its melting temperature (TM) 
upon binding of a ligand. The denaturation curve of VBC in buffer (Figure 4.5) 
reported an unfolding event at 51 °C, whereas in the presence of a nanomolar 
binder, HIF-1α 19-mer peptide, used as positive control, the melting 
temperature of the complex is increased to 59 °C, as expected. The bicyclic 
peptides were tested at a final concentration of 500 µM, whilst the protein 
concentration was kept at 7.5 µM. The analysis of the thermal denaturation 
curves (Figure 4.5) revealed that most of the peptides exhibited a level of 
fluorescence close to the detection limit at the lowest temperature and, 
therefore, no increase in fluorescence upon unfolding of the protein could be 
 
	
144 
readily detected. This could potentially be explained by the fact that the bicyclic 
peptides can, on their own, mimic protein interfaces with exposed hydrophobic 
patches that can bind SYPRO Orange. This phenomenon makes the assay 
unreliable for these peptides hence the results must be taken with caution. In 
the cases where it was possible to observe an appropriate denaturation curve, 
negative shifts in the melting temperature were generally observed, suggesting 
destabilisation of the VBC complex in the presence of the crude bicyclic peptide 
mixture. 
 All together, the thermal shift experiment results were inconclusive.  
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Figure 4.5 – Differential scanning fluorimetry experiment. A) Thermal denaturation 
curves of VBC (7.5 µM) in the presence of 500 µM of the each of the 86 bicyclic 
peptides tested. B) Derivatives of RFU relative to temperature are plotted for VBC 
(7.5 µM) in the presence of 500 µM of the each of the 86 bicyclic peptides tested. The 
melting temperatures of VBC and VBC in the presence of the HIF-1α 19-mer peptide 
(VBCH) are marked in black and red, respectively. The assay was performed in 
100 mM Bis-tris propane pH 7.5, 1 mM DTT, 10% DMSO, 0.02% Tween-20. 
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4.2.3.2 Biolayer interferometry 
The attention was then turned to the characterisation of peptide binding 
using BLI. The experiment was performed stepwise. Initially, the 86 bicyclic 
peptides were tested in a single-point concentration assay and then, 
dose-response curves were obtained from the ones originating a measurable 
response in the first round, to assess concentration-dependent effects. 
 
4.2.3.2.1 Single-point concentration assay 
In this assay, streptavidin-coated biosensor tips were loaded with 
biotinylated VBC or VBCH and were dipped into a solution of bicyclic peptide 
(approximately 500 µM). The assay was designed with an association step of 
60 seconds (when the tip is dipped into the well containing the ligand) and a 
dissociation step of 180 seconds (when the tip is dipped in a well containing 
only buffer and the ligand dissociates from the protein). All the 86 crude 
mixtures of cyclised peptides were tested in this assay against VBC and VBCH. 
Of these, 17 peptides showed a positive response against VBC and 41 peptides 
showed positive response against VBCH (15 being common to both assays) – 
data in Appendix I. This yielded 43 unique bicyclic peptides, which were taken 
forward to a concentration-dependent response assay against VBC and VBCH. 
 
4.2.3.2.2 Concentration-dependent response assays 
The aim of this experiment was to validate and further characterise the 
peptides previously identified in the single point screening as actual binders. To 
this end, the peptides (still as crude mixture) were titrated against VBC and 
VBCH starting at a top concentration of approximately 500 µM and using 
three-fold dilutions to a minimum concentration of approximately 2 µM. The set 
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up of the experiment was maintained. In some cases, the data at the top 
concentration of the peptides was consistent with aggregation, thus the 
measurements at this concentration were excluded from the analyses. Of the 
43 bicyclic peptides tested, 19 showed concentration-dependent responses 
against VBC and VBCH with estimated Kd values in the range of double-digit 
micromolar (Table 4.7, sensorgrams in Appendix I).  
 
 
	
148 
Table 4.7 – Concentration-dependent response BLI assays. Bicyclic peptides 
(crude mixture) were titrated against VBC and VBCH and 19 peptides showed 
concentration-dependent response. Kd values were determined based on the fitting 
associated to the response obtained in function of the concentration using a 1:1 model. 
The R2 values represent how well the data is fitted to the model. The assays were 
conducted in 100 mM Bis-tris propane pH 7.5, 1 mM DTT, 10% DMSO, 0.02% 
Tween-20.  
  
 
These 19 bicyclic peptides were selected for scale-up synthesis, 
purification and in-depth characterisation of binding towards VBC. 
 
Peptide Kd (µM) R2 Kd (µM) R2 
15 33 0.9913 72 0.9969 
22 26 0.9935 69 0.9995 
24 12 0.9972 26 0.9536 
27 8 0.9855 29 0.9769 
30 8 0.9902 8.8 0.9319 
34 19 0.8274 41 0.9708 
37 2.7 0.9962 4.1 0.9690 
41 6.7 0.9317 13 0.9750 
64 44 0.9943 44 0.9939 
66 37 0.9868 18 0.9492 
73 51 0.9772 60 0.9936 
74 180 0.9986 - - 
86 11 0.8741 59 0.9955 
93 9.2 0.8584 81 0.9989 
107 100 0.9967 - - 
108 21 0.9912 65 0.9878 
109 35 0.9859 55 0.9997 
113 14 0.9345 48 0.9960 
115 23 0.9948 49 0.9995 
VBC VBCH 
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4.2.4 Large-scale synthesis and purification of the hit peptides 
The 19 bicyclic peptides selected were synthesised in a larger scale. The 
peptide synthesis and cyclisation of the peptides was performed as described 
before. The following step, HPLC purification, was hindered as the solubilisation 
of the peptides proved a difficult task. Different ratios of H2O:ACN were tested 
in combination with variable percentages of DMSO. Also the presence (< 0.1%) 
of TFA, formic acid or ammonium sulfate in the solutions was tested. In 
addition, the peptide solutions were sonicated in an attempt to improve the 
solubilisation. Nonetheless, some peptides were not soluble in any of the 
conditions tested and due to these solubility issues the HPLC purification was 
only carried out for 12 of these peptides. The purification was performed in 
acidic conditions and the gradient of H2O:ACN was optimised for each peptide. 
However, the yield of the purifications was very poor (10-20%) and only a small 
amount of purified bicyclic peptide was recovered (1-3 mg). This low yield could 
be explained by two factors related to the conditions required for the 
solubilisation of the peptides that, on one side could have prevented the 
peptides to be retained in the HPLC column and, on the other side, could have 
prevented the detection by the UV-Vis detector due to the low concentration 
and, therefore, prevented their recovery. According to the analytical HPLC-MS 
traces (shown in Chapter 6), of the 12 recovered peptides only peptides 34, 66, 
86, 109, 113 and 115 (Figure 4.6) were satisfactorily pure (> 95%) to be tested 
biophysically for binding towards VBC. With the exception of peptide 66, which 
was identified 5 times in the screening of VL1 against VBC, the remaining 
peptides were observed only as a single instance during the phage display 
screening.  
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Figure 4.6 – Bicyclic peptides for validation. Chemical structures of bicyclic peptides 
34, 66, 86, 109, 113 and 115. 
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4.2.5 Validation of binders 
The binding of the bicyclic peptides 34, 66, 86, 109, 113 and 115 to VBC 
was investigated by three orthogonal biophysical techniques – BLI, DSF and 
ligand-observed NMR. The thermal shift experiment results determined 
neglegible shifts (< 1 °C) in the melting temperature of VBC in the presence of 
the bicyclic peptide (Figure 4.7). Moreover, in the cases of peptides 86 and 109 
these shifts were negative, suggesting a destabilisation of the complex. The 
extent of the shifts observed were in any cases minimal, suggesting weak 
binding if at all. 
 
 
Figure 4.7 – Derivative curves from the DSF experiment. Bicyclic peptides (250 µM) 
were mixed with 7.5 µM VBC in 100 mM Bis-tris propane pH 7.5, 1 mM DTT, 10% 
DMSO, 2.5x SYPRO Orange and the denaturation curves measured. The curves 
shown are the average of a duplicate. For reference, the curves of VBC (black dashed) 
and VBC in the presence of HIF-1α 19mer (red dashed) are shown.  
 
Next, the peptides were titrated by BLI against VBC. The range of 
concentrations tested varied from 500 µM to 2 µM. It was observed that after 
the purification only bicyclic peptides 34, 66 and 109 showed 
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concentration-dependent response by BLI (Figure 4.8). However, the responses 
observed for peptides 34 and 66 showed systematic deviations between the 
experimental data and the fitted values, suggesting that the simple 1:1 binding 
model used did not accurately reproduce the data. Thus, other effects in 
addition to genuine and reversible 1:1 binding were likely to be accounting for 
the observed signal. 
 
 
Figure 4.8 – BLI experiments. Bicyclic peptides were titrated against VBC in a 
concentration range from 500 µM – 2 µM. Biotinylated VBC was immobilised in 
streptavidin-coated sensors. The assays were conducted in 100 mM Bis-tris propane 
pH 7.5, 1 mM DTT, 10% DMSO, 0.02% Tween-20. 
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Finally, peptides 34, 66, 86 and 109 were also tested by ligand-observed 
NMR (the amount left of peptides 113 and 115 was not enough to test them in 
this experiment) - Figure 4.9. In the CPMG experiment, the 1H NMR spectrum 
of the sample was recorded in the absence and in the presence of VBC and, 
upon a binding event, it was expected to observe a decrease in the intensity of 
the peaks. Peptide 34 showed no binding, peptides 66 and 86 suggested a 
weak interaction and peptide 109 showed moderate binding in this experiment.  
 
 
Figure 4.9 – Ligand-observed NMR experiments. CPMG experiments were 
performed to assess binding of the bicyclic peptides to VBC and isolated peaks from 
each experiment are shown. Blue corresponds to the 1H spectrum of 1 mM of peptide 
and red corresponds to the 1H spectrum of 1 mM of peptide in the presence of 30 µM 
of VBC. 
 
The combination of results obtained from the different techniques 
(Table 4.8) suggested these bicyclic peptides to be weak binders of the VBC 
complex. Efforts were conducted to scale up the synthesis and purification of 
these peptides in order to perform a greater biophysical evaluation and use 
other techniques such as, isothermal titration calorimetry, X-ray crystallography 
and protein-observed NMR. However, their lack of solubility constituted the 
major obstacle for the cyclisation and purification steps and prevented the 
continuation of the work.  
Peptide 34 Peptide 66 Peptide 86 Peptide 109 
8.65 8.60 7.3 0.9 1.26 1.24 1H (ppm) 1H (ppm) 1H (ppm) 1H (ppm) 
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Table 4.8 – Validation of bicyclic peptides as binders. The peptides were tested by 
DSF, BLI and NMR. ND means not determined; X means no binding observed and a 
tick means binding observed. 
 
 
  
Peptide 
number 
Peptide  
sequence 
Peptide 
format 
ΔTM 
 (oC) 
BLI  
KD (M) 
NMR  
(CPMG) 
34 ACWKVSCPSSRNCG 4x5 ND 9.8 x 10-4  X 
66 ACRARCPLEQCG 3x4 + 0.4 (bad fitting) 
86 ACRFSTCNPQLECG 4x5 - 0.3 X 
109 ACGKARFCFGNALCG 5x5 - 0.7 9.4 x 10-4  
113 ACQPTSPCMAPLLCG 5x5 + 0.8 X ND 
115 ACFEMTCPKQSFLCG 4x6 + 0.3 X ND 
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4.3  Discussion 
Protein-protein interactions are challenging targets due to their large 
interface areas and relatively flat and featureless topologies. One avenue to 
overcome this challenge is by using mimetics of protein surfaces. Bicyclic 
peptides arise in this context as ideal candidates to accomplish this goal. They 
provide a large surface area with potential for tight binding affinities and 
selectivity and they present a constrained arrangement, which might enhance 
the binding properties as well as reduce the entropic penalty upon binding.63 
The phage display screening of bicyclic peptides performed against VBC 
and VBCH generated a set of 126 peptides with different formats and 
sequences. Libraries VL1 and VL3 yielded no unique consensus sequences, 
although the screening of VL3 against VBC originated one highly enriched 
sequence. Conversely, the screening of library VL2 resulted in some 
convergence, with the same motifs being repeated in different peptides. 
Moreover, five sequences from the VL2 library were simultaneously identified in 
the two independent screenings against VBC and VBCH, hinting at some 
specific binding. In addition, in the last round of biopanning, the 4x5 and 5x4 
format of bicyclic peptides seemed to be preferred for binding to VBC. In fact, 
the same trend has been reported against a different target,143 suggesting that 
the VL2 library might contain the preferred format of bicyclic peptides to act as 
binders. Taking into account the lack of unique consensus obtained from the 
phage display, all the bicyclic peptides identified were tested for binding. From 
the dose–response BLI experiments, 19 peptides showed binding affinities in 
the micromolar range, which was encouraging. The fact that the peptides had 
been tested as crude mixtures up until this point could be masking tighter 
binding affinities or hiding false positives. For this reason, some of these 
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peptides (34, 66, 86, 109, 113 and 115) were tested again in a purified state, 
which led to their confirmation as very weak binders. None of the peptides 
showed binding in all the three biophysical experiments performed (DSF, BLI 
and NMR), the Kd value determined by BLI for peptide 109 was close to the 
millimolar range (940 µM), and the BLI response for peptide 34 was 
unexpectedly high with the curves not reaching a plateau, thus suggesting 
aggregation. Despite weak, if these bicyclic peptides were real binders they 
could provide starting points for their optimisation into potent ligands. This could 
be achieved by small modifications at the side chain level or even replacement 
of some residues by D-amino acids,154 which could be guided by X-ray 
crystallography and protein-observed NMR, for instance. Having this in mind, it 
was decided to scale up the synthesis and purification of the bicyclic peptides 
tested. However, this proved very challenging as the peptides where extremely 
insoluble, complicating the purification step, where, invariably, large amounts of 
peptide were lost. Despite much effort, which involved different solvents, 
different approaches of solubilisation and even the addition of arginine residues 
at the N-terminus of the sequence of the bicyclic peptides to make them more 
hydrophilic, this was not achieved.  
Notwithstanding the solubility concerns, from the phage display 
screening it was expected to obtain reasonably potent (low micromolar)155 and 
selective hits, which was not the case when the peptides were tested after 
being purified. The results obtained suggested that the phage display screening 
was not successful with the two targets tested, VBC and VBCH. It was 
reasoned that, in this case, the failure to obtain potent ligands could have 
happened because: 1) VBC is not ligandable by bicyclic peptides; 2) the 
immobilisation of the target on the magnetic beads could have led to the 
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hindering of potential interaction surfaces; or 3) failure of the technology due to 
inherent challenges and limitations of solubility. It is noteworthy that much 
success has been achieved with symmetrical bicyclic peptides (namely the 6x6 
library)148,156-159 but not much has been reported with the VL1, VL2 and VL3 
libraries. It is therefore proposed that it could be of interest in the future to 
explore the 6x6 library against these targets instead. 
Phage display of bicyclic peptides is a powerful approach for the 
identification of ligands of protein surfaces. Nonetheless, as any other 
technique, it has its drawbacks and might not be applicable to all protein 
targets. In this case, it was also applied, to our knowledge for the first time, to a 
multi-subunit protein complex. Bicyclic peptides, as potential mimetics of protein 
surfaces, can be very challenging molecules to work with due to their observed 
low solubility. In fact, chemical strategies to improve the solubility of bicyclic 
peptides and their biological activity are an active area of research. To this end, 
recent efforts have led to the design of more polar and less hydrophobic core 
scaffolds compared to TBMB, for example, 2,4,6-tris(bromomethyl)-s-triazine, 
TBMT, and 1,1’,1”-(1,3,5-triazinane-1,3,5-triyl)tris(2-bromoethanone), TATB. 
TBMT and TATB are structurally very similar to TBMB but present very different 
chemical properties.160 
 
In summary, there is no universal technique to identify binders of a 
certain protein surface and each target, approach and technology must be 
studied as a particular case. 
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5.1  Concluding remarks 
Cullin RING E3 ubiquitin ligases play important roles in cellular 
homeostasis by controlling the abundance of different regulatory proteins. In 
many diseases including cancer this process is deregulated, which motivates 
the search for chemical probes targeting these complexes.161,162 Targeting 
CRLs for drug development is, consequently, an ambitious goal of mounting 
interest. Furthermore, the emerging role of CRLs as targets for induced protein 
degradation by glue molecules163 and PROTACs164 emphasise their potential 
as therapeutic targets.25,165 However, not all protein targets are druggable and 
assessing their ability to bind small molecules (ligandability) is critical. This 
project aimed at exploring the ligandability of a representative multi-subunit 
CRL complex, the CRL2VHL, combining three different avenues and a multiplicity 
of biochemical, biophysical and structure-based design tools. 
Initially, a structural and biophysical study was conducted, resulting in the 
first crystal structure of the whole CRL2VHL complex, in the biophysical 
characterisation of a particular PPI within the complex (Cul2–VBC), and in the 
identification of amino acids responsible for the selective recruitment of Cul2 
over Cul5 in EloBC-containing CRL complexes. This new structure revealed 
details of Cullin flexibility and disclosed a new conformation for the RING 
domain of Rbx1 that resembles a pose on a trajectory from the inactive to the 
active state of the enzyme. The challenges associated with the determination of 
the crystal structure were a consequence of the low-resolution of the data 
collected. Multi-subunit large protein complexes are usually very dynamic, thus 
hard to crystallise and to produce high-resolution data, which constitutes a 
problem for X-ray crystallography.71 This limitation can now be overcome by 
cryo-electron microscopy, a rising structural biology technique that allows 
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structure determination of proteins in their native environment, with no need for 
crystallisation of the sample. Initially, this technique was only applicable to 
complexes on the megadalton size range, but recent advances of the 
technology have now permitted the determination of enzyme structures as small 
as 170 kDa.166 In the future, this could be a potential way of exploring 
structurally, the dynamic features of the CRL2VHL complex. In addition, 
small-angle X-ray scattering (SAXS), a biophysical technique that allows the 
determination of the overall shape and structural transitions of biological 
molecules in solution167 could be useful to investigate the inherent flexibility of 
the pVHL β-domain in the context of the whole complex. 
 The second avenue pursued involved the structure-guided design of 
peptide molecules to probe the Cul2–VBC interaction in the CRL2VHL complex. 
Linear and cyclic peptides, short and long sequences were tested, however, 
targeting this interaction with peptides proved very challenging. The work led to 
the identification of some ligands that, nonetheless, exhibited weak binding 
affinities and could be optimised further in the future. The Cul2–VBC interaction 
appears to be a tertiary protein-protein interaction,51 involving multiple epitopes. 
In fact, as seen in the crystal structure, the interaction is directed by three points 
of contact between pVHL, Cul2 and EloC. Despite the N-terminal loop of Cul2 
being important for the specificity of the interaction, by itself it could not drive a 
tight binding event. Therefore, peptides that target only one of these interaction 
sites would likely not be able to mimic the native interaction and thus would not 
block the PPI site effectively. Considering these results combined with the 
merely hydrophobic nature of the EloC site, it can be concluded that this is a 
very low ligandability binding site. 
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Lastly, the surface of VBC was probed with bicyclic peptides originated 
from three different phage display libraries in an unbiased approach. There 
were concerns about the outcome of the phage display screening, as no unique 
consensus sequence was observed. Nevertheless, once proved to bind VBC, 
the diverse peptide sequences identified could provide starting points for ligand 
optimisation. The biophysical characterisation of these peptides binding to VBC, 
however, proved very problematic due to the lack of solubility of these 
molecules and it has remained inconclusive. Based on this experience, it 
seemed crucial that the next step in optimising this exciting new technology 
would be the enhancement of the solubility and physicochemical properties of 
the bicyclic peptides. 
 
All together, the work developed and presented in this thesis contributes 
to a better understanding of the structure and functioning of the CRL2VHL and 
provides important insights into the tractability of this complex. Moving forward, 
it is expected that the information contributed by this work could facilitate the 
design of chemical tools and modulators of the VHL ligase to study CRLs 
biology.  
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6.1  Molecular biology methods 
6.1.1 Plasmids 
The plasmid encoding his-tagged pVHL short isoform (54-213) was 
cloned by Dr. Inge van Molle, a former post-doctoral researcher in the Ciulli 
laboratory, and the EloBC plasmid was a gift from Dr. Alex Bullock (SGC, 
Oxford). The truncated Cullin-2 NTD plasmids were generated from an original 
plasmid kindly offered by Dr. Alexander Buchberger (University of Würzburg). 
The plasmid for the co-expression of full-length Rbx1 and Cul2 with a 
N-terminal Dac tag (affinity tag based on penicillin-binding protein 5)89  was a 
gift from Dr. Mark Peggie (MRC-PPU/DSTT). All the plasmids and respective 
mutations are summarised in Table 6.1. 
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Table 6.1 – Summary of all the constructs. 
 
The Δ = 89 Da observed for Rbx1 is consistent with the removal of initiator methionine from protein 
N-terminus, then acetylation of the new N-terminus. 
 
Plasmid ID Protein Vector Resistance Tags Cleavage site
Expected 
Mass (Da)
Measured 
Mass (Da)
pIVM02 pVHL54-113 pHAT4 Ampicillin 6xHis TEV 18676 18676
TFC024 pVHL54-113 V181G pHAT4 Ampicillin 6xHis TEV 18634 18635
TFC025 pVHL54-113 D187K pHAT4 Ampicillin 6xHis TEV 18689 18690
TFC026 pVHL54-113 K159E pHAT4 Ampicillin 6xHis TEV 18677 18678
pIVM26 EloB1-104/EloC17-112 pCDF1b-DUET Streptomycin - -
EloB:11733 
EloC: 10964
EloB:11733 
EloC: 10964
TFC027
EloB1-104/EloC17-112 
M105A pCDF1b-DUET Streptomycin - -
EloB:11733 
EloC: 10904
EloB:11733 
EloC: 10904
TFC028
EloB1-104/EloC17-112 
F109A pCDF1b-DUET Streptomycin - -
EloB:11733 
EloC: 10888
EloB:11733 
EloC: 10888
TFC012 Cul21-163 pTvHR21-SGC Ampicillin MBP-6xHis Fxa/TEV 64211
TFC014 Cul21-163 pTvHR21-SGC Ampicillin SUMO-6xHis TEV/SENP1 33220
TFC017 Cul21-384 pTvHR21-SGC Ampicillin MBP-6xHis Fxa/TEV 89968
TFC019 Cul21-384 pTvHR21-SGC Ampicillin SUMO-6xHis TEV/SENP1 58977
TFC020
Cul21-384 V340R, 
L344D, V384R pTvHR21-SGC Ampicillin MBP-6xHis Fxa/TEV 90084
TFC021
Cul21-384 V340R, 
L344D, V384R pTvHR21-SGC Ampicillin MBP-6xHis PreScission/TEV 90513
TFC003 Cullin-2/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87184 
Rbx1:12274
Cul2: 87184 
Rbx1:12185
TFC029 Cullin-2 K114E/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87185 
Rbx1:12274
Cul2: 87159 
Rbx1:12185
TFC030 Cullin-2 Q111L/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87169 
Rbx1:12274
Cul2: 87172 
Rbx1:12185
TFC031 Cullin-2 F39A/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87108 
Rbx1:12274
Cul2: 87111 
Rbx1:12185
TFC032 Cullin-2 Y43A/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87092 
Rbx1:12274
Cul2: 87097 
Rbx1:12185
TFC033 Cullin-2 V47A/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87156 
Rbx1:12274
Cul2: 87159 
Rbx1:12185
TFC034 Cullin-2 P5A/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87158 
Rbx1:12274
Cul2: 87161 
Rbx1:12185
TFC035 Cullin-2 R6A/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87099 
Rbx1:12274
Cul2: 87099 
Rbx1:12185
TFC036 Cullin-2 L3A/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87142 
Rbx1:12274
Cul2: 87147 
Rbx1:12185
TFC038 Cullin-2 L3G/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87128 
Rbx1:12274
Cul2: 87133 
Rbx1:12185
TFC039 Cullin-2 N36A/Rbx1 pFastBacDUAL Ampicillin Dac TEV
Cul2: 87141 
Rbx1:12274
Cul2: 87144 
Rbx1:12185
TFC054
pVHL54-113 K159Q 
D187Y S183R pHAT4 Ampicillin 6xHis TEV 18794 18794
TFC055
SOCS232-198 Q164K 
Y190D R186S pLIC-SGC1 Ampicillin 6xHis TEV 19128 19128
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6.1.2 Cloning of the truncated Cul2 NTD constructs 
All Cul2 constructs were obtained using pTvHR21-SGC, a plasmid that 
contains a C-terminal 6xHis tag (Figure 6.1). Initially MBP-TEVsite or SUMO 
tags were amplified by PCR from their parental plasmids using specific primers  
(Table 6.2) that allowed the insertion of EcoRI, NdeI and BamHI restriction sites 
at the 5’ end and XhoI restriction site at the 3’ end. Using NdeI and XhoI 
restriction enzymes, the amplified inserts containing MBP-TEVsite-6xHis or 
SUMO-6xHis tags, were cloned into pTvHR21-SGC using the DNA Ligation kit 
(DNA Ligation kit, TaKaRa), following the manufacturer guidelines. 
 
Figure 6.1 – Vector map representative of the final Cullin-2 plasmid. 
 
 Next, Cullin-2 inserts of different lengths (1-163 or 1-384) were amplified 
by PCR using specific primers (Table 6.2) that introduced different cleavage 
sites and restriction sites (EcoRI and NdeI at the 5’ end and BamHI at the 
Cullin-2 
EcorI 
NdeI 
BamHI 
MBP or SUMO 
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3’ end). The inserts were digested with NdeI and BamHI and ligated to the 
respective MBP- or SUMO-containing plasmid using the same protocol as 
described before. The identity of the constructs was verified by DNA 
sequencing. 
 Because the DNA sequence of full length Cullin-2 contained two NdeI 
restriction sites, before starting the cloning these sites were mutated by 
site-directed mutagenesis, using the primers reported in Table 6.2. 
 
Table 6.2 – Primers used for the cloning of the Cul2 constructs. 
  
 
6.1.3 Site-directed mutagenesis 
The pVHL, SOCS2, EloC and Cul2 mutants were prepared by PCR-
based method using the respective expression vectors encoding for the wild 
type proteins as template. The amplification of the expression vectors was 
performed using the KOD hot-start DNA polymerase (EMD Millipore), following 
the manufacturer guidelines and specific pairs of primers (Table 6.3) for the 
introduction of the desired mutation. The PCR products were treated with DpnI 
Primer name Primer sequence 5' --> 3'
Cul2 SDM 1 Fwd GTGTCCACTGGTTTACCTCACATGATTCAGGAGCTGC
Cul2 SDM1 Rev GCAGCTCCTGAATCATGTGAGGTAAACCAGTGGACAC
Cul 2 SDM 2 Fwd CTATTTGGGCAAACCACATGTAGCCATGGTTACAAC
Cul2 SDM2 Rev GTTGTAACCATGGCTACATGTGGTTTGCCCAAATAG
EcorI-NdeI-BamHI-SUMO (Fwd) GAATTCCATATGGACTCGGATCCGGCAGCGGCAGCGGCTCT
SUMO-XhoI (Rev) GGCAGCCTCGAGGCTGCCACCACCGGTTTGTTCCTG
EcoRI-NdeI-BamHI-MBP (Fwd) GAATTCCATATGGACTCGGATCCATGAAGATTGAAGAAGGC
MBP-TEVsite-XhoI (Rev) GGCTGCCTCGAGCGAGCCACCCTGGAAGTACAGGTT
EcoRI-NdeI-Cul2 (Fwd) GAATTCCATATGTCTTTGAAACCAAGAGTA
Cul2-BamHI 1-163 (Rev) GGATCCCAGCATTCGGATAAGGATG
Cul2-BamHI 1-384 (Rev) GGATCCAACAGACTTAGGTTCTCTG
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enzyme (NEB) to digest the parental DNA and then transformed in DH5α E. coli 
cells. The mutations were confirmed by DNA sequencing. 
Table 6.3 – Primers used for the mutations of Cullin-2, pVHL, EloC and SOCS2. 
 
 
6.1.4 Transformation 
50 µl of chemically E. coli competent cells [DH5α strain was used for 
cloning and BL21(DE3) strain was used for protein expression] were thawed on 
ice. To these, 100-150 ng of plasmid DNA (1-3 µl) were added and incubated 
for 30 min on ice. Then, the cells were heat-shocked for 45 sec in a water bath 
at 42 °C and immediately cooled on ice for 5 min. The cells were diluted by 
addition of 150 µl of lysogeny broth (LB) media and then incubated in a 37 °C 
water bath for 60 min (this step was skipped when the antibiotic resistance was 
ampicillin). Next, the cell suspension was plated on LB/agar plates containing 
the appropriate antibiotic and incubated at 37 °C overnight. 
 
6.1.5 BL21 pGro7 competent cells generation 
BL21(DE3) cells were transformed with the pGro7 plasmid (Chaperone 
plasmid set, TaKaRa) according to the protocol above. Competent cells were 
Protein Mutation Forward primer 5' -> 3' Reverse primer 5'->3'
L3A CAGGGCGGATCCATGTCTGCGAAACCAAGAGTAGTAG CTACTACTCTTGGTTTCGCAGACATGGATCCGCCCTG
L3G GTTCCGCGTGGATCCATGTCTGGGAAACCAAGAGTAGTAG CTACTACTCTTGGTTTCCCAGACATGGATCCACGCGGAAC
P5A CCGCGTGGATCCATGTCTTTGAAAGCAAGAGTAGTAGATTTTGATGAAACATGG CCATGTTTCATCAAAATCTACTACTCTTGCTTTCTCAGACATGGATCCACGCGG
N36A GGAATACGTCGAAAGAGCAACATGGGCTGACCGTTTCTCAGATATCTATGCTTTATG CATAAAGCATAGATATCTGAGAAACGGTCAGCCCATGTTGCTCTTTCGACGTATTCC
F39A CGTCGAAAGAGCAACATGGAATGACCGTGCCTCAGATATCTATGCTTTATGTGTGGCC GGCCACACATAAAGCATAGATATCTGAGGCACGGTCATTCCATGTTGCTCTTTCGACG
Y43A GGAATGACCGTTTCTCAGATATCGCTGCTTTATGTGTGGCCTATCCTGAACCCC GGGGTTCAGGATAGGCCACACATAAAGCAGCGATATCTGAGAAACGGTCATTCC
V47A CAGATATCTATGCTTTATGTGCGGCCTATCCTGAACCCCTTGGAG CTCCAAGGGGTTCAGGATAGGCCGCACATAAAGCATAGATATCTG
Q111L GGTATCTCAACACCCTGTTTATTAAAAAGAATAAATTAACAGAAGCGGACC GGTCCGCTTCTGTTAATTTATTCTTTTTAATAAACAGGGTGTTGAGATACC
K114E GTATCTCAACACCCAGTTTATTGAAAAGAATAAATTAACAGAAG CTTCTGTTAATTTATTCTTTTCAATAAACTGGGTGTTGAGATAC
K159E CACTGCCAGTGTATACTCTGGAAGAGCGATGCCTCCAGGTTGTCC GGACAACCTGGAGGCATCGCTCTTCCAGAGTATACACTGGCAGTG
K159Q CCAATTGAGATCCCTAACAATCTAAGGCGTTCGCAGCCATCAGCAGTTCC CCAATTGAGATCCCTAACAATCTAAGGCGTTCGCAGCCATCAGCAGTTCC
V181G GAATTACAGGAGACTGGACATCGGCAGGTCGCTCTACGAAGATC GATCTTCGTAGAGCGACCTGCCGATGTCCAGTCTCCTGTAATTC
S183R+D187Y CCAATTGAGATCCCTAACAATCTAAGGCGTTCGCAGCCATCAGCAGTTCC CGTCAGGCGGCTCTACGAATATCTGGAAGACCACCCAAATGTGC
D187K CATCGTCAGGTCGCTCTACGAAAAACTGGAAGACCACCCAAATG CATTTGGGTGGTCTTCCAGTTTTTCGTAGAGCGACCTGACGATG
M105A GAAATTGCACTGGAACTGCTGGCGGCTGCGAACTTCTTAGATTGTTAG CTAACAATCTAAGAAGTTCGCAGCCGCCAGCAGTTCCAGTGCAATTTC
F109A GGAACTGCTGATGGCTGCGAACGCCTTAGATTGTTAGGGATCTCAATTGG CCAATTGAGATCCCTAACAATCTAAGGCGTTCGCAGCCATCAGCAGTTCC
Q164K CCGCTCTACACGTCAGCACCATCTCTGAAGCATCTCTGTAGGCTCACCATTAAC GTTAAGTGTGAGCCTACAGAGATGCTTCAGAGATGGTGCTGACGTGTAGAGCGG
R186S+Y190D CATCTGGGGACTGCCTTTACCAACAAGCCTAAAAGATGACTTGGAAG CTTCCAAGTAATCTTTTAGGCTTGTTGGTAAAGGCAGTCCCCAGATG
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prepared from a single colony of transformant following the protocol from 
Sambrook and Russel 2006.168 The competent cells containing the pGro7 
plasmid were aliquoted, flash frozen in liquid nitrogen and stored at  -80 °C.  
 
6.1.6 Preparation of DH10Bac competent cells 
DH10Bac cells from Dr. Axel Knebel were streaked on a LB agar plate 
supplemented with kanamycin and tetracycline. The plate was incubated 
overnight at 37 °C. A single colony of DH10Bac was used to inoculate 5 ml of 
LB supplemented with kanamycin and tetracycline. The starter culture was 
incubated overnight at 37 °C and 180 rpm. A larger culture of 300 ml of LB with 
antibiotics was inoculated with 3 ml of the starter culture and incubated at 
37 °C, 180 rpm, until reaching an OD600 ~0.380. At this point the cells were 
aliquoted in 50 ml Falcon tubes pre-chilled in ice and incubated in ice for 
10 min. The cells were pelleted by centrifugation at 180 x g for 15 min and the 
pellet was then re-suspended in 10 ml of ice-cold 60 mM CaCl2, 15% (v/v) 
glycerol, 10 mM PIPES pH 7.0 (adjusted with KOH). This centrifugation and 
re-suspension procedure was repeated and the cells were incubated in ice for 
30 min. After this time, the cells were again pelleted and then re-suspended in 
2 ml of CaCl2 solution. The DH10Bac competent cells were aliquoted, flash 
frozen in liquid nitrogen and stored at -80 °C. 
 
6.1.7 Bacmid generation 
30 ng (3 µl) of Rbx1–Cul2 plasmid were transformed into DH10Bac 
competent cells following the protocol described in section 6.1.4. The recovery 
time was extended to 4 h and then the cells were plated onto LB agar 
containing tetracycline, kanamycin, X-gal and IPTG. The bacmid propagates in 
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E. coli DH10Bac as a large plasmid that confers resistance to kanamycin and 
can complement a lacZ deletion present on the chromosome to form colonies 
that are blue (Lac+) in the presence of a chromogenic substrate such as X-gal 
and the inducer, IPTG. The resistance to tetracycline is conferred by the helper 
plasmid present in the DH10Bac cells. The plates were incubated for 48 h 
(at least) at 37 °C in order to discriminate between blue and white colonies. 
5 white colonies and one blue colony were streaked onto a new LB agar plate 
containing the adequate supplements to discard false positives. One of the 
white colonies from the second plate was used to inoculate 300 ml of LB 
supplemented with tetracycline, gentamycin and kanamycin. The culture was 
incubated at 37 °C under shaking (130 rpm) for 24 h. Then the cells were 
pelleted and submitted to the DNA sequencing facility for isolation of the bacmid 
through maxiprep. The bacmids were stored at 4 °C until transfection and then 
were aliquoted, flash frozen in liquid nitrogen and stored at -80 °C. 
 
6.1.8 Insect cells tissue culture 
Spodoptera fugiperda 21 (Sf21) cells were cultured in suspension in 
Insect-XPRESS media (Lonza) supplemented with amphotericin B, penicillin 
and streptomycin (Antimycotic-antibiotic 100x solution, Gibco). The cultures 
were incubated at 26.5 °C with 130 rpm shaking and in the dark. Every 48-72 h 
the cells were split to a density of 1.5 x 106 cells/ml in fresh media. 
 
6.1.9 Bacmid transfection into Sf21 cells 
The transfections were performed in adherent cell culture. To do that, 
1.5 x 106 cells were seeded in a T25 flask 30 min prior to the transfection. The 
transfection mixture was prepared in a 24-well plate, where 500 µl of media 
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without antibiotic, 15 µl of Cellfectin (ThermoScientific) and 1-3 µg of bacmid 
were added to a well. The mixture was incubated at room temperature, in the 
dark, for 30-60 min. After this period, 1.5 ml of media were added to the well 
and the solution was mixed by gently pipetting up and down. Then the solution 
was transferred to the T25 flask with the cells (the media in the flask must be 
removed first) and media was added to make up 5 ml. The flask with the cells 
was incubated overnight at 26.5 °C. The morning after, the transfection mixture 
was aspirated and 7 ml of fresh media supplemented with antimycotic-antibiotic 
solution were added to the flask. The flask was incubated at 26.5 °C for 7 days. 
Finally, the cells were harvested by scrapping the flask, the solution was 
transferred to a falcon tube and the cells were spun down (180 x g, 4 min). The 
supernatant (P0 virus) was stored in a new, sterile, falcon tube at 4 °C in the 
dark. The efficiency of the transfection was assessed by analysing the presence 
of Cul2 in the cell pellet by immunoblot with anti-Cul2 (Abcam, Ab166917) at 
1:5000 dilution. 
 
6.1.10 Baculovirus amplification 
The baculovirus was amplified in suspension cell culture. 150 ml of cells 
at a density of 1.5 x 106 cells/ml were infected with 1.5 ml of P0 virus. The 
culture was incubated for 5 days at 26.5 °C, 130 rpm shaking in the dark. After 
this period the cells were harvested by centrifugation (180 x g, 10 min) and the 
supernatant (P1) was stored at 4 °C in the dark.  
 
6.1.11 Protein expression in bacteria 
VBC and SBC ternary complexes and variant proteins were purified as 
described previously.52,116 BL21(DE3) E. coli cells were co-transformed with the 
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plasmid for expression of pVHL/SOCS2 and the bi-cistronic pDUET plasmid for 
expression of EloBC. A single colony of transformant was used to inoculate LB 
media for bacterial culture. Protein expression was induced with 0.3 mM IPTG 
(when OD600 reached 0.8) at 24 °C for 18 h. Co-expression of these proteins 
resulted in the formation of the respective trimeric complex (VBC/SBC) that was 
then purified by two steps of affinity chromatography, followed by ion-exchange 
chromatography and finally by size-exclusion chromatography. The His-tag was 
cleaved between the two affinity chromatography steps with TEV protease. 
Following this protocol the yield of protein was about 15-20 mg per litre of 
culture. 
Cul5NTD (residues 1−386) was also expressed in BL21(DE3) E. coli 
cells.115 After transformation and inoculation of LB media for bacterial growth, 
protein expression was induced with 0.5 mM IPTG at 18 °C for 18 h. His-tagged 
Cul5NTD was purified by affinity chromatography and by size-exclusion 
chromatography with a yield of ~40 mg of protein per litre of culture. 
For the Cul2NTD constructs, a single colony from BL21(DE3) E. coli cells 
transformed with the respective plasmid was inoculated in 100 ml of LB media 
with ampicillin and incubated overnight at 37 °C and 180 rpm shaking (starting 
culture). The following day, the starting culture was used to inoculate Terrific 
Broth (TB) media supplemented with ampicillin, tetracycline and arabinose for 
large-scale expression to an OD600 of 0.05. Cell cultures were incubated at 
37 °C and 180 rpm shaking until reaching an OD600 of 0.6 and then protein 
expression was induced with the appropriate IPTG concentration (see 
Chapter 3) and the temperature was lowered to 16 °C. The cultures were 
incubated in these conditions for 16-20 h. Then, cells were harvested by 
centrifugation (30 min at 5,000 x g), the cell pellet was re-suspended in lysis 
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buffer (supplemented with DNAse, MgCl2 and protease inhibitors) and the cells 
were lysed by French press. The cell debris was removed by centrifugation 
(20 min at 50,000 x g) and the supernatant was applied into an MBP-trap 
column. The protein of interest was eluted from the column with a gradient of 
maltose. Next, the sample was applied in a gel filtration column (analytical, 
Superdex Increase 10/300, or preparative HiLoad 16/600 Superdex 200).  
The protein’s identities were confirmed by electrospray mass 
spectrometry analysis (Figure 6.2 – 6.8). 
 
 
Figure 6.2 – Deconvoluted electrospray MS spectrum of pVHL V181G from 
purified VBC. 
 
 
Figure 6.3 – Deconvoluted electrospray MS spectrum of pVHL D187K from 
purified VBC. 
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Figure 6.4 – Deconvoluted electrospray MS spectrum of pVHL K159E from 
purified VBC. 
 
Figure 6.5 – Deconvoluted electrospray MS spectrum of EloC M105A from 
purified VBC. 
 
 
Figure 6.6 – Deconvoluted electrospray MS spectrum of EloC F109A from 
purified VBC. 
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Figure 6.7 – Deconvoluted electrospray MS spectrum of pVHL K159Q D187Y 
S183R from purified VBC. 
 
 
Figure 6.8 – Deconvoluted electrospray MS spectrum of SOCS2 Q164K Y190D 
R186S from purified SBC. 
 
6.1.12 Protein expression in insect cells 
Sf21 cells at a density of 1.5x106 cells/ml were infected with the P1 virus 
in a 1:100 ratio and incubated at 26.5°C, 130 rpm, in the dark for 72 h. The cells 
were harvested by centrifugation, the pellet was re-suspended in lysis buffer 
6x10
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
+ESI Scan (31.7915-32.7086 min, 37 scans) Frag=170.0V VBC-K159Q.d  Deconvoluted (Isotope Width=7.7)
18793.5
16663.8
9397.6 11733.6 18070.416047.5 23466.114743.4 20332.0 21856.87691.9 13584.56265.3
Counts vs. Deconvoluted Mass (amu)
5000 6000 7000 8000 9000 10000 11000 12000 13000 14000 15000 16000 17000 18000 19000 20000 21000 22000 23000 24000 25000
6x10
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6
6.5
7
7.5
8
+ESI Scan (29.0652-29.7785 min, 29 scans) Frag=170.0V SBC-R186S_Y190D.d  Deconvoluted (Isotope Width=7.7)
19128.1
11733.8
9565.0 18393.212752.1 23465.420269.1 21660.315342.310830.76376.8 7652.0
Counts vs. Deconvoluted Mass (amu)
5000 6000 7000 8000 9000 10000 11000 12000 13000 14000 15000 16000 17000 18000 19000 20000 21000 22000 23000 24000 25000
 
	
179 
containing 50 mM HEPES pH 8.0, 250 mM NaCl, 2 mM TCEP and 0.2% (v/v) 
Triton-X and supplemented with DNAse, MgCl2 and protease inhibitors 
(leupeptin and Pefabloc). The cells were lysed by French press, the lysate was 
clarified by centrifugation and the supernatant was mixed with 
ampicillin-modified sepharose resin. As mentioned earlier, Cul2 contains a 
N-terminal Dac tag, which binds ampicillin. Therefore, the affinity purification is 
performed using ampicillin-modified resin (see section 6.1.18). After 1 h 
incubation at room temperature, the resin was washed three times with 20 mM 
HEPES pH 8.0, 100 mM NaCl, 5% (v/v) glycerol, 2 mM TCEP. At the last wash 
step the resin was suspended in the same buffer and incubated with TEV 
enzyme for 2.5 h at room temperature. The cleaved Rbx1–Cul2 was recovered 
through filtration and the filtrate, after concentration, was loaded on a Superdex 
200 gel filtration column (GE Healthcare) for further purification. 
 The protein’s identities were confirmed by electrospray mass 
spectrometry analysis (Figure 6.9 – 6.18). 
 
 
Figure 6.9 – Deconvoluted electrospray MS spectrum of purified Cul2 K114E 
from purified Rbx1–Cul2. 
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Figure 6.10 – Deconvoluted electrospray MS spectrum of Cul2 Q111L from 
purified Rbx1–Cul2. 
 
Figure 6.11 – Deconvoluted electrospray MS spectrum of Cul2 F39A from purified 
Rbx1–Cul2. 
 
Figure 6.12 – Deconvoluted electrospray MS spectrum of Cul2 V47A from 
purified Rbx1–Cul2. 
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Figure 6.13 – Deconvoluted electrospray MS spectrum of Cul2 Y43A from 
purified Rbx1–Cul2. 
 
Figure 6.14 – Deconvoluted electrospray MS spectrum of Cul2 P5A from purified 
Rbx1–Cul2. 
 
Figure 6.15 – Deconvoluted electrospray MS spectrum of Cul2 R6A from purified 
Rbx1–Cul2. 
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Figure 6.16 – Deconvoluted electrospray MS spectrum of Cul2 L3A from purified 
Rbx1–Cul2. 
 
Figure 6.17 – Deconvoluted electrospray MS spectrum of Cul2 L3G from purified 
Rbx1–Cul2. 
 
Figure 6.18 – Deconvoluted electrospray MS spectrum of Cul2 N36A from 
purified Rbx1–Cul2. 
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6.1.13 Isotopically-labelled VBC expression 
Protein expression was performed in 2H, 15N enriched media 
(E.coli-OD2, Silantes). The cell cultures were incubated at 37 °C until reaching 
an OD600 of 0.8 (13 h) and then protein expression was induced with 0.6 mM of 
IPTG and the cultures were incubated for 16 h at 24 °C (OD600 ~ 2). The protein 
was purified according to the protocol previously described in section 6.1.11. 
Considering the purity of the sample achieved, the gel filtration step was 
skipped. The protein was obtained with a yield of 4 mg/litre. The success of the 
isotopic enrichment of the sample was assessed by mass spectrometry 
(Figure 6.19). The percentage of deuteration was calculated assuming the total 
incorporation of 15N, and it was determined to be 99.1% for pVHL, 99.0% for 
EloC and 98.9% for EloB. 
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Figure 6.19 – Electrospray MS of purified 2H,15N-VBC. Spectra for Elongin B, pVHL 
and Elongin C. The expected mass accounting for fully incorporation of 15N and 2H was 
14220.8 Da for EloB, 20264.3 Da for pVHL and 11860.9 Da for EloC. 
 
5x10
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6
6.5
+ESI Scan (21.1609-21.5909 min, 20 scans) Frag=170.0V TC-VBC.d  Deconvoluted (Isotope Width=8.4)
14071.2
6989.7
13112.7
28897.226812.721564.1 23239.58990.4 17721.910836.45376.9
Counts vs. Deconvoluted Mass (amu)
6000 8000 10000 12000 14000 16000 18000 20000 22000 24000 26000 28000 30000
5x10
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
+ESI Scan (22.1566-22.5866 min, 20 scans) Frag=170.0V TC-VBC.d  Deconvoluted (Isotope Width=8.4)
20064.8
13016.3
29836.410007.1 21435.9 28317.226257.814119.36658.8 23708.515923.1
Counts vs. Deconvoluted Mass (amu)
6000 8000 10000 12000 14000 16000 18000 20000 22000 24000 26000 28000 30000
5x10
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2
2.25
2.5
2.75
3
3.25
3.5
3.75
4
+ESI Scan (24.9628-25.5964 min, 29 scans) Frag=170.0V TC-VBC.d  Deconvoluted (Isotope Width=8.4)
11752.4
10562.1
13071.9
8488.8 23343.314131.4 19098.47031.9 17006.9 25681.6 28199.0
Counts vs. Deconvoluted Mass (amu)
6000 8000 10000 12000 14000 16000 18000 20000 22000 24000 26000 28000 30000
Elongin B 
pVHL 
Elongin C 
 
	
185 
6.1.14 Biotinylation of proteins 
Proteins were biotinylated using the EZ-link NHS-biotin kit (ThermoFisher 
Scientific) and following the manufacturer guidelines. Briefly, the protein was 
dialysed into a buffer that did not contain primary amines and then mixed with 
biotin in equimolar ratio and incubated for 30 min at room temperature. The 
excess of biotin was removed by desalting column (Zeba Spin desalting column 
0.5 ml, ThermoFisher Scientific). 
 
6.1.15 DNA and protein concentrations 
The concentration of DNA and protein samples was estimated measuring 
the absorbance at 260 nm and 280 nm, respectively, using a Nanodrop 
Microliter UV/Vis spectrophotometer (ThermoScientific). DNA purity was 
assessed by the A260/A280 ratio and in all the samples used A260/A280 > 1.7. 
Protein concentration was calculated based on the theoretical molar extinction 
coefficient predicted using ProtParam.169  
 
6.1.16 Immunoblotting 
The cells lysates were run on a SDS-PAGE and transferred to a 
nitrocellulose membrane using i-Blot 2® (Life Technologies). The membrane 
was blocked with 10% of BSA in Tris-buffered saline (TBS) with 0.1% (v/v) 
Tween-20 (TBST) for 1 h at room temperature. Then, the membrane was 
incubated overnight at 4 °C with the primary antibody - anti-Cul2 (Abcam, 
Ab166917) at 1:5000 dilution in TBST. The membrane was brought to room 
temperature for 10-30 min and then washed three times with TBST (15 min, 5 
min, 5 min). After this step the membrane was incubated with the secondary 
antibody - anti-rabbit (Abcam, Ab191866) at a dilution of 1:2000 in 5% BSA in 
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TBST for 1 h at room temperature. The washing steps were repeated and the 
protein detection was performed using the Pierce ECL chemiluminescence kit 
(Thermo Scientific). 
 
6.1.17 Neddylation assay 
The neddylation assay was performed according to the protocol provided 
by Dr. Axel Knebel (MRC-PPU). 
The assay buffer consisted on 30 mM HEPES pH 7.5. 100 mM NaCl, 1 
mM DTT and 100 mM MgCl2, 2 mM ATP (both solutions were prepared as 10x 
solution). 10 µg of protein (Rbx1–Cul2, CRL2VHL or CRL2VHL:HIF) were mixed 
with 1.2 µg of E1 enzyme, 2 µg of E2 enzyme and 13 µg of NEDD8 in a total 
volume of 25 µl. The reaction was prepared in PCR tubes and those were 
incubated at 37 °C for 2 h. The reaction was stopped by adding 4x SDS buffer 
and heating up the samples at 95 °C for 10 min. The samples were then run on 
two SDS-PAGE - one for staining with Coumassie and other for immunoblotting 
with anti-Cul2. 
 
6.1.18 Preparation of ampicillin-modified sepharose resin 
25 ml of resin (NHS-activated sepharose 4 Fast-flow, GE Healthcare) 
were poured on a filtering device (e.g. stericup, column filter). The resin was 
washed abundantly with 1 mM HCl (> 500 ml), and then transferred to a 50 ml 
Falcon tube. The excess of HCl solution was removed by spinning down the 
resin and pouring out the liquid. Next, the resin was re-suspended in 25 ml of 
0.4 M ampicillin in 0.1 M NaHCO3 pH 7.5 and incubated in a roller at room 
temperature for 1-2 h. After this, the excess of ampicillin was removed by 
washing the resin thoroughly with any buffer at pH < 7.0  (in the filter device). 
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Finally, the resin was washed several times with 30% (v/v) ethanol and 
transferred to a 50 ml Falcon tube. The excess of liquid was removed as before 
and the resin was re-suspended in an equal volume of 30% (v/v) ethanol 
solution (50% slurry). The ampicillin-modified resin was stored at 4 °C (stable 
up to 6 months). 
 
6.2 Crystallography 
6.2.1 CRL2VHL complex crystallisation 
VBC was incubated with a HIF-1α 19-mer peptide (residues 559-557) 
and the resulting complex (VBCH) was purified on a Superdex 75 gel filtration 
column (GE Healthcare) as previously described.52 Next, VBCH and Rbx1–Cul2 
were mixed in equimolar ratio and incubated for 30 min at room temperature. 
The CRL2VHL complex was purified in an analytical Superdex 200 Increase gel 
filtration column (GE Healthcare) equilibrated with 50 mM Tris-HCl, 150 mM 
NaCl, 5 mM dithiothreitol (DTT). The pentameric complex was concentrated to 
4.2 mg/ml. Equal volumes of CRL2VHL:HIF complex and liquor solution were 
mixed in the hanging-drop vapour diffusion method at 20 °C. The liquor solution 
contained 0.1 M Tris pH 7.6, 0.15 M ammonium sulphate, 15% 
polyethyleneglycol 4000 and 3% 1,4-dioxane or 4% acetonitrile as additive. 
After equilibration, the drop was streaked with seeds of disrupted CRL2VHL:HIF 
crystals. Crystals would generally appear within 48 h. Crystals were 
cryoprotected with 20% ethyleneglycol or 20% glycerol and screened for 
diffraction patterns using an in-house Rigaku M007HF X-ray generator and 
Saturn 944HG+ CCD detector.  
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6.2.1.1 Data collection and structure solving 
X-ray data were collected at 100 K and a wavelength of 0.9282 Å at 
Diamond Light Source beamline I04-1. Indexing and integration of reflections 
was performed using DIALS, and scaling and merging with AIMLESS in 
CCP4i.170,171 The isomorphous datasets were refined using REFMAC598 and 
COOT.172 The MOLPROBITY173 server was used to validate the geometry and 
steric clashes in the structures. The Ramachandran analysis indicated 90.7% 
residues in preferred regions, 9.1% residues in allowed regions and 0.2% 
outliers. The data collection and refinement statistics are presented in Table 2.1 
in Chapter 2.  
 
6.2.2 VBC crystallisation and soaking 
The VBC complex was crystallised according to the protocol described 
previously.58 The crystallisation solutions contained 0.1 mM sodium cacodylate, 
pH 6.2–6.5, 16–18% polyethylene glycol 3350, 0.2 M magnesium acetate and 
10 mM DTT. VBC and crystallisation solution were mixed in equal volumes and 
crystals were grown using the hanging-drop vapour diffusion method at 18 °C. 
To slow the vapour diffusion rate, a thin layer of Al's Oil (Hampton Research) 
was applied on top of crystallisation solutions. The drops were streak seeded 
with crushed VBC crystals grown in the same conditions originating 
well-diffracting crystals. 
Peptides were soaked overnight in 1–100 mM solutions of ligand in 
1-10% dimethylsulfoxide, 99–90% liquor solution. Crystals were cryo-protected 
in 20% glycerol and flash frozen in liquid nitrogen. Crystals were screened 
using an in-house Rigaku M007HF X-ray generator and Saturn 944HG+ CCD 
detector. 
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6.3 Phage display 
6.3.1 Library amplification 
The phage display libraries VL1, VL2 and VL3 were a gift from 
Dr. Christian Heinis (EPFL Lausanne). New stocks of the libraries were 
prepared by re-suspending the content of each tube in 10 ml of 2xYT media 
supplemented with chloramphenicol and plating the cells in large 2xYT/agar 
plates. The cells were incubated overnight at 37 °C. The following day the cells 
were scrapped from the surface of the plates with 5 ml of 2xYT media. 15% 
glycerol was added and each library was dispensed into 0.5 ml aliquots, flash 
frozen in liquid nitrogen and stored at -80 °C. 
Before each panning experiment, the respective library was amplified. To 
do this, 2 x 500 ml of 2xYT media supplemented with chloramphenicol (in 2 L 
flasks) were inoculated with 2 x 0.5 ml of the corresponding library and 
incubated overnight at 30 °C with 250 rpm shaking. Then, the cells were 
centrifuged at 5,000 x g for 30 min at 4 °C and the phage-containing 
supernatant was transferred to a new tube containing ¼ (v/v) solution of 
ice-cold 20% PEG-6000 and 2.5 M NaCl. After inverting the tube several times, 
the phage solution was kept in ice for 30 min to precipitate the phages. After 
this time, the solution was centrifuged for another 30 min (5,000 x g, 4 °C), the 
supernatant was discarded and the excess of liquid was removed with a filter 
paper. The precipitated phages were re-suspended in 20 ml reaction buffer 
(Table 6.4) and stored in a 50 ml Falcon tube at 4 °C. 
 
6.3.2 Peptide cyclisation 
Initially, the cysteine residues were reduced by adding 1 ml of 20 mM 
tris-(2-carboxyethyl)phosphine (TCEP) to 19 ml of phage solution and incubated 
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for 1 h at 42 °C. After this time, the solution was cooled down by incubation in 
ice for about 5 min and then transferred to a 100,000 Da centricon. The volume 
of the solution was concentrated to 1 ml and 10 ml of ice-cold reaction buffer 
were used to re-suspend the phage. This procedure was repeated a couple of 
times and finally the solution was transferred to a 50 ml tube, where the volume 
was adjusted to 32 ml with reaction buffer. 
To cyclise the peptides, 8 ml of 50 µM TBMB in acetonitrile were added 
to the 32 ml of phage solution and the tube was incubated at 30 °C for 1 hour. 
Then, the phages were precipitated with 10 ml of ice-cold PEG/NaCl solution 
and incubated in ice for 15 min. The solution was centrifuged for 30 min at 
5,000 x g, 4 °C, the supernatant was discarded and the precipitate was 
re-suspended in 3 ml of binding buffer (Table 6.4). The phages were stored at 
4 °C until used for phage selection (stable for 3-5 days). 
 
6.3.3 Biopanning 
VBC/VBCH (4-5 µg) were immobilised in tosyl-activated magnetic beads 
(Dynabeads M-280 tosyl-activated, Invitrogen) following the protocol of the 
manufacturer. Unbound protein was washed with binding buffer (Table 6.4). 
The phages  and the protein attached to the beads were incubated with 
blocking buffer (Table 6.4) for 30 min on the slow rotating wheel at room 
temperature, the phages were added to the protein-beads and incubated again 
for another 30 min. The beads were washed several times with washing buffer 
(Table 6.4) and twice with binding buffer before elution with 100 µl of elution 
buffer (Table 6.4) for 5 min and then neutralised in 50 µl of 1 M Tris-HCl pH 8.0. 
The eluted phages were used to infect 25 ml of E. coli cells (ER2738 strain, this 
K-12 strain expresses the F pilus and is suited for phage propagation and 
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production; it is an amber suppressor strain, translating the stop codon UAG as 
glutamine) at OD600 between 0.3-0.5 for 90 min at 37 °C. Finally the cells were 
plated in large 2xYT/chloramphenicol plates. The selection rounds were 
repeated 3-4 times and in the last round 30 colonies of E. coli infected with the 
phages were submitted to DNA sequencing. A sample from each round of 
panning was aliquoted and stored in 20% glycerol at -80 °C. 
 
Table 6.4 – Phage display buffers. 
 
 
6.4  Peptide synthesis and characterisation 
Peptides were synthesised in an INTAVIS ResPepSL automated peptide 
synthesiser by standard solid-phase synthesis using Fmoc-protected amino 
acids (5 eq., Novabiochem) and Rink amide AM resin (1 eq., 0.4-0.8 mmole/g, 
Novabiochem). The peptides were synthesised in a 96-well plate set up (bicyclic 
peptides) or in a 24-column set up. Each cycle started with Fmoc deprotection 
with 20% piperidine in DMF, followed by two coupling reactions, the first one 
using 1 eq. of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) and the second one using 1 eq. of 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) as coupling reagents. Unreacted amino acids 
were capped with 5% acetic anhydride and N-methylmorpholine (NMM) in DCM 
Reaction buffer 20 mM NH4HCO3 pH 8.0, 5 mM EDTA
Binding buffer 10 mM Tris-Cl pH 7.4, 150 mM NaCl, 10 mM MgCl2 and 1 mM CaCl2
Blocking buffer binding buffer containing 0.3% (v/v) Tween-20 and 3% (w/v) BSA
Washing buffer binding buffer containing 0.1% (v/v) Tween-20
Elution buffer 50 mM glycine pH 2.2
Neutralisation buffer 1 M Tris-Cl pH 8.0
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and washed off with DMF. At the last cycle, a final deprotection step was 
performed and the resin was washed with DMF and dichloromethane (DCM). 
Cleavage from the resin and deprotection of the amino acid side chains 
was performed with a solution of 92.5:5:2.5 (v/v) TFA:triisopropylsilane:H2O or 
90:2.5:2.5:2.5:2.5 (v/v) TFA:H2O:phenol:thioanisole:1,2-ethanedithiol (bicyclic 
peptides) for 3 h at room temperature. Then, the cleaved peptides were filtered 
through a single-fritted column and precipitated with cold diethyl ether. The thin 
white precipitate was filtered and washed several times with diethyl ether and 
finally dissolved in water or acetonitrile:water mixture and lyophilised in a 
centrifugal evaporator (Genevac EZ-2 series, SP Scientific). The peptides were 
then purified by high-pressure liquid chromatography (HPLC) in the most 
adequate conditions (described in each section). 
 
6.4.1 Cullin-2 peptides, 15-mer peptide and clamp peptides 
The peptides were dissolved in water and purified on preparative HPLC 
System with a Waters X-Bridge C18 column (100 mm x 19 mm; 5 µm particle 
size) and a gradient from 5% to 95% of acetonitrile in water over 20 min, under 
a flow of 25 ml/min, with 0.1% ammonia in the aqueous phase. The fractions 
collected were lyophilised in the centrifugal evaporator (Genevac EZ-2 series, 
SP Scientific) and the identity and purity of the peptides was confirmed by 
analytical HPLC-MS on an Agilent Technologies 1200 series HPLC connected 
to an Agilent Technologies 6130 quadrupole LC/MS linked to an Agilent diode 
array detector (Figure 6.20 – 6.47). The column used was an Agilent ZORBAX 
StableBond 80Å C18, 4.6 x 250 mm, 5 µm column and the compounds were 
eluted with a gradient of 5−95% acetonitrile/water + 0.1% ammonia. The clamp 
peptides were purified and analysed in acidic conditions (0.1% TFA). 
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Figure 6.20 – Analytical LC-MS trace of peptide MSL (UV trace recorded at 
214 nm). 
 
 
Figure 6.21 – Analytical LC-MS trace of peptide MSLK (UV trace recorded at 
214 nm). 
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Figure 6.22 – Analytical LC-MS trace of peptide MSLKP (UV trace recorded at 
214 nm). 
 
 
Figure 6.23 – Analytical LC-MS trace of peptide MSLKPR (UV trace recorded at 
214 nm). 
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Figure 6.24 – Analytical LC-MS trace of peptide MSLKPRV (UV trace recorded at 
214 nm). 
 
 
Figure 6.25 – Analytical LC-MS trace of peptide MSLKPRVV (peptide A) (UV trace 
recorded at 214 nm). 
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Figure 6.26 – Analytical LC-MS trace of peptide MSLKPRVVD (UV trace recorded 
at 214 nm). 
 
 
Figure 6.27 – Analytical LC-MS trace of peptide MSLKPRVVDF (UV trace 
recorded at 214 nm). 
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Figure 6.28 – Analytical LC-MS trace of peptide MSLKPRVVDFD (UV trace 
recorded at 214 nm). 
 
 
Figure 6.29 – Analytical LC-MS trace of peptide MSAKPRVV (UV trace recorded at 
214 nm). 
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Figure 6.30 – Analytical LC-MS trace of peptide MSLAPRVV (UV trace recorded at 
214 nm). 
 
 
Figure 6.31 – Analytical LC-MS trace of peptide MSLKARVV (UV trace recorded at 
214 nm). 
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Figure 6.32 – Analytical LC-MS trace of peptide MSLKPAVV (UV trace recorded at 
214 nm). 
 
 
Figure 6.33 – Analytical LC-MS trace of peptide MSLKPRAV (UV trace recorded at 
214 nm). 
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Figure 6.34 – Analytical LC-MS trace of peptide MSLKPRVA (UV trace recorded at 
214 nm). 
 
 
Figure 6.35 – Analytical LC-MS trace of peptide B (UV trace recorded at 214 nm). 
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Figure 6.36 – Analytical LC-MS trace of peptide C (UV trace recorded at 214 nm). 
 
 
Figure 6.37 – Analytical LC-MS trace of peptide D (UV trace recorded at 214 nm). 
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Figure 6.38 – Analytical LC-MS trace of peptide E (UV trace recorded at 214 nm). 
 
 
Figure 6.39 – Analytical LC-MS trace of peptide F (UV trace recorded at 214 nm). 
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Figure 6.40 – Analytical LC-MS trace of peptide G (UV trace recorded at 214 nm). 
 
 
Figure 6.41 – Analytical LC-MS trace of peptide H (UV trace recorded at 214 nm). 
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Figure 6.42 – Analytical LC-MS trace of peptide I (UV trace recorded at 214 nm). 
 
 
Figure 6.43 – Analytical LC-MS trace of peptide J (UV trace recorded at 214 nm). 
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Figure 6.44 – Analytical LC-MS trace of peptide L (UV trace recorded at 214 nm). 
 
 
Figure 6.45 – Analytical LC-MS trace of peptide M (UV trace recorded at 214 nm). 
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Figure 6.46 – Analytical LC-MS trace of Clamp peptide derived from peptide A 
(UV trace recorded at 214 nm). 
 
 
Figure 6.47 – Analytical LC-MS trace of Clamp peptide derived from peptide J (UV 
trace recorded at 214 nm). 
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6.4.2 Cyclic pentapeptides 
The procedure for cyclisation was based on the protocol described by 
White et al.139 
The linear peptides (0.03 mmole) were synthesised in the automated 
peptide synthesiser using a low loading capacity resin (Rink amide AM LL 
100-200 mesh, Novabiochem, 0.2-0.4 mmole/g). For the side chain to 
backbone cyclisation, Fmoc-Asp(O-allyl) or Fmoc-Glu(O-allyl) were used  as C-
terminal residue. Next, the resin was transferred to a syringe filter and washed 
thoroughly with DMF, then DCM, and finally DMF again. The syringe was then 
capped and the resin was incubated with 1 eq. of Pd(PPh3)4 in THF and 10% 
piperidine for 3 h under constant shaking. After this step, the resin was washed 
again with DMF and then with a mixture of 5% (w/v) NaDEDTC and 5% (v/v) 
DIPEA in DMF and finally with DMF again. The cyclisation was performed with 
3 eq. of HATU, 3.2 eq. of HOAT and 5 eq. of DIPEA in DMF for 3 h, shaking. 
Then the resin was washed with DCM and the peptides were cleaved from the 
resin with 90% TFA in water for another 3 h with constant shaking. Finally the 
resin was filtered and the cyclic peptides were precipitated in cold diethyl ether. 
The cyclic pentapeptides were dissolved in water and purified on a Gilson 
Preparative HPLC System with a Waters X-Bridge C18 column (100 mm x 19 
mm; 5 µm particle size) and a gradient from 5% to 95% of acetonitrile in water 
over 20 min, flow 25 mL/min, with 0.1% ammonia in the aqueous phase. The 
identity and purity of the peptides was confirmed by analytical HPLC-MS on an 
Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 
6130 quadrupole LC/MS linked to an Agilent diode array detector (Figure 6.48 – 
6.53). The column used was an Agilent ZORBAX StableBond 80Å C18, 4.6 x 
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250 mm, 5 µm column and the compounds were eluted with a gradient of 
5−95% acetonitrile/water + 0.1% ammonia. 
 
6.4.3 Bicyclic peptides 
The linear peptides were synthesised according to the method described 
in section 6.4. For the cyclisation reaction, the protocol consisted of an 
alkylation reaction achieved by the dilution of the peptide to 0.5 mM in a 
solution of 20% ACN and 80% 40 mM NH4HCO3 pH 8.0 in the presence of 
1 mM of TBMB for 1 h at 30 °C.153 At the end of the reaction, the peptides were 
lyophilised in the centrifugal evaporator (Genevac EZ-2 series, SP Scientific). 
The crude peptides were dissolved in solution of H2O:ACN at different ratios 
according to the optimal condition for each peptide and purified on a Gilson 
Preparative HPLC System with a ZORBAX Stable bond 80Å C18 column 
(9.4 mm x 250 mm; 5 µm particle size) and a gradient from 5% to 95% of 
acetonitrile in water over 20 min, flow 25 ml/min, with 0.1% TFA in the aqueous 
phase. The fractions containing the bicyclic peptides were lyophilised and the 
identity and purity of the peptides was confirmed by analytical HPLC-MS on an 
Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 
6130 quadrupole LC/MS, connected to an Agilent diode array detector. The 
column used was an Agilent ZORBAX StableBond 80Å C18, 4.6 mm x 250 mm, 
5 µm column and the compounds were eluted with a gradient of 5−95% 
acetonitrile/water + 0.1% TFA. 
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Figure 6.48 – Analytical LC-MS trace of Peptide 34 (UV trace recorded at 214 nm). 
 
 
Figure 6.49 – Analytical LC-MS trace of Peptide 66 (UV trace recorded at 214 nm). 
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Figure 6.50 – Analytical LC-MS trace of Peptide 86 (UV trace recorded at 214 nm). 
 
 
Figure 6.51 – Analytical LC-MS trace of Peptide 109 (UV trace recorded at 214 
nm). 
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Figure 6.52 – Analytical LC-MS trace of Peptide 113 (UV trace recorded at 214 
nm). 
 
 
Figure 6.53 – Analytical LC-MS trace of Peptide 115 (UV trace recorded at 214 
nm). 
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6.5  Biophysical techniques 
6.5.1 Isothermal titration calorimetry 
ITC experiments were carried out in an ITC200 microcalorimeter 
(Malvern). All protein solutions were dialysed into 100 mM Bis-tris propane 
pH 8.0, 50 mM NaCl, 2 mM TCEP prior to the titrations. 
For the titrations of protein into protein, VBC (wild type and variant 
proteins) or SBC (wild type and variant proteins) were titrated into Rbx1–Cul2. 
For the experiments with Cul5NTD the latter was loaded in the syringe and 
titrated against VBC (wild type and variant proteins) or SBC (wild type and 
variant proteins). The titrations consisted of 19 injections of 2 µl each (120 sec 
spacing and 600 rpm stirring speed) at 25 °C or 30 °C.  
For the titrations of peptide into protein, the peptide (< 1 mM) was titrated 
into VBC (100 µM unless noted). The titrations consisted of 19 injections of 2 µl 
each (120 sec spacing and 600 rpm stirring speed) at 30 °C. 
Control experiments were performed injecting the titrant into buffer and 
were subtracted to the relevant experiment to account for heat of dilution. Data 
analyses for the ITC experiments were performed using the MicroCal Origin 7.0 
software package. Binding enthalpy, dissociation constants, and stoichiometry 
were determined by fitting the data using a one-set-of-sites binding model.  The 
experiments were performed twice for to assess data reproducibility. 
 
6.5.2 Differential scanning fluorimetry 
Differential scanning fluorimetry (DSF) assays were performed in a 
Mx3005P Real Time PCR machine (Stratagene) or in a CFX96 Touch Real-time 
PCR detection system (Biorad). SYPRO Orange (Invitrogen Molecular Probes) 
at a dilution of 1:1000 was used as a reporter dye to monitor the thermal 
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denaturation process of the proteins. Samples were assayed on a 96-well plate 
with final protein concentration of 7.5 µM. The temperature was raised from 
25 °C to 95 °C in increments of 1 °C per minute, collecting fluorescence 
readings at the end of each interval. Each sample was run in triplicate and data 
were reported as an averaged value. 
 
6.5.3 Biolayer interferometry 
BioLayer Interferometry experiments were performed in an Octet 
RED384 (FòrteBio). The biotinylated proteins (25 µg/ml) were immobilised on 
Super Streptavidin biosensor (FòrteBio) and the reference sensors were 
quenched with biocytin (1 mg/ml). The assays were conducted at 25 °C, in 20 
mM HEPES pH 7.6, 100 mM NaCl, 1 mM DTT and 0.02% (v/v) Tween-20 
buffer. The experiments were performed in triplicate in a black solid 384-well 
plate under agitation at 1000 rpm. Common cycle steps for the analyses 
included 60 sec of baseline equilibration in buffer, 60 sec for association in 
wells containing the ligand and 180 sec for the dissociation in wells containing 
only buffer. The response of the reference tips was subtracted from the signal 
to account for unspecific binding. The data points were fitted using a 1:1 model 
and the Kd values were calculated according to the following equations80: 
. 
 
6.5.4 NMR spectroscopy 
NMR experiments were carried out in an AV-500 MHz Bruker 
spectrometer equipped with a 5 mm CTPXI 1H-13C/15N/D Z-GRD cryoprobe. 
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For ligand-observed experiments three samples were prepared: 
A) 30 µM VBC (protein control) 
B) 500 µM-1.5 mM peptide (ligand control) 
C) 30 µM VBC + 500 µM-1.5 mM peptide 
The samples were prepared in 3-mm capillary tubes (Bruker) using a 
buffer containing 20 mM KH2PO4 pH 7.0, 50 mM KCl, 1 mM DTT, 0.02% NaN3, 
20 µM of TSP (for calibration purposes) and 15 % D2O in a total volume of 
200 µl. Samples B and C were prepared from the same ligand solution to avoid 
differences in concentration and while protein was added to C, the same 
amount of buffer was added to B. The experiments were carried out at 20 °C 
using the CPMG78 sequence previously developed and optimised in the Ciulli 
laboratory. The resulting spectra were analysed in TopSpin.  
For protein-observed experiments were used 100 µM 2H,15N-VBC 
samples in a buffer containing 20 mM KH2PO4 pH 7.0, 50 mM KCl, 1 mM DTT, 
0.02% NaN3 and 15% of D2O. The total volume of the sample was 200 µl and 
the experiments were performed in a capillary tube. The 2D 
1H,15N-HSQC-TROSY spectra (in the presence or absence of peptides) were 
recorded with 32 scans and acquisition times of 200 ms for 1H and 100 ms for 
15N, at 30 °C. The spectra were analysed in CCPNMR174 and the chemical shift 
perturbation  (CSP) were calculated according to the following equation: 
𝐶𝑆𝑃 =  ∆H! + (∆N × 0.14)!, where ΔH is the change in proton chemical shift, 
ΔN is the  change in nitrogen chemical shift and 0.14 is a scaling factor required 
to account for the difference in the range of amide proton and amide nitrogen 
chemical shifts.79 The backbone assignment of VBC has been made available 
as by Dr. Mark Bycroft (Laboratory of Molecular Biology, MRC, Cambridge) and 
shared as a gift. 
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6.5.5 AlphaLISA 
For the AlphaLISA experiments Anti-6xHis acceptor beads and 
Streptavidin donor beads (PerkinElmer) were used. The competition assay was 
performed in a 384-well plate by mixing V6xHisBC (500 nM) and biotinylated 
Rbx1–Cul2 (150 nM) and the competitor in a concentration range from 6.25 µM 
to 35 nM (final concentration). The mixture was incubated for 1 h at room 
temperature. Next, the anti-6xHis beads were added to the mixture in the dark 
and the mixture was incubated for another hour. Finally, the streptavidin beads 
were added, followed by another hour of incubation. All the incubation steps 
were performed with the plate sealed and protected from the light. The final 
volume of each well was 20 µl. The plate was then read in a PHERAstar FS 
(BMG LABTECH). Each of the competitors was titrated in quadruplicate. The 
fitting and IC50 determination were performed in GraphPad Prism 7 (GraphPad 
Software, USA). 
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APPENDIX I
 
Figure AI.1 – AlphaLISA raw data of the titration of VBC and Cul2 mutants as 
displacers. The experiments were performed in quadruplicate and the results 
are an averaged value. The error bars represent the standard deviation of each 
point. The fitting was performed with GraphPad Prism 7 software. 
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Table AI.1 – Alphalisa data of the titration of VBC and Cul2 mutants as 
displacers.  
Displacer 
 
IC50 (M) 
 
95% CI 
 
R2 
 
pIC50 (M) 
 
VBC wt 7.80E-08 5.65E-08 to 1.08E-07 0.9550 -7.11 ±	 0.07 
VBC K159E 1.87E-07 1.34E-07 to 2.63E-07 0.9504 -6.73 ±	 0.07 
VBC D187K 1.59E-06 8.52E-07 to 2.97E-06 0.8773 -5.80 ±	 0.13 
VBC V181G 3.34E-07 2.21E-07 to 5.05E-07 0.9339 -6.48 ±	 0.09 
VBC M105A 3.90E-06 1.89E-06 to 8.02E-06 0.8978 -5.41 ±	 0.15 
VBC F109A 2.89E-06 1.40E-06 to 5.94E-06 0.8796 -5.54 ±	 0.15 
Cullin-2 wt 5.16E-08 2.77E-08 to 9.63E-08 0.9629 -7.29 ±	 0.13 
Cullin-2 L3A 4.08E-07 2.11E-07 to 7.91E-07 0.8816 -6.39 ±	 0.14 
Cullin-2 L3G 2.88E-07 1.26E-07 to 6.57E-07 0.8353 -6.54 ±	 0.18 
Cullin-2 P5A 8.11E-07 1.46E-07 to 4.50E-06 0.8302 -6.09 ±	 0.36 
Cullin-2 N36A 1.97E-07 1.16E-07 to 3.36E-07 0.9000 -6.71 ±	 0.11 
Cullin-2 F39A 1.59E-07 5.14E-08 to 4.91E-07 0.7952 -6.80 ±	 0.24 
Cullin-2 Y43A 2.40E-07 7.94E-08 to 7.27E-07 0.7529 -6.62 ±	 0.24 
Cullin-2 V47A 2.54E-07 1.43E-07 to 4.51E-07 0.8869 -6.59 ±	 0.12 
Cullin-2 Q111L 4.74E-07 2.27E-07 to 9.87E-07 0.8509 -6.32 ±	 0.16 
Cullin-2 K114E 1.04E-07 4.51E-08 to 2.41E-07 0.8798 -6.98 ±	 0.18 
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Figure AI.2 – Isothermal Titration Calorimetry raw data of the titrations of VBC 
mutants versus Rbx1–Cul2. 
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Figure AI.3 – Two-dimensional 1H,15N-HSQC spectra of VBC (500 µM), 64 
scans, 302K. 
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Figure AI.4 – Two-dimensional 1H,15N-HSQC spectra of VBC (100 µM), 32 
scans, 302 K (blue) and in the presence of 1 mM peptide J (grey), 2 mM 
peptide J (red) and 3 mM peptide J (purple).  
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Figure AI.5 – Two-dimensional 1H,15N-HSQC spectra of VBC (100 µM), 32 
scans, 302 K (blue) and in the presence of 1 mM 15-mer peptide (red) and 
2 mM 15-mer peptide (purple). 
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Figure AI.6 – Biolayer Interferometry data of 8-mer N-terminal Cul2 peptides 
with leucine replacement versus VBC tested on a concentration-dependent 
assay. 
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Figure AI.7 – Biolayer Interferometry data of 8-mer N-terminal Cul2 peptides 
with leucine replacement versus VBCH tested on a concentration-dependent 
assay. 
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Figure AI.8 – Biolayer Interferometry data of bicyclic peptides versus VBC 
tested on a single point concentration assay. 
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Figure AI.9 – Biolayer Interferometry data of bicyclic peptides versus VBCH 
tested on a single point concentration assay. 
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Figure AI.10 – Biolayer Interferometry data of bicyclic peptides versus VBC 
tested on a concentration-dependent assay. 
 
 
	
264 
 
 
  
 
	
265 
Figure AI.11 – Biolayer Interferometry data of bicyclic peptides versus VBCH 
tested on a concentration-dependent assay. 
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